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ABSTRACT 
Vaccinia virus (VAC) is the prototypical member of the orthopoxvirus 
genus of the poxvirus family and the virus used for smallpox vaccinations.  The 
following describes the testing of VAC variants designed to have similar immuno-
protective profiles with decreased pathogenicity, examines the immune response 
to VAC after lethal infection in wild type and lupus-prone mice, and describes a 
method that allows for the enumeration of VAC-specific CD8+ T in naïve and 
VAC-immune mice. 
The first part describes work examining VAC Wyeth (VAC-Wy) variants 
engineered to be less pathogenic in vivo. VAC-Wy variants included genes that 
code for three immunomodulatory proteins, an interferon-γ (IFNγ) binding protein 
(B8R), an interleukin 18 (IL-18) binding protein (C12L), and a complement 
binding protein (C3L, or C21L) or various combinations of the three knockouts, 
and a triple knockout (VAC-Wy -/-/-) in which all three genes were knocked out of 
a variant virus.  
 The immunomodulatory effects of other IFNγ binding proteins on VAC-Wy 
pathogenesis in the mouse were also examined. Virus recombinants where the 
B8R gene was replaced with a truncated mouse IFNγ receptor gene or a gene 
that encodes a B8R/IFNγ fusion that allows for dimerization of the secreted IFNγ 
receptor were studied.  
As the knockouts and variants were made in the current vaccine VAC-Wy 
strain, only high dose (1x107 PFU’s) intra nasal (I.N.) infection of mice reliably 
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resulted in detectable virus in the lungs.  Further testing revealed that all 
knockout and variant viruses grew to similar levels after high dose I.N. infections.   
Protection induced by vaccination with the VAC-Wy variants was studied 
in comparison to immunizations with the VAC-Wy parental strain.  Mice were 
immunized by tail skin scarification to mimic human immunizations, and this was 
followed months later by I.N. challenge with 20 LD50’s of VAC-WR.  All VAC-Wy 
recombinants tested, including the VAC-Wy -/-/-, provided similar levels of 
protection as the parental VAC-Wy strain from a lethal VAC-WR I.N. infection.  
Mice immunized with the VAC-Wy -/-/- induced similar amounts of neutralizing 
antibody and similar numbers of CD8+ T cells specific to a subdominant 
determinant as VAC-Wy. 
While examining high dose, normally lethal, VAC-WR I.N. infections, a 
profound splenic CD8+ T cell immune suppression was noted that might have 
been caused by Fas dependent activation induced cell death (AICD).  Using high 
dose intra-peritoneal (I.P.) and I.N. models of VAC-WR infection, decreased 
weight loss, decreased virus titers, and increased T cell numbers were found in 
Fas mutant (B6.MRL-Faslpr/J) mice in comparison to B6 wild type mice on day 6.  
It would be expected that Fas-deficient CD8+ T cells from B6.MRL-Faslpr/J mice 
(B6-lpr) would survive a high dose VAC-WR infection better than CD8+ T cells 
that could express Fas if T cells were being eliminated by Fas-dependent AICD, 
but co-adoptive transfer experiments using splenocytes from B6-lpr and B6.Cg-
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IgHaThy-1aGPi-1a/J (IgHa) wild type counterparts found no difference in the 
numbers or proliferation of donor CD8+ T cells at day 6.  
As the B6-lpr mice were better protected from VAC-induced weight loss 
early after lethal VAC-WR infections, it was possible that B6-lpr mice might be 
protected early in infection.  In fact, Fas mutant mice had decreased virus loads 
in the fat pads, livers, and spleens in comparison to B6 wild type mice at days 2 
and 3.  In addition to the decreased virus titers, the severe splenic lymphocyte 
deficiency noted in B6 wild type mice as early as day 2 after high dose I.P. 
infection was ameliorated in B6-lpr mice.  Further experiments demonstrated that 
uninfected B6-lpr mice had increased numbers of memory phenotype (CD44+) 
CD4+, CD8+ and γδ+ T cells, with an increased number of γδ+ T cells and NK cells 
in splenic lymphocytes in comparison to wild type B6 mice. Uninfected B6-lpr 
mice also had increased numbers of IFNγ+ CD8+ T cells after polyclonal 
stimulation with an antibody against CD3ε.  In lymphocyte depletion experiments 
performed at day 3, antibody depletion of CD4, CD8, or NK or treatment with an 
antibody that was specific to the γδ+ TCR did not significantly alter virus loads in 
B6-lpr mice.  In co-adoptive transfer experiments, splenocytes from wild type or 
B6-lpr mice survived high dose VAC-WR challenge similarly suggesting that B6-
lpr splenocytes were not intrinsically better protected from lymphocyte depletion 
by lack of the Fas protein.   On day 2 after high dose I.P. VAC-WR infection, B6-
lpr mice had increased numbers of IFNγ+ NK cells, IFNγ+ CD8+ T cells, and IFNγ+ 
CD4+ T cells.  B6-lpr and B6 mice treated with an antibody against IFNγ had 
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significantly increased virus titers in the spleens and livers.  Interestingly, there 
was no significant difference in liver or spleen virus titers when comparing anti-
IFNγ antibody treated B6 mice or anti-IFNγ antibody treated B6-lpr mice.  These 
results suggest that multiple leukocyte populations co-operatively or redundantly 
provide B6-lpr mice with increased protection from high dose VAC-WR infections 
through increased production of IFNγ. 
The third part of this work describes the enumeration of total numbers of 
pathogen-specific CD8+ T cells in a mouse through use of an in vivo limiting 
dilution assay (LDA).  The extensive proliferation of virus-specific CD8+ T cells 
that occurs after virus infection was used to enumerate numbers of virus-specific 
CD8+ T cells in a naïve mouse.  By transferring limiting amounts of 
carboxyfluorescein succinimidyl ester (CFSE)-labeled Thy1.1+Ly5.2+ 
heterogeneous CD8+ T cells into Thy1.2+Ly5.1+ hosts, CD8+ T cell precursor 
frequencies to whole viruses can be calculated.  The calculations are based on 
finding the number of donor CD8+ T cells that results in CFSElo (i.e. proliferated) 
donor CD8 T cells in 50% of the hosts.  Using probit or Reed and Muench 50% 
endpoint calculations, CD8+ T cell precursor determinations were made for naïve 
and immune states to a virus challenge.  It was found that in naïve B6 mice, 1 in 
1444 CD8+ T cells proliferated in response to VAC-WR (~13,852 VAC-WR-
specific CD8+ T cells per mouse) and 1 in 2956 proliferated in response to 
lymphocytic choriomeningitis virus (LCMV) (~6,761 LCMV-specific CD8+ T cells 
per mouse). In mice immune to VAC-WR, the number of VAC-WR-specific LDA 
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precursors, not surprisingly, dramatically increased to 1 in 13 (~1,538,462 VAC-
WR-specific CD8+ T cells per mouse) consistent with estimates of VAC-WR-
specific memory T cells.  In contrast, precursor numbers to LCMV did not 
increase in VAC-WR-immune mice (1 in 4562, ~4384 LCMV-specific CD8+ T 
cells in a VAC-WR-immune mouse) consistent with the fact that VAC-WR 
provides no heterologous immunity to LCMV.  Using H-2Db-restricted LCMV 
GP33-specific P14 transgenic T cells it was found that, after accounting for take 
of donor T cells, approximately every T cell transferred underwent a full 
proliferative expansion in response to an LCMV infection and a high efficiency 
was also seen in memory populations.  This suggests that most antigen-specific 
T cells will proliferate in response to infections at limiting dilution.  These results, 
which are discussed in comparison to other methods, show that naïve and 
memory CD8+ T cell precursor frequencies to whole viruses can be remarkably 
high. 
In total this work further advances knowledge of the immunity, 
pathogenesis, and prevention of poxvirus infections.  This was accomplished by 
studying VAC-Wy recombinants as improved vaccines, by examining the 
mechanisms and cell types important in early protection from high dose poxvirus 
infections in B6 and B6-lpr mice, and by describing a method to enumerate total 
numbers of virus-specific CD8+ T cells in a mouse. 
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CHAPTER I: INTRODUCTION 
A. Variolation 
 The devastation and death that smallpox caused throughout the millennia 
were profound, but the observations that survivors of the infection were rarely re-
infected gave hope that there might be a way to fight or even prevent the 
disease.  There are descriptions of infections with smallpox material in controlled 
circumstances to prevent later more severe smallpox infections as far back as 8th 
century India by the author Madhav in a chapter of the Nidana (a book describing 
diseases and symptoms) that focused on smallpox (Holwell 1767; Hopkins 
2002).  It would seem that this practice was not widely adopted until the Sung 
Dynasty (960 to 1280 A.D.) and interestingly was only first practiced in 
southwestern China near the border with India (Hopkins 2002).  The purposeful 
infection procedure was only well described later by Yu Chang in his book Notes 
on my Judgment published in 1643 (Temple 1986).  The procedure was 
eventually widely described to Europeans by physician Emmanuel Timoni.  Dr. 
Timoni characterized the infection as an inoculation, which seems to be the first 
time this word is used to label infections (Timonius and Woodward 1714).  He 
explains…  
“They make choice of some boy, or young lad, of a found healthy Temperament, 
that is seized with the common Smallpox…on the twelfth or thirteenth day from 
the beginning of his sickness:  they with a needle prick the Tubercles (chiefly 
those on the shins and hands) and press out the matter coming from them into 
2
some convenient vessel…” then to the inoculation “The patient therefore being in 
a warm chamber, the operator is to make several little wounds with a needle in 
one, two or more places of the skin, till some drops of blood follow, and 
immediately drop out some drops of the matter in the glass, and mix it well with 
the blood effusing out; one drop of the matter is sufficient for each prick’d.  These 
punctures are made indifferently in any of the fleshy parts, but succeed best in 
the muscles of the arm or Radius” 
This publication describes the outcome of this controlled infection as being less 
harmful than contracting smallpox in the usual way, and while it does mention 
individuals that succumb to the inoculation as might happen during a natural 
infection, explains the inoculation procedure as wholly protective against 
smallpox infection.   
Inoculation, or variolation, began to become somewhat widespread in 
Europe after small demonstrations of the relative safety of the procedure.  A 
demonstration in 1721 on six inmates of Newgate prison set up by the then 
Prince and Princess of Wales and witnessed by twenty-five members of the 
Royal Society showed the successful inoculations and subsequent protection 
against smallpox challenge (Oldstone 2000).  This incident was reported on 
publicly in newspapers, and while the inoculation itself was associated with a 2% 
death rate, this was much better than the threat imposed by natural smallpox 
infection.   
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B. Vaccination and the Elimination of Smallpox from The Human 
Population 
 While variolation was proving to be a successful preventive measure 
against smallpox, there was still concern as to the high death rate associated 
with the procedure.  Discussion was ongoing as to ways that this procedure 
might be made less lethal and publications on the procedure questioned how 
attenuation of variolation might be accomplished.  An interesting phenomenon 
noticed at the time was the relative resistance of dairymaids to smallpox 
infection. As dairymaids would often interact with cows, one interesting thought 
was that the contraction of cowpox by dairymaids might provide some kind of 
cross-protection from smallpox infection.  In fact a farmer in 1764 named 
Benjamin Jesty inoculated his wife and two sons with pustulous material taken 
from the lesion of a cow as protection against smallpox infection, noting that his 
two servant girls who had contracted cowpox seemed to be resistant to smallpox 
(Oldstone 2000).  A more rigorous testing of the hypothesis that cowpox could 
protect against smallpox infections came from a country physician named 
Edward Jenner (Jenner 1800).  Dr. Jenner began by attempting to variolate 
individuals with past histories of cowpox infection, and in every case described 
he found that the people who had been previously infected with cowpox had 
symptoms that were much less severe than what would normally occur with 
variolation.  Jenner remarks “It is remarkable that variolous matter, when the 
system is disposed to reject it, should excite inflammation on the part to which it 
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is applied more speedily than when it produces the Small Pox”, seeming to 
remark on the quick response in these individuals to the variolation procedure.  
The individuals had described being infected with cowpox anywhere from a year 
to up to fifty-two years previously, and so he felt whatever protection the cowpox 
infection provided was long lasting.  He then describes a more controlled 
examination of the phenomenon in which he inoculates an eight year-old boy 
with material from the sore of a dairymaid.  The boy fell ill to the infection, but 
recovered, and a year later Jenner variolated the boy and found that the boy was 
protected from the smallpox infection that normally occurred after variolation.  
This and two similar experiments described in the publication, along with the rest 
of his studies seemed to solidify the phenomenon for Jenner. With Jenner’s 
publication of these observations, and later experiments that confirmed the 
results, there seemed to at last be a method to protect populations from the 
scourge of smallpox.  The purposeful infection of a human being with material 
that typically makes them sick (and was lethal in about 1 to 100,000 to 1 in a 
1,000,000 people) protected them from an infection that killed anywhere from 20-
40% of those infected.  Jenner deemed the procedure vaccination (from the Latin 
vaccinus, “from cows”) in 1803.   
Smallpox vaccination began to be practiced throughout the world, and by 
the 1950’s many countries had contained the spread of smallpox.  It was 
suggested (actually all the way back to Jenner and some others of his time) that 
this procedure might be able to rid the world of smallpox, but it took a few pushes 
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before a worldwide effort to eliminate the virus from the human population as a 
whole gained momentum (Oldstone 2000).  Individual countries would eradicate 
the disease from their soil, but it wasn’t until 1967, when a measure passed by 
two votes at the World Health Organization, that there became an explicit 
mission to eradicate smallpox from the human population.  Dr. Donald Ainslie 
Henderson was put into the position of Chief Medical Officer of the Smallpox 
Eradication Program and remained director until smallpox was officially declared 
eradicated by the WHO in 1980 (Fenner, Henderson et al. 1988).  
C.  Concerns Today 
The successful eradication of smallpox through a worldwide vaccination 
program was a great biomedical achievement of the 20th century.  Smallpox, the 
causative agent being eventually named variola virus, was a devastating 
disease, with two variants being described, one variola major with an estimated 
mortality rate of 5-35%, with the related variola minor designation having a 
mortality rate of 0.5-2% (Fenner, Henderson et al. 1988).  Subsequent genomic 
analysis has been successful in identifying discrete genetic sequences allowing 
for the identification of the two variola strains, although no mutation described 
was able to explain the reduced mortality of variola minor (Shchelkunov, 
Totmenin et al. 2000).  While the eradication of the disease within the human 
population was a resounding success, the threat of accidental or purposeful 
reintroduction of variola virus remains a concern.  There has also been concern 
regarding recent monkeypox outbreaks (Di Giulio and Eckburg 2004).  
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Monkeypox, while seemingly less lethal than variola major, is still associated with 
a 10% mortality rate, and it is thought that smallpox vaccination would provide 
some protection from monkeypox infection (Hammarlund, Lewis et al. 2005).  It is 
therefore important to continue to learn of the immune mechanisms important in 
fighting poxvirus infections, and to develop vaccines that elicit protection equal to 
or better than the current vaccine, while lowering the incidence of harmful side 
effects associated with smallpox vaccination.   
The vaccine used to elicit protective immunity to smallpox was found to be 
a live virus inoculation with the closely related virus, vaccinia virus (VAC).  It is 
not known if the vaccination procedure early on used cowpox as stated, or 
whether the inoculum given was actually VAC, but it is known that the virus now 
given to immunize from smallpox infection is not cowpox.   VAC infection seems 
to provide long-term protective immunity from infection with variola virus, but the 
inoculation is not without side-effects.  Milder harmful effects include fever and 
body aches, as had been described by Jenner, but there are other risks from 
vaccination, including accidental exposure and generalized rash on the skin that 
historically occurred in about 1 in 2,000 vaccinated, a generalized spread of the 
virus on the skin termed eczema vaccinatum which occured in about 1 in 20,000 
primary vaccinations, and in more severe cases vaccinia necrosum and 
postvaccinial encephalitis which can lead to death (Copeman and Wallace 1964; 
Fulginiti, Papier et al. 2003).  Other side effects are still being described, as 
demonstrated in the more recent vaccination efforts.  Cardiac complications such 
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as myocarditis and myopericarditis were noted, with the rate of myopericarditis 
being about 1 in 2000, much higher than had previously been seen with smallpox 
immunization (Nalca and Zumbrun 2010).   In 14-52 out a million people, the 
vaccination itself may prove life threatening, with about 1 in a million people 
dying from the vaccine (Cono, Casey et al. 2003).   
Unfortunately, the threat of the smallpox vaccination is also increased in 
individuals that have skin conditions such as eczema or atopic dermatitis (AD).  
The vaccine is also not recommended for individuals with immune systems 
compromised by immunosuppressive drugs or infections, as the live virus 
inoculum might overwhelm the suppressed immune system (Redfield, Wright et 
al. 1987; Edghill-Smith, Bray et al. 2005) (Fulginiti, Papier et al. 2003).  
Unfortunately, the HIV epidemic has most likely led to an increased number of 
immuno-compromised individuals within the population and with the continued 
success of organ transplantation, which typically require immunosuppressive 
drug regiments, it is important to identify vaccinations that offer similar protective 
immunity, with decreased pathogenic effects. 
D.  Better Smallpox Vaccination Through VAC Modification 
VAC variants used as smallpox vaccines have been characterized as 1st 
generation (original vaccines grown in many different ways Ex. Dryvax), 2nd 
generation (the 1st generation vaccines plaque purified and adapted to grow in 
cell culture Ex. ACAM2000), 3rd generation (passaging of virus in cell culture to 
attenuate Ex. MVA) and 4th generation (VAC recombinants with targeted 
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mutations to enhance immunity or decrease pathogenicity) (Kennedy, 
Ovsyannikova et al. 2009).  The 1st generation vaccines were typically a mix of 
VAC strains. The previously licensed smallpox vaccine in the United States, 
Dryvax (also known as VAC-Wyeth), was a mix of New York City Board of 
Health (NYCBH) strains grown on calf or sheep skin (Nalca and Zumbrun 2010), 
and while the vaccination was effective, the sterility of the vaccination material 
was questionable (Fenner, Henderson et al. 1988).  The newly licensed smallpox 
vaccine in the United States is ACAM2000, a 2nd generation preparation made 
from plaque purified Dryvax propagated in cell culture (Weltzin, Liu et al. 2003; 
Monath, Caldwell et al. 2004).  This vaccination was shown to be as protective as 
Dryvax in multiple animal models, and to induce similar amounts of 
immunological memory as Dryvax if given at similar doses (Nalca and Zumbrun 
2010).  While ACAM2000 looks to have a similar immuno-protective profile with 
the benefit of being propagated in a more controlled fashion, it remains important 
to develop smallpox vaccines which are as immuno-protective, with decreased 
adverse reactions, especially in light of the recent realization that the new 
smallpox vaccine may be associated with previously rare cardiac side effects 
(Nalca and Zumbrun 2010).  The recent renewed interest in the highly attenuated 
modified vaccinia Ankara (MVA) as a smallpox vaccine strain is therefore not 
surprising.  MVA was originally generated by serial passage (>500) in chicken 
embryo fibroblasts of material from a poxvirus lesion on a horse (Hochstein-
Mintzel, Huber et al. 1972; Mayr, Hochstein-Mintzel et al. 1975).  MVA was 
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demonstrated to have decreased pathogenesis in many models early on, and in 
more recent analyses, MVA has been shown to grow to lower titers in vitro, and 
to lack many genes that code for immuno-modulatory proteins that increase VAC 
pathogenesis (Blanchard, Alcami et al. 1998).  Also, MVA, when given at multiple 
doses, as it replicates poorly in comparison with Dryvax, is able to protect 
rhesus macaques from lethal infections with monkeypox (Earl, Americo et al. 
2004).  These results are promising, but the requirement for an increased virus 
dose, and the recent revelation that introduction of the six major genomic 
deletions in MVA into the parental VAC strain did not recapitulate the MVA 
phenotype (Meisinger-Henschel, Spath et al. 2010), suggests that a more 
directed approach might help in generating viruses with similar immuno-
protective phenotypes and reduced pathogenicity. 
Discovering variants of VAC that are as protective but less pathogenic 
may not only be important in developing better smallpox vaccines.  VAC variants 
have been engineered to express proteins of non-vaccinia origin are currently 
being considered as a potential platform for immunizations against other 
pathogens, with success already being described with a recombinant VAC 
expressing the rabies glycoprotein (Pastoret and Brochier 1996).  It has also 
been described that some poxvirus infections are directly oncolytic, possibly 
revealing a new mode of cancer treatment (Thorne, Hwang et al. 2007).  As 
these stories unfold, it becomes even more important to understand how the 
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immune system responds to VAC infection and to develop less pathogenic 
vaccinations. 
E.  Early Studies Examining Correlates of Protection In Acute and Immune 
States 
 Studies examining immunological smallpox correlates of protection 
typically compared smallpox-vaccinated (immunized with VAC) and unvaccinated 
patients.   An early study described that vaccinated individuals responded more 
quickly to contact with smallpox, with increased levels of neutralizing antibody, 
vaccinial antihaemagglutinin activity, and complement-fixing antibody when 
compared to unvaccinated individuals (Downie and Mc 1958).  They characterize 
this result as not surprising, as the smallpox infection would be considered a 
second antigenic stimulus, but this result confirms, as Jenner had illustrated, the 
robust smallpox-specific response in VAC-immune individuals.  A later study of 
142 individuals found that neutralizing antibody levels of greater than 1/32 as 
detected by plaque inhibition on a monkey kidney cell line (Cutchins, Warren et 
al. 1960), were protected from subsequent smallpox infections (Mack, Noble et 
al. 1972).  Later research described 57 contacts of 6 smallpox cases where all 
vaccinated individuals, as determined by note of a pock, did not develop clinical 
smallpox and 6 of 42 with titers under 1/20 (6 of 14 unvaccinated patients) 
developed smallpox (Sarkar, Mitra et al. 1975).  Although the presence of 
poxvirus-induced antibody was demonstrated to be important, and experiments 
had demonstrated that transfer of neutralizing antibody helped to prevent 
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smallpox disease in individuals in close contact with smallpox patients (Kempe, 
Bowles et al. 1961; Marennikova 1962) there was an indication that neutralizing 
antibody was not the only immune mechanism providing protection from poxvirus 
infections.  Other investigations revealed that agammaglobulinemic patients 
could sometimes be vaccinated without side effects (Kempe 1960) and mouse 
experiments with ectromelia (mousepox) virus and VAC described a cellular 
poxvirus-specific antiviral activity that was not neutralizing antibody or interferon.   
Original experiments describe increases in mortality and VAC spread in 
anti-thymocyte sera treated mice (Hirsch, Nahmias et al. 1968).  Later 
experiments demonstrated a non-interferon, non-neutralizing antibody, cellular 
activity in day 6 infected mice, which was neutralized by anti-thymus sera that 
reduced ectromelia virus titers (Blanden 1970; Blanden 1971).  These 
experiments also described the passive transfer of this cellular anti-ectromelia 
activity to other mice.  It was further described that this activity helped 
mononuclear cell invasion of infected foci, and it was suspected that this activity 
would help clear an ectromelia virus infection (Blanden 1971).  The potential role 
of thymus-derived cells was further solidified by use of fowlpox-infected 
thymectomized or bursectomized chickens, and found that at week 2, 
thymectomized chickens had increased virus loads in skin lesions (Morita 1973).  
Eventually it was demonstrated that splenocytes from mice infected 4-6 weeks 
previously, after in vitro culture with the same pathogen and cells, could act much 
like the protective cell-mediated effectors that had been described to appear 
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starting at day 6, and that this protection was H-2 and pathogen-restricted (Kees 
and Blanden 1977; Dunlop 1978).  Further, much of the cytotoxic activity in mice 
could be removed by treatment with an anti-sera against Ly2.1 (later designated 
CD8α) both in primary and secondary ectromelia immune response (Pang, 
McKenzie et al. 1976).  The combination of these works seems to be the first 
time that the role of thymus-derived CD8+ cells (CD8+ T cells) was examined in 
poxvirus infections, with the initial findings suggesting that CD8+ T cells were 
important in control of poxvirus infections.  Later studies examined intra-dermal 
infections of β2-microglobulin knockout mice (lack CD8+ T cells) with VAC-WR, 
and found no difference in lesion size when compared to wild-type mice, 
suggesting that CD8+ T cells did not participate in protection against acute 
infections (Spriggs, Koller et al. 1992).  These results seemed to contrast with the 
earlier studies with ectromelia, but actually serve to highlight the important 
differences that result when examining VAC infections or ectromelia infections in 
mice.  Although the WR strain of VAC was generated by 18 intra-cerebral 
passages of the NYCBH strain in mice, followed by a passage in rabbit skin 
(Parker, Bronson et al. 1941) and is therefore a mouse-adapted neurovirulent 
strain of VAC, ectromelia, as a mouse poxvirus is more lethal.  Therefore the 
immune mechanisms necessary to protect against either may be different. 
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F.  Recent Work Examining Correlates of Protection In Acute and Immune 
States 
More recent studies have also examined the importance of different cell 
subsets in protection from acute poxvirus infections and have tried to determine 
what mechanism in immune mice offers protection from lethal challenge.  In one 
study, CD4 or CD8 cells were dispensable in protecting intra-muscularly 
immunized MVA-immune mice from VAC-WR challenge, but in mice without B 
cells, both CD4 and CD8 cells were necessary to protect immune mice from 
lethal challenge, and CD8 cells were found to be important in acute intra-nasal 
(I.N.) VAC-WR challenge (Belyakov, Earl et al. 2003).  The observation that 
CD8+ T cells helped protect mice from lethal VAC-WR challenge was consistent 
with results in the ectromelia infection model, with B cells, and most likely 
neutralizing antibody the main protection mechanism against subsequent lethal 
poxvirus infections. Later experiments examined protection afforded by different 
components of immunized mice, and found that naïve mice that received 2x107 
CD8+ T cells or 300µl sera from an immunized mouse, had comparable 
decreases in virus titers in the ovaries 6 days after I.P. VAC-WR challenge, and 
suggested that both cellular and humoral immunity could provide protection 
against poxvirus infections (Xu, Johnson et al. 2004). 
A later study examined footpad injections with ectromelia, and suggested 
that both CD8+ T cell and B cell responses were important in resolving ectromelia 
infections by examining CD8-/- mice and CD40-/- mice, and suggested that B cell 
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responses were important in later control with CD8+ T cells playing an earlier role 
in controlling ectromelia virus infection (Fang and Sigal 2005).  These studies 
complemented the early studies done with ectromelia, and the more recent VAC-
WR studies in that acute resolution of poxvirus infection seemed to require CD8+ 
T cells, while later time points required a B cell response.  Other studies found 
that early control of poxvirus infection could be mediated by γδ+ T cells for I.P. 
VAC-WR infections (Selin, Santolucito et al. 2001) and natural killer (NK) cells for 
ectromelia (Parker, Parker et al. 2007) and VAC-WR (Bukowski, Woda et al. 
1983; Martinez, Huang et al. 2008) infections.  The results generated by poxvirus 
infections in mice seem to support the importance of multiple leukocyte types in 
protection from poxvirus infections.  More recent primate studies reinforce some 
of these observations. 
Early studies in rhesus macaques had described that lethal monkeypox 
infection could be prevented by three methods of vaccination, either MVA 
followed by MVA, MVA followed by Dryvax, or Dryvax alone, with the 
macaques immunized with MVA/MVA developing poxvirus lesions that eventually 
cleared (Earl, Americo et al. 2004).  In studies published soon thereafter, it was 
found that MVA/MVA/Dryvax, NYVAC/NYVAC/Dryvax, or a single 
immunization with Dryvax could not protect simian immunodeficiency virus 
(SIV)-infected macaques that had CD4+ T cell counts of <300/mm3 from 
monkeypox (12 of 13), in contrast to SIV-infected macaques with CD4+ T cell 
counts of >300/mm3 (5 of 5) (Edghill-Smith, Bray et al. 2005).  Further analysis 
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demonstrated that there was a deficient switch to IgG antibody in macaques with 
CD4+ T cell counts of <300/mm3, and this was probably the determining factor in 
susceptibility.  These studies pointed to the important role of CD4+ T cells in 
developing protective immunity to poxvirus immunizations.  Later experiments 
building on this study found that depletion of B cells with anti-CD20 antibody 
during Dryvax vaccination, but not depletion of CD8 cells during monkeypox 
infection, resulted in death by day 13 of 3 of 4 macaques, with the remaining 
macaque shown to not have efficient depletion of B cells (Edghill-Smith, Golding 
et al. 2005).  In other experiments in this study, depletion of CD4 or CD8 cells 
immediately before monkeypox infection in vaccinated macaques had no effect 
on protection, but passive transfer of immune sera was able to protect macaques 
from death.  These studies support the idea that, in immune hosts, VAC-specific 
neutralizing antibody is probably the best correlate of protection against smallpox 
infection, although these studies did not rule out a role of memory CD8+ T cells in 
protection, and never examined acute infections. 
Examining the immune mechanisms and leukocyte types important for 
protection from poxvirus infections is important, but it is also important to know 
how long poxvirus-specific immunity after smallpox vaccination might last, and 
recent studies have described promising results. 
G.  Immunological Memory Induced By Smallpox Vaccination 
Recent investigations of poxvirus-specific immunity in individuals that had 
been immunized against smallpox up to 75 years previously found that the half-
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life of VAC-specific CD4+ T cells was 8-12 years as detected by an intracellular 
cytokine assay and also described long lived antibody responses as detected by 
ELISA which directly correlated with neutralizing antibody titers (Hammarlund, 
Lewis et al. 2003).  The half-life of VAC-specific CD8+ T cells was about 8-15 
years as detected by an intracellular cytokine assay.  Paradoxically, the VAC-
specific CD8+ T cell response was more variable in that it seemed that 50% of 
individuals had VAC-specific CD8+ T cells no matter the time since vaccination, 
although this result was not discussed. These results were quickly followed by 
another study examining poxvirus immunity in humans.  This study also 
demonstrated that VAC-neutralizing activity in the sera is detectable in most 
individuals throughout life, and this activity directly correlated with the number of 
VAC-specific B cell memory, as detected by a B cell memory assay (Crotty, 
Felgner et al. 2003).  Analysis of VAC-specific CD4+ T cells detected by 
ELISPOT demonstrated a drop occurring within a few years of vaccination, with 
VAC-specific CD4+ T cells slowly declining throughout life, with a measured half-
life of about 14 years.  These results are promising, in that VAC-induced B cell 
memory seems to be maintained throughout life, and that antibody seems to 
correlate most strongly with protection in the immune state.  Recent studies have 
suggested that previous immunization against smallpox provides some protection 
against monkeypox infection (Hammarlund, Lewis et al. 2005), although infection 
with monkeypox may generate a decreased poxvirus-specific response as 
detected by assays using VAC (Sivapalasingam, Kennedy et al. 2007).  
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Promisingly, more recent work has suggested that the levels of immunity induced 
by variola virus infection or smallpox vaccination were indistinguishable, further 
strengthening the idea that smallpox vaccination may provide a similar immuno-
protective profile as smallpox infection (Hammarlund, Lewis et al. 2010).   
H.  Description of T Cell Epitopes 
In many studies, it has been demonstrated that T cells are important in 
resolving pathogenic poxvirus infections in mice, (Pang, McKenzie et al. 1976; 
Belyakov, Earl et al. 2003; Xu, Johnson et al. 2004; Fang and Sigal 2005), 
rhesus macaques (Edghill-Smith, Bray et al. 2005), and in humans (Redfield, 
Wright et al. 1987), and so it was important to determine what regions within 
poxviruses would encode T cell epitopes in order to more closely examine 
immune responses within animal models and to determine what vaccinations 
would induce strong T cell responses. 
The first description of an epitope encoded by a poxvirus was done by 
screening early VAC nonstructural gene products by an epitope prediction 
algorithm for human leukocyte antigen A*0201 (HLA) (Drexler, Staib et al. 2003).  
This was quickly followed by screening early and early/late gene VAC peptides 
predicted to have high binding affinity to HLA-A*0201 in VAC-specific CD8+ T cell 
lines established from Dryvax immunized HLA-A*0201 individuals, and this 
defined two more HLA-A*0201 restricted VAC epitopes (Terajima, Cruz et al. 
2003).  As this HLA type is quite common in the human population, the 
description of these epitopes enhances the ability to follow VAC-specific CD8+ T 
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cell responses, and the eventual description of many human VAC-specific CD4+ 
and CD8+ T cell epitopes soon followed, which are reviewed here (Sette, Grey et 
al. 2009).   
The first mouse major histocompatibility complex (MHC)-restricted 
epitopes encoded within VAC was identified by molecular mimicry.  Earlier 
studies had demonstrated that VAC-WR infection of LCMV-immune mice would 
often result in expansion of LCMV nucleoprotein (NP)205 epitope specific CD8+ 
T cells, and this result suggested that an epitope presented after VAC-WR 
infection mimicked the LCMV NP205 peptide (Kim, Cornberg et al. 2005).  By 
searching for nucleotide and amino acid homologies to LCMV NP205 in VAC, 
and then screening the resulting 115 peptides that were predicted to bind H-2Kb 
against VAC-specific CD8+ T cells, the VAC determinants A11R198 and E7R130 
were found, the first mouse MHC-restricted VAC epitopes (Welsh, Selin et al. 
2004; Cornberg, Sheridan et al. 2007).  This was soon followed by the 
identification of five other CD8+ T cell epitopes, B8R20 (B8R), A19L47, A47L138 
(A47L), A42R88, and K3L6 (K3L), by expressing plasmids encoding each of the 
predicted 258 open reading frames of VAC in cells expressing H-2Db or H-2Kb, 
and screening these against splenocytes from day 7 VAC-infected C57BL/6J 
(B6) mice (Tscharke, Karupiah et al. 2005), and the same group used a similar 
methodology to describe epitopes in BALB/c mice (Tscharke, Woo et al. 2006).  
The description of these epitopes was followed by description of many other 
CD8+ T cell epitopes by a consensus epitope prediction algorithm (Moutaftsi, 
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Peters et al. 2006), and other broad screening methods were used to find other 
VAC-specific CD8+ T cell epitopes (Mathew, Terajima et al. 2005) and CD4+ T 
cell epitopes (Moutaftsi, Bui et al. 2007).   
The description of these T cell determinants not only allows for the 
tracking of T cell responses in humans after different vaccination protocols, but 
also allows for the testing of various poxvirus vaccines in animal models, and 
allows for improved vaccine testing and characterization. 
I.  In Search of a Better Vaccine 
There are many strategies to overcome the potential harmful effects of 
smallpox vaccination, including using a different immunization protocol altogether 
that avoids infecting humans with live VAC.  While this might seem attractive, the 
striking success of the smallpox eradication effort and the protection the 
immunization affords against further smallpox infection, some say lifelong 
protection, would suggest that the vaccinia platform, while flawed, is a beginning 
and not an end.  It has already been described that infection with VAC offers 
long-term VAC-specific immunological memory.  This memory has been most 
extensively described in the form of virus specific CD4+ T cells, CD8+ T cells, and 
B cells, and it might therefore be more beneficial to work on ways to limit the 
pathogenicity of VAC while retaining the immunological memory induced by 
infection with VAC.   
As VAC is a large double stranded DNA virus that encodes many proteins 
that seek to evade or shut down the immune response, one strategy to limit 
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pathogenicity is to create viruses that lack genes which code for proteins that 
have been shown to limit the host immune response to the virus.  To this end, the 
pathogenicity of and protection provided by VAC-Wy knockouts that lack one, 
two, or three genes that code for previously described pathogenic 
immunomodulatory proteins, and some other VAC recombinants, is described 
using a mouse model.  The immunomodulatory proteins targeted for knockout 
included an interferon-γ (IFNγ) binding protein B8R, an interleukin 18 (IL-18) 
binding protein C12L, and a complement binding protein (C3L).   
J.  The Discovery of Interferon-γ  and the Interferon-γ Receptor 
The description of soluble effectors induced by virus stimulation of cells 
interfering with virus infectivity was first described as interferon when 
investigations were made into the inhibition of influenza hemagglutinin activity by 
a membrane soaked in a buffer containing heat-inactivated influenza virus 
(Isaacs and Lindenmann 1957).  This designation of interferon was subsequently 
used to describe a virus-inhibitor that had been detected in the media of 
leukocytes treated with phytohemagglutinin (Wheelock 1965).  In these 
experiments it was demonstrated that inhibition of Sindbis virus cytopathic effect 
(CPE) was probably not a byproduct of phytohemagglutinin and was inducible in 
cells only at 37°C, but not at 4°C, suggesting that the product was of cellular 
origin.  Interestingly, when comparing it to the interferon effect previously 
described to be induced by virus infection of cells, this factor was unstable at pH 
2 or when heated to 56°C, unlike the previously described interferon effect.  This 
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virus-inhibitor product produced by leukocytes seems to have been described in 
earlier studies with mouse leukocytes stimulated with Newcastle disease virus 
(NDV) or VAC (Glasgow and Habel 1963; Glasgow 1965), but before the 
resolution of the activities of interferon into discrete factors, it was difficult to 
make sense of the phenomenon.  Even after the description of discrete interferon 
activities, the interferon effect was still discussed as being attributed to a single 
heterodimeric protein (Colby and Morgan 1971).  Later studies confirmed the 
classification of the interferons into at least two separate factors by examining the 
differences in size, stability at acidic pH (pH of 2), and the biochemical properties 
of the interferon factors induced by either NDV or anti-lymphocyte globulin and 
divalent F(ab’)2 fragment stimulation of human peripheral lymphocytes from a 
single donor (Falcoff 1972).  
As evidence for multiple interferon types began to grow, the separation of 
the interferons into two types was proposed. Type I interferon would be 
distinguished by their ability to be induced by various pathogens or components 
of pathogens, and Type II interferon would be defined as interferon produced by 
activated immunocytes through mitogenic or some other stimulation (Ho and 
Armstrong 1975).  A further distinction was later made, and Type I interferons 
were given the designation IFNα and IFNβ and the only known Type II interferon 
would be named IFNγ (Stewart and Blalock 1980).  Further studies were made 
on the actions of both types of interferon, but the eventual cloning of IFNγ from a 
cDNA library, and the ability to produce large quantities of pure protein now 
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simplified the biological characterization of this protein (Gray, Leung et al. 1982).  
Subsequent experiments demonstrated that IFNγ could up-regulate MHC class I 
and II on macrophages and B cells (Wong, Clark-Lewis et al. 1983), was the 
lymphokine that had been previously identified to enhance hydrogen peroxide 
activity in macrophages and stimulate the macrophage’s ability to kill intracellular 
pathogens (Nathan, Murray et al. 1983), and was also found to enhance 
production of IgG2A and inhibit production of IgG1 and IgE in an in vivo mouse 
model of infection with Brucella abortus (Finkelman, Katona et al. 1988).  These 
and many other findings demonstrated the important role that IFNγ played in the 
immune response.  The major producers of IFNγ were found to be CD4+ and 
CD8+ T cells after mitogenic stimulation (Sandvig, Laskay et al. 1987) and NK 
cells which produce IFNγ after culture in IL-2 (Handa, Suzuki et al. 1983). 
Early studies had suggested that the receptor for IFNγ and the receptors 
for the known Type I interferons did not share a common receptor (Branca and 
Baglioni 1981), and a realization eventually arose that the IFNγ receptor (IFNγR) 
would only function biologically as a  heterodimer.  Initial experiments that looked 
to identify the chromosomal location of the IFNγR used hamster-human or 
mouse-human cell hybrids, as human IFNγ does not bind or activate mouse or 
hamster cells (Finbloom, Hoover et al. 1985), and demonstrated that only hybrids 
that contained human chromosome 6 were able to bind IFNγ (Rashidbaigi, 
Langer et al. 1986).  Interestingly, this binding activity did not result in protection 
of these hybrids from vesicular stomatitis virus (VSV)-induced cytotoxicity, and it 
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was later found by the same group that hybrids containing both chromosomes 6 
and 21 were required to be able up-regulate MHC in response to IFNγ, 
suggesting that both chromosomes were needed to respond to IFNγ binding 
(Jung, Rashidbaigi et al. 1987).  It would prove necessary to clone and transfect 
two separate genes into cells to confer biological responsiveness to IFNγ.  The 
first gene described was found to express a protein that was demonstrated to be 
the IFNγ binding subunit (later IFNγRα), and discovery of this gene was 
accomplished by screening of a cDNA library of mRNA products with polyclonal 
rabbit anti-sera directed against highly purified human IFNγR (Aguet, Dembic et 
al. 1988).  Expressing this gene in L1210 mouse lymphocytic leukemia cells 
allowed binding of radioactive human IFNγ, but it did not result in MHC up-
regulation upon human IFNγ treatment, further confirming the necessity of a 
second human protein (at least) to confer biological activity.  The identification 
and cloning of the gene that expressed the protein that bound IFNγ in the human 
was soon followed by the cloning of the homologous gene in the mouse (Gray, 
Leong et al. 1989; Hemmi, Peghini et al. 1989; Munro and Maniatis 1989).  
Further biochemical analysis suggested that an IFNγ dimer bound to two 
molecules of IFNγR, suggesting that IFNγ binding to its receptor would induce 
dimerization (Fountoulakis, Zulauf et al. 1992), and a crystal structure would 
eventually confirm the this stoichiometry (Walter, Windsor et al. 1995). 
The identification and cloning of the second factor necessary to confer 
biological responsiveness to IFNγ was described through use of cDNA 
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complementation studies, using hamster cells expressing the human IFNγ 
binding component to screen for the human counterpart (Soh, Donnelly et al. 
1994), and monkey cells expressing the mouse IFNγ binding component to 
screen for the mouse counterpart (Hemmi, Bohni et al. 1994).   
Many cell types were demonstrated to respond to treatment with IFNγ, and 
early experiments in mice provided evidence that IFNγR expression was 
widespread, as daily I.P. injection of IFNγ for 6-9 days induced heightened 
expression of MHC class I and II in multiple cell types and organs (Skoskiewicz, 
Colvin et al. 1985).  Later experiments confirmed these results by use of 
immunohistochemistry and fluorescence-activated cell sorting (FACS) performed 
with anti-IFNγR purified rabbit polyclonal antibodies and found IFNγR expression 
in multiple lymphocytes and organs (Valente, Ozmen et al. 1992).  Therefore, it 
was likely that IFNγ would play an important role in immune responses to 
infection.   
K.  The Role of IFNγ in Virus Infections 
The first in vivo demonstration of the role of IFNγ in virus infections was 
performed using sheep anti-sera specific for IFNγ.  It was found that B6 mice 
infected with lymphocytic choriomeningitis virus (LCMV, strain Aggressive) 
treated daily with anti-IFNγ sera had increased virus loads in the livers and 
spleens, with decreased cytotoxic killer cell activity, and, paradoxically increased 
survival rates when compared to mice treated with normal sera (Leist, Eppler et 
al. 1989).  Subsequent experiments demonstrated that treatment with anti-IFNγ 
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sera one day before ectromelia infection, followed by daily treatment with anti-
IFNγ sera, resulted in a typical nonlethal footpad dose now becoming lethal in the 
anti-IFNγ treated mice (Karupiah, Fredrickson et al. 1993).  The treatment of mice 
with anti-IFNγ also significantly increased viral titers in the livers, spleens and 
ovaries.  When other investigators instead used VAC infections, they found 
similar results.  In this case continuous treatment with a monoclonal antibody 
(mAb) against IFNγ transformed a sub-lethal dose into a lethal dose, and these 
experiments further went on to demonstrate that protection afforded by adoptive 
transfer of CD8+ T cells from a mouse that had been previously infected with 
VAC, could be neutralized when mice were treated with a mAb against IFNγ 
(Ruby and Ramshaw 1991).  Further evidence that IFNγ played an important role 
in limiting pathogen spread was described in IFNγR gene knockout mice (Huang, 
Hendriks et al. 1993).  There was increased mortality in IFNγR knockout mice 
intra-venously infected with VAC-WR in comparison to wild type mice, and 
increases in the amount of virus per gram of tissue in the spleens, lungs, testes, 
and ovaries in IFNγR knockout mice when compared to wild type.  The enhanced 
amount of VAC in IFNγR knockout mice was later repeated (Muller, Steinhoff et 
al. 1994), and similar results were found in mice that lacked the gene that 
encodes IFNγ (Cantin, Tanamachi et al. 1999).  Other experiments suggested 
that IFNγ might have a direct negative effect on poxvirus replication and 
determined that both infected primary macrophages and RAW264.7 mouse 
leukemic monocyte macrophage cell lines, when treated with recombinant IFNγ 
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released decreased amounts of two poxviruses, ectromelia virus and VAC 
(Karupiah, Xie et al. 1993).  Competitive inhibition of nitric oxide activity by Nw-
methyl-L-arginine (L-NMA) would negate the virus-inhibition effect of IFNγ in 
these studies.  Subsequent studies using VAC-WR-expressing luciferase under a 
late promoter, found decreased DNA synthesis, and determined that in the 
J774.G8 monocyte/macrophage cell line, there was a dose dependent decrease 
of VAC late gene expression and total VAC DNA when macrophages were 
treated with recombinant IFNγ, and this decrease in VAC gene expression 
seemed to correlate with increased production of nitric oxide, as detected by 
examining nitric oxide intermediates in IFNγ-treated or untreated VAC-infected 
macrophages (Melkova and Esteban 1994).  In total, it was found that IFNγ was a 
protein with many immune modulating activities that could inhibit virus spread 
both directly and indirectly and might therefore be an interesting target to inhibit 
virus spread or increase immune reactivity. 
L.  Poxvirus IFNγ  Binding Proteins 
 Interestingly, poxviruses were already targeting the IFNγ pathway.  
Analysis of a major secretory protein encoded by the myxoma poxvirus revealed 
a protein that was found to have 20% amino acid identity to the extracellular 
domain of the IFNγR with homologs in many other poxviruses including VAC 
(Upton, Mossman et al. 1992).  Further analysis demonstrated that this protein 
(T7) was able to bind IFNγ, and when T7 was mixed with IFNγ, it was able to 
block the IFNγ-mediated inhibition of VSV-induced CPE.  Later studies confirmed 
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that multiple poxviruses, including VAC-WR, cowpox, camelpox (Alcami and 
Smith 1995), and in a separate study shope fibroma, VAC (WR and IHDW), 
ectromelia, cowpox, and rabbitpox viruses (Mossman, Upton et al. 1995) all 
encoded proteins that could bind IFNγ.  Human, bovine and rat IFNγ bound the 
soluble IFNγ receptor encoded by VAC-WR, cowpox, or camelpox with similar 
affinities, but the IFNγ-binding protein encoded by VAC (B8R) had lower affinity 
for mouse IFNγ (Alcami and Smith 1995).  In a separate study, ectromelia T7 was 
found to bind to human, murine, and rabbit IFNγ, but, as described above, B8R 
had lower relative affinity to mouse IFNγ than to human or rabbit IFNγ (Mossman, 
Upton et al. 1995).  It is known that human IFNγ will not bind cells that express 
murine IFNγR (Finbloom, Hoover et al. 1985), and that murine IFNγ will not bind 
to cells that express either hamster IFNγR or human IFNγR (Langer, Rashidbaigi 
et al. 1986), so the finding that B8R did not bind to mouse IFNγ may not be 
surprising. 
 To more closely examine the role of the B8R protein, many groups 
created VAC variants in which the gene encoding B8R was knocked out.  The 
first description of B8R knockout VAC was done through homologous 
recombination of VAC-WR, and compared the virus to the parental strain, and 
also created a recombinant B8R knockout in an already recombinant VAC that 
expressed VSV for easier analysis of the antibody response (Verardi, Jones et al. 
2001).  In these experiments, supernatants from B8R knockout (B8R-/-) VAC-
infected HeLaS3 epithelial carcinoma cells could not block IFNγ-mediated 
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inhibition of encephalmyocarditis virus (EMCV)-induced CPE as could 
supernatant from VAC wild type infected cells, thereby confirming the lack of B8R 
protein activity.  The knockout viruses grew as well as the wild type VAC in vitro 
on A459 lung adenocarcinoma cells and L929 cells.  Interestingly, there was 
decreased weight loss and lethality in CB6F1 mice I.N. infected with B8R-/- VAC 
when compared to wild type VAC-infected mice, and decreased lethality in nude 
mice I.P. infected with B8R-/- VAC when compared to infection with wild type 
VAC, with similar amounts of VAC-specific neutralizing antibody induced by intra-
muscular infection of any of the four viruses.  A second group created two B8R-/- 
VAC variants (WR and PrHa strain) and found that knocking out the B8R gene 
eliminated the capacity of supernatant from VAC-infected CV-1 African Green 
monkey kidney cells to crosslink to human and mouse IFNγ, confirming the 
knockout VAC (Sroller, Ludvikova et al. 2001). Furthermore, they showed that 
intra-dermal inoculation of B8R-/- VAC induced smaller lesions than wild type 
VAC when infecting on either side of the dorsal spine in rabbits.  In a third study, 
B8R-/- VAC-WR were generated alongside a recombinant that instead of B8R, 
expressed the mouse IFNγR α-chain truncated after Ser-257 so as to be 
secreted as an IFNγ binding protein, and named the virus “virus that expressed a 
soluble version of the mouse IFNγR” (vsmIFNγR) (Symons, Tscharke et al. 
2002).  The two recombinant VAC’s, the revertant VAC, and the parental strain 
were found to replicate similarly on African Green monkey kidney BSC-1 cells, 
but only the supernatant from vsmIFNγR VAC-infected L929 cells was shown to 
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be able to bind mouse IFNγ.  I.N. infection of mice with vsmIFNγR VAC increased 
signs of illness when compared to the B8R-/-, revertant, and parental VAC’s.  In 
an intra-dermal rabbit model of infection, B8R-/- VAC induced greater infiltration 
of inflammatory cells and this infection had decreased amounts of VAC antigen 
when compared to infection with the revertant or parental VAC’s.  The most 
recent study used an attenuated strain of VAC, VAC Lister, and generated B8R 
knockout viruses via a homologous recombination method (Denes, Gridley et al. 
2006).  This study found no difference in induction of humoral or cellular 
immunity induced by the knockout virus infection when compared to wild type 
infection.  In I.P. infection of nude BALB/c mice, the revertant VAC infection 
resulted in decreased survival, increased weight loss, and increased pock lesion 
appearance as compared to the B8R-/- VAC infection. 
 The negative influence of VAC spread by IFNγ has consistently been 
demonstrated, but the effect of deleting the B8R gene from VACV, and its effect 
on virus spread is still a matter of debate.  This is most likely due to the fact that 
many of these experiments are performed in the mouse model, and B8R has 
been shown to have low relative affinity to mouse IFNγ.  Interestingly, deletion of 
B8R from VAC does consistently attenuate the virus in rabbit models of infection, 
and studies that have examined the immune response to B8R knockout viruses 
have not found differences in poxvirus-specific immunity induced by infection.  
These results support the further examination of this knockout as a strategy to 
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decrease VAC pathogenicity, while maintaining the same immuno-protective 
phenotype of VAC infection 
M.  The Discovery of Interleukin-18 and the Interleukin-18 Receptor 
Interleukin-18 (IL-18) was first described as a co-stimulator of IFNγ 
production in Mycobacterium bovis Bacillus Calmette-Guérin-infected mice 
treated I.P. with Escherichia coli 0127:B8 lipopolysaccharide (LPS), and was 
originally termed IFNγ inducing factor (IGIF) (Nakamura, Okamura et al. 1989).   
Later reports described the purification of this activity from mouse serum, 
described it as a co-stimulator of IFNγ production and proliferation in T cells when 
combined with concanavalin A (conA), IL-2, or a mAb against CD3, and in this 
same study ruled out interleukin-1 (IL-1), interleukin-4 (IL-4), interleukin-5 (IL-5), 
interleukin-6 (IL-6) and TNF as possible candidates of this activity by use of 
neutralization antibody assays (Nakamura, Okamura et al. 1993).  Further work 
described the same activity in livers of mice challenged with Propionibacterium 
acnes (P. Acnes) (Okamura, Nagata et al. 1995), and IGIF protein induced by 
this model was used to clone and identify IGIF (Okamura, Tsutsui et al. 1995).  
Briefly, IGIF was subjected to tryptic digestion to allow sequencing of peptide 
fragments, which were then used to create a DNA probe that allowed for cloning 
from IGIF-expressing cells, and this probe was finally used to screen a cDNA 
library which allowed for identification of IGIF.  These experiments also described 
an interesting synergistic effect of interleukin-12 (IL-12) and IL-18 in inducing 
IFNγ.  Further analysis described structural homology of murine IL-1α and IL-1β 
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to murine IGIF (12 and 19% respectively) when compared by the fold recognition 
method, and when amino acid sequence homologies were compared between 
human IGIF and human IL-1α and IL-1β, the similarity was 15% and 18% 
respectively (Bazan, Timans et al. 1996).  The cloning of the human IGIF protein 
led to the designation of IL-18, and also led to the observation that conA 
stimulated peripheral blood mononuclear cells (PBMC’s) cultured with IL-18 not 
only had increased production of IFNγ when compared to cultures without IL-18, 
but also had increased production of Granulocyte-macrophage colony-stimulating 
factor (GM-CSF), and decreased production of IL-4 and interleukin-10 (IL-10).  It 
was also described that if IL-18 were combined with interleukin-2 (IL-2), there 
was an increase in NK cell mediated cytotoxicity in comparison to IL-2 treated 
cultures alone.   
Later work found that the IL-18 receptor (IL-18R) was a heterodimeric 
complex composed of an orphan receptor of the IL-1R family called IL-1Rrp (later 
IL-18Rα) (Parnet, Garka et al. 1996) and a novel member of the IL-1R family 
(later IL-18Rβ).  IL-18Rα was identified by first screening multiple cell lines with a 
radioactively labeled IL-18 (125I-IL-18) to identify a line with constitutively high 
levels of the protein that bound IL-18.  The line chosen, the L428 Hodgkins 
disease cell line was then used to immunize BALB/c mice to make a mAb to 
purify this protein, which was then subjected to tryptic digest and sequenced, and 
in sequence analysis it was discovered that the protein that bound IL-18 was 
actually an orphan receptor of the IL-1R family called IL-1Rrp (Torigoe, Ushio et 
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al. 1997).  Transfection of this protein (IL-18Rα) into COS-1 SV40-immortalized 
African green monkey kidney cells showed low-affinity binding of IL-18 (Kd46nM) 
and allowed for nuclear factor kappa β (NF-κB) activation after addition of IL-18.  
IL-18Rα (then identified as IL-1Rrp) mRNA was detected in the spleen, thymus, 
leukocytes, liver, lung, heart, small and large intestine, prostate, and placenta but 
not in the brain, skeletal muscle, kidney or pancreas (Parnet, Garka et al. 1996).  
IL-18Rβ was identified based on its homology to IL-1R AcP, and after 
demonstrating this protein had no identifiable role in IL-1 or IL-8 signaling, 
signaling through IL-18 was examined as IL-18 had been classified as a member 
of the IL-1 family of cytokines (Born, Thomassen et al. 1998).  It was then 
demonstrated that IL-R AcP (later IL-18Rβ) was not necessary for binding to IL-
18, but was instead found to be important in activation of NK-κB and c-Jun N-
terminal kinase (JNK), and thus important in downstream signaling once IL-18 
binds to its receptor. IL-18Rβ mRNA was detected in the lung, spleen, 
leukocytes, and colon, but not in the heart, kidney or muscle, mimicking many of 
the expression patterns of IL-18Rα expression.  IL-18R protein was expressed 
on a large number of cell lines including B cell, T cell, NK cell, myeloid cell, 
monocytoid cell, erythroid cell, and megakaryocytic cell lines (Nakamura, Otani et 
al. 2000).  IL-18R was also found on T helper 1 (Th1), but not T helper 2 (Th2) 
cells in a separate study (Xu, Chan et al. 1998). 
While originally identified as a co-stimulator of IFNγ production, especially 
when combined with IL-12, IL-18 was eventually found to have a broader role 
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than originally described.  IL-18 could not only work as a co-stimulator of IFNγ 
production, but IL-18 has also been shown to increase the cytotoxic capacity of 
NK cells (Tsutsui, Nakanishi et al. 1996) and Th1 cells (Dao, Ohashi et al. 1996) 
through up-regulation of FasL.  Later work demonstrated that IL-18 could have a 
more complicated role in that CD4+ T cells cultured in IL-18 produced interleukin-
13 (IL-13) and GM-CSF, especially when IL-2 was added (Hoshino, Wiltrout et al. 
1999), and found that naïve CD4+ T cells cultured in IL-2 and IL-18 without T cell 
receptor (TCR) engagement for 4 days expressed CD40 ligand (CD40L) and 
produced large amounts of IL-13 and IL-4,  and that anti-CD3 stimulation of these 
cells now allowed them to develop into Th2 cells (Yoshimoto, Mizutani et al. 
2000).  If this same protocol was repeated, but anti-IL-4 was added to the culture, 
Th1 cells developed, suggesting that IL-18 might play a complicated role in 
differentiation of T helper subsets, depending on conditions available.   
N.  Interleukin-18 Binding Protein, and An Interleukin Binding Protein 
Encoded By Poxviruses 
While trying to identify the IL-18R, one group was able to purify a protein 
that bound IL-18 from human urine and named this protein sIL-18R for soluble IL-
18 receptor.  In an early review, there was speculation that the IL-18R might be a 
heterodimer with the newly identified sIL-18R as the major determinant of IL-18 
binding in the heterodimer, as the IL-18R identified at that time did not have high 
affinity to IL-18 (Dinarello, Novick et al. 1998).  The then named sIL-18R was 
able to prevent LPS-induced IFNγ production as did neutralizing antibodies to IL-
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18, but did not affect IFNγ production after stimulation with the mitogen conA, 
once again much like IL-18 neutralizing antibodies.  They also found that sIL-18R 
did not possess species specificity, as it neutralized both human and murine IL-
18.  It was later found that this factor was not the IL-18R or even a component of 
the receptor, but was instead a soluble IL-18 binding protein (IL-18-BP) (Aizawa, 
Akita et al. 1999; Novick, Kim et al. 1999).  Further work described the ability of 
this protein to block the binding of IL-18 to the IL-18R, although the IL-18BP 
shares no amino acid or structural homology to either IL-18R component.  It is 
now thought that the IL-18BP works as a soluble decoy receptor, analogous to 
the membrane associated IL-1R2 for Type 1 interferon signaling, and might work 
as a soluble regulator of IL-18.   
In examining poxviruses, a number of proteins were found that seemed to 
have a similar function as the IL-18BP.  Originally, two proteins, MC53L and 
MC54L, from the human poxvirus molluscum contagiosum were tested and found 
to both bind IL-18 and inhibit IL-18’s IFNγ stimulatory capacity, with MC53L 
having slightly higher affinity to IL-18 and a greater ability to inhibit IL-18’s IFNγ 
stimulatory capacity (Xiang and Moss 1999).  A later study described a protein in 
ectromelia virus that acted as an IL-18 decoy receptor (p13) (Born, Morrison et 
al. 2000).  This viral protein was also shown to bind IL-18, and inhibit IL-18-
induced NFκB reporter activity as determined by a luciferase assay.  It was also 
demonstrated that peritoneal exudate cells (PEC’s) of mice infected with a p13 
knockout ectromelia virus had increased NK cell activity as measured by a YAC 
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killing assay with no increase in NK cell numbers at days 2 and 3 when 
compared to mice infected with a wild type ectromelia virus.  Subsequent 
analysis also revealed that the p13 deletion virus exhibited decreased levels of 
infectivity at day 3 when compared to wild type ectromelia virus.  Finally, a later 
study provided evidence confirming the existence of the two IL-18BP’s in 
molluscum contagiosum, but importantly went further and also described proteins 
that bound IL-18 in cowpox, VAC Ankara, VAC Lister, VAC-WR, and MVA, with a 
deletion in VAC Copenhagen (Smith, Bryant et al. 2000).  The VAC IL-18 binding 
activity was subsequently mapped to the C12L open reading frame by other 
researchers, who then described the creation of a C12L knock out (C12L-/-) in 
VAC-WR (Symons, Adams et al. 2002).  The C12L-/- VAC-WR had similar virus 
growth curves when compared to wild type or knock-in viruses when grown on 
BS-C-1 African green monkey kidney cell, but the knockout virus resulted in less 
weight loss and signs of illness when BALB/c mice were infected I.N..  In later 
work, the same group once again demonstrated the decreased weight loss and 
signs of illness when mice were infected I.N. with the C12L-/- VAC-WR as 
compared to wild type or revertant, but also went on to show decreased viral 
titers in the lungs and brains of mice infected with the C12L-/- VAC-WR (Born, 
Morrison et al. 2000).  Further experiments found that mice infected with the 
C12L-/- VAC-WR had increased NK and T cell cytotoxicity measured by 
chromium release assays, with greater amounts of IFNγ in bronchiolar lavage 
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exudates and increased IFNγ production in lung CD4+ T cells and CD8+ T cells 
when compared to mice infected with the wild type or revertant virus.  
Work that had occured shortly before identification of poxvirus-encoded IL-
18-BP’s had demonstrated that I.P. treatment of BALB/c mice with IL-18 two 
hours after intra-venous VAC-WR inoculation limited pock formation.  These 
studies also described increased NK and cytotoxic T lymphocyte (CTL) killing 
activity in mice I.P. treated with IL-18 after infection, so it had been known that IL-
18 treatment could limit the pathogenicity of a poxvirus infection before an IL18-
BP was described (Tanaka-Kataoka, Kunikata et al. 1999).  
This work thus demonstrates that infection with VAC in mice is attenuated 
by treatment with IL-18, and that IL-18BP knockout virus variants of the 
poxviruses ectromelia and VAC are significantly attenuated in mouse models of 
infection.  This supports the further examination of this knockout as a strategy to 
decrease VAC pathogenicity, while maintaining the same immuno-protective 
phenotype. 
O.  The Complement Cascades 
 The observation that blood did not seem to decompose as quickly as other 
organic material, and that it might have some bactericidal effect had been 
suggested early on, but experimental investigations of this effect and therefore of 
the complement system only started in the late 1800’s.  The work is commonly 
described to have begun with the demonstration that defibrinated but not heat 
inactivated blood of Anthrax bacilli inoculated animals, when mixed with Anthrax 
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bacilli, had a measurable destructive effect on the bacteria (Nuttall 1888).  In 
work that quickly followed with Clostridium tetani and Corynebacterium 
diphtheria, the specific anti-bacterial activity was confirmed, the observation that 
this activity could be passively transferred to other animals was described, and 
the bactericidal factor was named “alexin” (von Buchner 1889) (from reviews  
(Zinsser 1918; Crist and Tauber 1997; Cooper 2006).  This work was extended 
upon in what was eventually termed “Pfeiffer’s Phenomenon”, wherein lysis of 
Vibrio cholera occurred in the peritoneal fluids of animals injected with attenuated 
Vibrio cholera, and also re-demonstrated that the activity could be passaged to 
other animals and was pathogen-specific, and also that the effect was not heat 
labile.   Further examinations of the phenomenon demonstrated that this effect 
could be separated into two activities in the sera, one that would agglutinate the 
blood and was not heat labile (55 or 56°C for half hour), and the other component 
was found to be heat labile but was the component responsible for the lytic 
activity (Bordet 1896; Bordet 1898) (from reviews (Zinsser 1918; Crist and 
Tauber 1997; Cooper 2006), and this heat labile component was subsequently 
termed complement (Ehrlich and Morgenroth 1899).   
As more work was done on the complement phenomenon, it became clear 
that there was more than one factor at work.  This was evidenced early on by 
separation of the complement activity into two components, a water soluble and 
insoluble fraction neither having the complement activity alone (von Buchner 
1889).  Later work confirmed this and demonstrated that the insoluble fraction 
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bound antibody with the soluble fraction imparting lytic activity (Ferrata 1907).  
Eventually a third heat stable component of complement was described by the 
removal of complement activity by yeast cells followed by addition of a heat-
inactivated guinea serum (Flexner and Noguchi 1902; A.F. 1914).  Further 
experiments built on these observations, and described inactivation of the third 
component more reliably using zymosan-treated sera, and this third component 
became known as the third component or heat stable component of complement 
(Whitehead, Gordon et al. 1925).  This same group later demonstrated that 
treatment with ammonia could destroy another heat stable component, and that 
zymosan-treated and ammonia-treated sera could complement one another, and 
therefore demonstrated a fourth component of the complement cascade 
(Gordon, Whitehead et al. 1926).  The complement components were numbered 
in order of their discovery, but the biological order of action of the four 
components of complement was eventually biochemically worked out to be C1, 
C4, C2, C3 (Bier, Leyton et al. 1945).  It was eventually determined through 
chromatography on diethylaminoethyl (DEAE) cellulose that the first component 
of complement was made up of three separate proteins (C1q, C1s, and C1r), and 
that these individual three components were necessary for the C1 factor to 
function.  Further biochemical characterizations describe C1 (C1q) as the early 
binder of antibody-antigen complexes (Augener, Grey et al. 1971), and once 
bound, the complex now had proteolytic activity (C1s) (Becker 1956).  This 
cleaves C4 (Borsos and Rapp 1963) and C2 (Polley and Muller-Eberhard 1968) 
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into components C4b and C4a and C2b and C2a.  C4b then binds C2a and 
cleaves C3 (Muller-Eberhard, Polley et al. 1967), thus activating it, and the 
C4bC2a complex acts as a C3 convertase, enzymatically cleaving C3 to C3b and 
C3a, and C3b then binds to the surface of pathogens or cells allowing for 
opsonization or lysis (Figure 1.1A).  Thus, the early cascade of the main mediator 
of lysis of antibody treated pathogens or cells, either directly or through 
opsonization, had now been worked out.  The latter part of the pathway which 
leads to formation of a membrane attack complex allowing for direct pathogen or 
cellular lysis is reviewed here (Muller-Eberhard 1986).   
The story becomes more interesting with the identification of two other 
pathways that activate the complement cascade.  The first was originally 
described as a factor dubbed properdin that would activate the complement 
cascade, resulting in lysis of certain red cells, bacteria (Shigella dysenteria) and 
inactivation of infectivity of viruses (Pillemer, Blum et al. 1954).  This original 
observation was soon suggested to instead be an artifact caused by residual 
natural antibody (Nelson 1958).  Subsequent studies indirectly suggested that 
there was an alternative way of inducing the complement cascade, as edema 
and hemorrhage to injection of two purified anti-human serum albumin (HSA) 
antibodies along with purified HSA was detected in C4 deficient guinea pigs 
(Ellman, Green et al. 1970), and this reaction in previous studies had been 
demonstrated to be complement dependent (Maillard and Zarco 1968; Cochrane, 
Muller-Eberhard et al. 1970).  Other in vitro work demonstrated that endotoxin 
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and antigen-antibody complexes could induce the late activities of the 
complement cascade (Frank, May et al. 1971).  As evidence mounted, the 
isolation of the initiator protein of this alternate system was described (Gotze and 
Muller-Eberhard 1971) and finally purified and described as a β- pseudoglobulin.  
This initiator protein was eventually named Factor B.  A second factor was found 
to be important in this alternate pathway (Muller-Eberhard and Fjellstrom 1971), 
and it’s subsequent isolation and naming as Factor D happened soon afterwards 
(Hunsicker, Ruddy et al. 1973).  In this pathway, C3 undergoes spontaneous 
hydrolysis that allows Factor B to bind. Factor D can now cleave Factor B into 
two portions, Bb and Ba, and this becomes a positive feedback loop as the C3Bb 
can now cleave more Factor B.  Thus an alternative manner to activate the 
complement cascade was described and named the alternative complement 
pathway (Figure 1.1B). 
The second description of an alternative manner in which to activate 
complement started with the description of a mannose binding lectin (MBL).  MBL 
recognizes sugars normally only exposed on envelopes of non-vertebrate origin 
(Robinson, Phillips et al. 1975).  Further work described the action of MBL in 
conjunction with proteins later named MBL serine proteases (MASP’s 1 and 2) 
(Takayama, Takada et al. 1994) that acted similarly to C1s and C1r.  This 
MBL/Masp1,2 complex was found to activate the classical pathway of 
complement by activating C4, C2 and finally C3 as was demonstrated in the 
classic model of complement activation, and so this was described as a separate 
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way to activate the classic complement pathway without need of antibody-
antigen complexes.  As the complement pathway can lead to direct cell lysis, 
there are many proteins that serve to control initial activation and serve to shut 
down the pathway.  One of these inhibitor pathways involves a C4 binding 
protein (C4BP) that works with a second protein, the C3b inactivator (C3bINA, 
later named Factor I) to degrade C4b and to a lesser extent C3b to limit 
complement activation (Gigli, Fujita et al. 1979), and evidence suggests that 
poxviruses have taken advantage of the this pathway to limit complement 
activation and virus spread after infection (Figure 1.1A). 
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A.  (Adapted from Figure 2.11, 2.13 (Janeway, Travers et al. 2005)). 
 
B.  (Adapted from Figure 2.17 (Janeway, Travers et al. 2005)). 
Figure 1.1.  The complement cascade.   
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Figure 1.1.  The complement cascade.   
(A) C1q or MBL binds antigen, with C1q binding antigen/antibody complexes, 
releasing restriction by C1r of C1s, (or MBL binding pathogen activating 
MASP’s).  These cleave and activate C4 to C4b and C4a.  C4b binds C2 allowing 
cleavage of C2 to C2b and C2a, C4bC2a acts as a C3 convertase cleaving C3 to 
C3b and C3a.  (Adapted from Figure 2.11, 2.13 (Janeway, Travers et al. 2005)). 
(B) Auto-hydrolyzed C3b binds surface of pathogen, C3b binds Factor B, bound 
Factor B is cleaved by Factor D, producing Bb and Ba.  C3bBb acts as C3 
convertase.  (Adapted from Figure 2.17 (Janeway, Travers et al. 2005)). 
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P.  A Poxvirus Encoded Inhibitor of the Complement Cascade 
 Early work examining the in vivo effect of complement on poxvirus 
infections was done using fowlpox, and it was found that the alternative 
complement cascade worked to inhibit fowlpox virus spread in chicken embryo 
cells (Ohta, Kai et al. 1983).  A follow-up using cobra venom factor (CVF) to 
inhibit the complement cascade, found that chickens treated for three days with 
CVF following sub-lethal fowlpox all died by day 10, with significant virus 
dissemination and a 2 log increase in virus in poxvirus lesions (Ohta, Yoshikawa 
et al. 1986).   This early work demonstrated the importance of complement in 
limiting poxvirus pathogenicity.  In work examining the major proteins secreted 
from VAC-WR-infected RK-13 rabbit kidney cell, two important immune 
modulators were discovered.  One of these secreted proteins had previously 
been identified as a protein with structural similarity to epidermal growth factor 
(EGF) (Blomquist, Hunt et al. 1984; Brown, Twardzik et al. 1985; Reisner 1985) 
and was subsequently shown to behave similarly to EGF in vitro (Twardzik, 
Brown et al. 1985; King, Cooper et al. 1986) and in vivo (Buller, Chakrabarti et al. 
1988).  The other was found to have structural similarity to the superfamily of 
complement control proteins.  This protein was predicted to be most similar to the 
C4BP component of this superfamily and was later found to act similarly to C4BP 
in that virus supernatant from wild type infected RK-13 cells but not knockout 
virus-infected cells could inhibit the classical complement cascade as assessed 
by inhibition of human complement-mediated lysis of IgM sensitized red blood 
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cells, but not the alternative complement pathway (Kotwal and Moss 1988).  A 
more purified isolation of the proteins did the same and was also found to bind to 
C4b-coated red blood cells and block binding of these coated cells to human 
erythrocytes, which have a C3b/C4b receptor on their cell surface (Kotwal, 
Isaacs et al. 1990).  Interestingly, a later study using inhibition of virus growth to 
measure VAC-specific antibody-enhanced complement inhibition found that not 
only was the classical complement pathway inhibited but now also found that the 
alternative complement pathway was inhibited by the complement binding protein 
(Isaacs, Kotwal et al. 1992).  This work also mapped and named the VAC 
complement binding protein (C21L, or C3L), and after generating a knockout 
VAC-WR variant, found that intra-dermal infection with the C21L knockout VAC-
WR on the shaved back of rabbits resulted in decreased lesion size when 
compared to VAC-WR wild type inoculation, and this difference was noted in both 
wild type and C4-deficient rabbits starting at about Day 5.  These in vivo results 
are consistent with the idea that the knockout virus has decreased virus spread, 
leading to decreased inflammation, after an antibody response begins to be 
generated due to the lack of a protein that inhibits complement, and suggests 
that both the classical and alternative complement cascade are inhibited.  As it 
was found that both the classical and alternative pathway of the complement 
cascade was inhibited, it did not seem likely that C21L only inhibited complement 
by binding C4b.  Later experiments indeed confirmed that not only did C21L bind 
C4b allowing for degradation by Factor I, but also bound C3b, which also 
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increased Factor I’s degradation of C3b (McKenzie, Kotwal et al. 1992; Sahu, 
Isaacs et al. 1998).  These results suggest that C21L limits inflammation and 
poxvirus spread, and this was later confirmed using a knockout cowpox virus 
infection of mice (Miller, Shchelkunov et al. 1997), and the results in total suggest 
that C21L might be an attractive knockout target to limit poxvirus spread while 
inducing a comparable or stronger immune response when designing 
recombinant VAC.   
Q.  The Discovery and Cloning of Fas and Fas Ligand 
The control of an infecting pathogen by a host immune response requires 
the tightly coordinated action of many cell subtypes and soluble mediators that 
work in tandem to eliminate or contain the infecting pathogen.  This response 
must be swift, specific and tightly regulated so as not to cause more harm than 
necessary to the host than required to fend off the pathogen.  Unfortunately, in 
some individuals there are mutations that predispose them to autoimmune 
disorders where an immune response will develop and result in cellular or 
humoral attack against the host’s own tissues. 
One family of genetic mutations that can often lead to autoimmune 
disorders in individuals are mutations in the genes encoding the Fas and FasL 
proteins and genes encoding proteins in the Fas and FasL signaling pathways. 
Fas was first described when the screening of a library of >20,000 hybridoma 
clones revealed a clone which produced an antibody that had cytolytic activity 
against a variety of human cell lines(Yonehara, Ishii et al. 1989).  The cytolytic 
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activity of the anti-Fas antibody was found to be similar in many ways to the 
cytolytic effect that had been previously noted when cells were treated with 
recombinant tumor necrosis factor α (TNFα), in that the cytolytic effect of the 
antibody was enhanced after treatment with IFNγ, mitomycin C, a DNA cross-
linker that induces cell death, actinomycin D, a transcriptional inhibitor, or 
cycloheximide, a protein synthesis inhibitor, and also seemed to induce cell 
death on most cell types that TNFα worked on as well.  Interestingly, there were 
human cell lines where the anti-Fas antibody, but not TNFα, induced cytotoxicity.  
Further results suggested that the anti-Fas antibody worked on a protein that did 
not bind TNFα.  Pull-down experiments with the anti-Fas antibody revealed a 
protein of a different size than the TNF receptor (TNF-R).  It was found that in 
cells that were responsive to anti-Fas but not TNFα, there was no detectable 
down-regulation of TNF-R after treatment with the anti-Fas antibody, and that 
TNFα treatment did not down-regulate Fas, but did down-regulate the TNF-R.  In 
parallel, a separate cytolytic mAb was described that reacted with a cell surface 
protein named Apo-1, and this interaction also induced apoptosis, but in this 
study the protein was described as being expressed on activated lymphocytes as 
well as malignant cells lines of leukemic origin (Trauth, Klas et al. 1989).  Further 
investigations into the cell surface protein that the anti-Fas antibody bound led to 
the identification and cloning of the Fas gene (Itoh, Yonehara et al. 1991).  To 
confirm that the gene cloned was indeed necessary for anti-Fas antibody-
apoptosis, it was then demonstrated that recombinant expression of this gene in 
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a cell that is not normally sensitive to anti-Fas antibody induced apoptosis 
rendered the cell susceptible to apoptosis induced by the antibody.  
Characterization of the cell surface receptor that bound the anti-Apo-1 antibody 
revealed that anti-Fas and anti-Apo-1 antibody were binding to the same protein 
(Oehm, Behrmann et al. 1992).  It was also demonstrated that the Fas protein 
belonged to the same family as both the TNF-R and the low-affinity nerve growth 
factor receptor.  The subsequent isolation of the gene that encoded the Fas 
protein in mice allowed for the examination of mRNA expression in different 
tissues, and it was found that Fas mRNA was detected in the liver, ovaries, 
thymus, and heart, but not in mouse spleens or brain, and that IFNγ up-regulated 
Fas mRNA expression in L929 and macrophage BAM3 cell lines (Watanabe-
Fukunaga, Brannan et al. 1992).   
The identification of the protein that bound Fas was done by use of a Fas-
Ig antibody to enrich high expressors of Fas in a d10S-2 murine Th2 cell line 
from AKR/J mice, which then allowed for creation of a cDNA library and the 
eventual cloning of the FasL protein (Suda, Takahashi et al. 1993).  This protein 
was a type II transmembrane protein of the TNF family, and further experiments 
demonstrated that expression of FasL on COS cells conferred the cells with the 
ability to kill Fas-expressing cells, and that the concentrated supernatant of FasL-
expressing COS cells was able to induce apoptosis in Fas-expressing cells.  The 
biochemical processes that led to apoptosis still needed to be worked out. 
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R.  Fas/Fas Ligand Signaling in Inducing Apoptosis 
 It is clear that FasL can induce cells expressing Fas to undergo apoptosis, 
and one of the first actions observed after FasL interacts with Fas was 
aggregation of Fas, first demonstrated using apoptosis-inducing antibodies 
(Dhein, Daniel et al. 1992).  This aggregation was later demonstrated to quickly 
(within 1 second) recruit a set of four factors termed CAPS (cytotoxicity-
dependent APO-1 associated proteins) to form a DISC (death-inducing signaling 
complex), but only with apoptosis inducing antibodies, whose formation was 
shown to be required to induce cell death by use of truncated Fas proteins 
(Kischkel, Hellbardt et al. 1995).  These studies also identified CAP1 and CAP2 
as “phosphorylated mediator of receptor induced toxicity 1”/ “Fas associated 
protein with death domain” (MORT1/FADD), which had recently been described 
as proteins that interacted with Fas through homologous domains known as 
death domains (DD) (Boldin, Varfolomeev et al. 1995; Chinnaiyan, O'Rourke et 
al. 1995).  These studies were soon followed by the identification of CAP3 and 
CAP4. In one study, this was accomplished through nanospray mass 
spectrometry, and the CAP3 and CAP4, which were found to be the same 
protein, was named FADD-homologous ICE/CED-3–like protease (FLICE) 
(Muzio, Chinnaiyan et al. 1996).  In a second study, the same protein was 
identified through two-hybrid screening with FADD, and the protein was named 
MORT1-associated CED-3 homolog (MACH) (Boldin, Goncharov et al. 1996).   
The identification of these binding partners of FADD, MACH and FLICE which 
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were eventually identified as the same protein, caspase 8, and of an inhibitor of 
the apoptosis inducing complex termed FLICE inhibitory protein (FLIP) that was 
found to bind and inhibit caspase 8 and FADD (Irmler, Thome et al. 1997) 
resolved the major components of the DISC.  Caspase 8 activation was 
eventually shown to initiate apoptosis through two pathways, one involving 
activation of caspase 3 by caspase 8 through high level DISC formation, and the 
other through activation of a protein named BH3 interacting domain death 
agonist (BID) to activate the mitochondrial apoptosis pathway directly (Li, Zhu et 
al. 1998; Luo, Budihardjo et al. 1998; Scaffidi, Fulda et al. 1998).  (Figure 1.2) 
Interestingly, in examining in vitro proliferation of human T cells, Fas co-
stimulation was described to increase levels of proliferation in comparison to CD3 
stimulation alone (Alderson, Armitage et al. 1993).  This proliferation was 
eventually shown to depend on caspase activation (Kennedy, Kataoka et al. 
1999), and in murine transgenic CD4+ T cells, also seems to be controlled by 
NKκB signaling (Maksimow, Soderstrom et al. 2006).   
The description of the Fas and Fas L interaction, signaling pathways and 
the cloning of the genes, allowed for the identification of the cause of two mouse 
lupus-like lymphoproliferative disorders that had previously been of unknown 
etiology. 
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Figure 1.2.  Fas-FasL signaling.  (Adapted from Figure 1 (Strasser, Jost et al. 
2009)). 
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Figure 1.2.  Fas-FasL signaling.   
FasL interacts with Fas inducing trimerization. This leads to the formation of the 
DISC, which includes two FADD proteins and two caspase 8 proteins that 
interact through DD.  cFLIP can inhibit this interaction through binding of caspase 
8 or FADD.  Activation of caspase 8 in high amounts allows cleavage of caspase 
3, leading to apoptosis. Alternatively BID is cleaved, which can be inhibited by 
Bcl-2, and BID cleavage cleaves Bax allowing for cytochrome C release from the 
mitochondria, leading to apoptosis through induction of the apoptosome. 
(Adapted from Figure 1 (Strasser, Jost et al. 2009)). 
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S.  The lpr and gld Mouse Models of Lupus 
The first of these lymphoproliferative disorders had been dubbed lpr, and 
the disorder had been originally described during derivation of the MRL/MpJ 
mouse strain, which was a cross of the  AKR/J, B6, C3H/Di, and LG/J strains 
(Murphy and Roths 1978).  This disorder (lpr) was found to mimic mouse models 
of lupus such as the NZW/B mice in that, at 6 months of age, there was an 
increase in the number of immune complexes in the sera, in the amount of anti-
double stranded and anti-single stranded DNA activity in the sera, and in total 
and anti-nuclear antibody in the sera when compared to BALB/c mice (Andrews, 
Eisenberg et al. 1978).  There was also a marked increase in mouse mortality in 
these lupus prone animals, with mice typically succumbing to glomerulonephritis, 
with a severe lymph node hyperplasia noted at the end of life.  These symptoms 
in many ways mimicked symptoms of humans with systemic lupus 
erythematosus (SLE).  When first describing the MRL/Mp lpr (MRL-lpr) mouse 
there was some question as to whether the lupus-like disorder was multigenic, or 
derived from a single mutation.  Further studies that examined B6 mice crossed 
to MRL-lpr mice (B6-lpr) suggested that there might be a single region change in 
lpr mice that had a profound role in the lupus-like disorder.  It was found that B6-
lpr mice had increased levels of antibody against double stranded DNA (dsDNA) 
as did MRL-lpr mice, although the disorder occurred at a later time point than in 
MRL-lpr mice (Pisetsky, Caster et al. 1982).  Subsequent studies where the lpr 
mutation was backcrossed to C3H/HeJ (C3H), B6, and AKR/J mice at least 8 
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times confirmed the observation that the lpr region belayed a large part of the 
lupus-like disorder.  C3H and B6 mice with the lpr mutation had a significantly 
reduced lifespan when compared to their wild type counterparts, although life 
span could not be examined in AKR/J mice as these mice spontaneously 
develop and die of thymic lymphoma.  All three lpr strains had increased 
lymphadenopathy at four months of age when compared to their counterpart wild 
type mice (Izui, Kelley et al. 1984).  All three lpr strains also had increased 
amounts of antibody against single stranded DNA (ssDNA), increased amounts 
of anti-IgG antibody, and increased levels of IgM and IgG immune complexes by 
six months of age when compared to their respective wild type counterparts.  
These studies provided strong evidence that a single genetic region imparted a 
significant portion of the lpr phenotype. 
Further work included the description of a new strain of mice designated 
lprcg (lpr complementing gld) that had a similar lymphoproliferative disorder, that 
by backcrossing studies was identified to very likely be a mutation in the same 
region as the original lpr mutation (Matsuzawa, Moriyama et al. 1990).  The same 
group that had cloned Fas in the mouse next examined MRL-lpr and C3H/HeJ lpr 
(C3H-lpr) strains of mice and found that there was no Fas mRNA detected in the 
lpr strains tested, even after cDNA conversion and amplification by polymerase 
chain reaction (PCR), and this loss of Fas mRNA was attributed by Southern 
blots to a re-arrangement of exon 2 in the Fas gene (Watanabe-Fukunaga, 
Brannan et al. 1992).  When analysis of the lprcg mutation was examined, it was 
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found that Fas mRNA was expressed from cells that contained the lprcg mutation, 
but that there was a single point mutation in the Fas gene, and when this gene 
was expressed in L929 cells, which are not sensitive to Fas-antibody induced 
apoptosis, it did not impart sensitivity to Fas-antibody induced apoptosis while 
the wild type gene did.  Later studies from the same laboratory determined that 
the lpr mutation was likely due to insertion by retrotransposition of the RMg2 
early transposable element (ETn) (Shell, Collins et al. 1990) into intron 2 of the 
Fas gene, and while no Fas mRNA could be detected in the lpr mice, 
experiments inserting the RMg2 ETn into an intron of an unrelated gene 
encoding granulocyte colony stimulating factor (G-CSF) suggested that the 
insertion might only severely depress expression of functional protein, and 
therefore the lpr mutation might not behave like a full Fas-null mutation (Adachi, 
Watanabe-Fukunaga et al. 1993).  Later results would support this hypothesis, 
with some of the strongest evidence resulting from the Fas knockout mouse.  It 
was discovered that B6 Fas-null mice developed lymphadenopathy, 
splenomegaly, and increased Ig levels much sooner than even the most severe 
strain of lpr, MRL-lpr mice (Adachi, Suematsu et al. 1995; Adachi, Suematsu et 
al. 1996). 
The second murine lymphoproliferative disorder described by the 
identification of the Fas and FasL pair was originally discovered in C3H mice 
after the lpr mutation was suggested to be generated by a single mutation, and 
was termed gld (generalized lymphoproliferative disorder) (Roths, Murphy et al. 
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1984). C3H/HeJ gld (C3H-gld) mice seemed similar to MRL-lpr mice in many 
ways, in that they had an early onset lymphoid hyperplasia, increased amounts 
of all Ig classes tested, increased amounts of antibodies that bound dsDNA, 
decreased life spans, and increased amounts of anti-nuclear antibodies when 
compared to the normal C3H wild type mice.  Although there were many 
similarities, it was determined through linkage studies that the lpr and gld were 
not allelic, and initial results suggested that disease onset in C3H-gld mice was 
different from MRL-lpr mice in that the C3H-gld lymphoproliferation was followed 
by a regression of lymph node size before the lymphoproliferation set back in.  
Furthermore, the life span of C3H-gld mice was increased when compared to 
MRL-lpr mice.  MRL-lpr typically died of glomerulonephritis and C3H-gld died of 
chronic interstitial pneumonitis, and the marked lymphoid infiltrates of the kidney, 
liver and other organs normally found in MRL-lpr mice were not found in the 
C3H-gld mice.  Further analysis of the lpr or gld mutations on the same 
background, C3H, suggested that the mutations might be in a similar pathway 
(Izui, Kelley et al. 1984; Davidson, Holmes et al. 1985), with some suggesting 
that the lpr and gld mutations might be in the same metabolic system (Davidson, 
Holmes et al. 1985).  Later studies directly comparing C3H-lpr and C3H-gld mice 
demonstrated the outgrowth of a very similar abnormal Thy1.1+B220+CD4-CD8- 
cell population in both sets of mice (Davidson, Dumont et al. 1986).  Further 
studies demonstrated similar increased total IgM and IgG serum levels, ssDNA 
binding IgM and IgG in sera, and dsDNA binding IgM and IgG in the sera of C3H-
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lpr and C3H-gld mice when compared to wild type C3H mice, supporting the idea 
that the lpr and gld mutations were different mutations in a single pathway 
(Seldin, Reeves et al. 1987).  Studies examining the phenotype of lprcg mice 
crossed with gld mice described an ameliorated lymphoproliferative phenotype 
when compared to either the lprcg mice or gld mice, further supporting the idea 
that lpr and gld mutations were in the same metabolic pathway (Matsuzawa, 
Moriyama et al. 1990).  Interestingly, when bone marrow chimera experiments 
were performed, it was postulated that the lpr and gld mutations might not be in 
the same metabolic pathway, but that the lpr and gld mutations might be 
individual mutations on interacting proteins (Allen, Marshall et al. 1990).    
The cloning and description of Fas, and shortly thereafter FasL, and the 
evidence that the lpr and gld mutations might be individual mutations on 
interacting molecules helped lead to the discovery that the gld mutation was an 
inactivating mutation of FasL (Takahashi, Tanaka et al. 1994).  Initial analysis 
indicated no gross realignments in the FasL gene in gld mice, and no differences 
in the levels of FasL mRNA as had been observed with Fas mRNA in lpr mice, 
but further analysis through sequencing described a point mutation in gld FasL 
DNA, and described that expressing this variant of FasL into COS cells did not 
confer the ability to kill Fas expressing cells as would expression of the non-gld 
FasL gene.   
Later experiments suggested, that as with the lpr mutation, the gld 
mutation might also be leaky (Adachi, Suematsu et al. 1995), and the eventual 
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description of a mouse with the FasL gene floxed, and then ubiquitously knocked 
out provided evidence that this was the case (Karray, Kress et al. 2004). These 
experiments demonstrated that B6 FasL-null (B6-FasL-/-) mice developed 
hypergammaglobulinemia, splenomegaly, and lymphadenopathy at earlier time 
points than B6-gld mice, with residual ability to induce Fas-mediated cytotoxicity 
in splenocytes from B6-gld as compared to B6-FasL-/-  splenoctyes. 
T.  Deleterious Mutations In Fas and FasL In Humans Are Associated With 
Autoimmune Lymphoproliferative Disorders (ALPS) 
 The identification of Fas and FasL as the mutations that led to the severe 
lymphoproliferative disorders in the lpr, lprcg, and gld mutations, suggested that 
mutations in this gene family might also explain some autoimmune 
lymphoproliferative disorders (ALPS) in humans.  In publications quickly following 
the identification of Fas as the mutant gene in lpr mice and lprcg mice, mutations 
in Fas that led to either decreased protein levels, or decreased activity were 
found in patients with ALPS.  In the first example, three children with ALPS were 
described to have two separate mutations in the Fas gene (Rieux-Laucat, Le 
Deist et al. 1995).  All three patients had a significant population of CD3+CD4-
CD8- cells (as seen in lpr and gld mice) and the patient with the most severe 
phenotype (hemolytic anemia, neutropenia, and thrombocytopenia) had a 290 
nucleotide base pair (BP) knockout in the Fas gene, with very little Fas protein 
detected on the surface of activated cells, and little apoptosis induced by mAb to 
Fas.  The other two patients were found to have a 2BP frame shift in one copy of 
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the Fas gene that when cloned and tested in vitro, led to a decrease in Fas 
mediated apoptosis.  This gene was found to be from the mother, and a second 
unknown mutation outside of the Fas gene was suspected to derive from the 
father, as his cells were also less susceptible to Fas mediated apoptosis, 
although the mechanism was not described.  A study published very soon 
afterward also described deleterious Fas mutations in five children diagnosed 
with ALPS, also characterized by autoimmune hemolytic anemia, 
thrombocytopenia, and neutropenia, with four of the five children requiring 
removal of enlarged spleens, and one patient requiring dialysis for 
glomerulonephritis (Fisher, Rosenberg et al. 1995).  All five patients were found 
to have increased percentages of CD3+CD4-CD8- cells, and all were found to 
have mutations in the Fas gene, two mutations leading to little cell surface 
expression of the Fas protein, one mutation led to Fas that could not interact with 
anti-Fas antibody, and two mutations that could not transmit a death signal 
through Fas.  Further analysis revealed that co-expression of four of the mutant 
Fas genes with wild type Fas resulted in a dominant negative effect, where 
expression of the mutant Fas gene resulted in decreased Fas expression on the 
cell surface and decreased anti-Fas- antibody mediated apoptosis.  Subsequent 
studies associated heterozygous Fas mutations, in this case predicted to impair 
signal transduction, with Canale-Smith ALPS (Drappa, Vaishnaw et al. 1996) and 
in a broader study in kindred of ALPS patients, found a 14 and 51 times greater 
fold risk of non-Hodgkin’s and Hodgkin’s lymphomas respectively, with all 
60
patients that had lymphomas having deleterious Fas mutations resulting in 
decreased Fas mediated lymphocyte apoptosis (Straus, Jaffe et al. 2001).  A 
more recent study described an ALPS disorder in a patient caused by a 
homozygous FasL gene mutation (Del-Rey, Ruiz-Contreras et al. 2006).  This 
disorder, as were the Fas mutant disorders, was initially characterized by 
increased numbers of CD3+CD4-CD8- cells in blood, but in this case Fas induced 
apoptosis was normal and AICD was impaired, which suggested a mutation in 
FasL.  Further results demonstrated that the cells transfected with the FasL gene 
from the patient could not induce apoptosis in Fas expressing cells, while 
transfection of wild type FasL did, and subsequent analysis described a point 
mutation in the FasL gene that seemed to effect function and FasL protein 
expression. 
 The recent observation that individuals with dual hypoactive mutations of 
Fas or FasL genes have quicker recovery of their CD4+ T cell counts after 
antiretroviral therapy may suggest a different phenomenon that could be 
occurring (Nasi, Pinti et al. 2005).  A hypoactive mutation in a pathway many 
times thought to be involved in killing infected cells, or leading to an autoimmune 
disorder, may be leading to increased protection against certain high dose virus 
infections. 
U.  Measuring T Cell Diversity 
The immune response to a viral infection often involves the rapid 
proliferation of CD8+ effector T cells that recognize virus-infected targets 
61
expressing 8-11 amino acid long peptides on class I MHC molecules.  This 
recognition is mediated by membrane-bound TCR’s that are generated through 
largely random DNA recombination events of the many TCRα and β genes, 
whose encoded polypeptide chains heterodimerize to form the recognition 
structure of T cells.  The recombination of the segments also involves addition or 
deletion of nucleotides during the joining process, causing even greater diversity, 
and these processes allow for a very broad range of T cell specificities, with a 
calculated theoretical diversity of ~1015 T cell receptors in the mouse (Davis and 
Bjorkman 1988).  Using PCR, complement determining region 3 (CDR3) 
spectratyping, and sequencing techniques, it was estimated that there are 
approximately 2 x 106 distinct TCR specificities in a mouse spleen (Casrouge, 
Beaudoing et al. 2000; Baum and McCune 2006).  This is far below the 
theoretical T cell diversity, but, considering estimates of T cell degeneracy that 
propose that a single TCR can recognize up to 106 pMHC (peptide MHC) 
complexes (Mason 1998; Wilson, Wilson et al. 2004), it is likely that the 
functional diversity is much greater than the number of individual TCR’s.   
It has been of interest to calculate the number of T cells that would either 
recognize or respond to a pathogen or to a specific peptide-MHC (pMHC) 
complex.  Early estimates of the number of CD8+ T cells that are specific to a 
single virus, i.e. precursor frequencies, took advantage of an in vitro limiting 
dilution assay (LDA), and calculated CD8+ T cell virus-specific precursor 
frequencies to be on the order of 1 in 100,000 in naïve mice and predicted that 
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these cells needed to undergo about 15 divisions to reach the higher precursor 
frequencies found at day 8 post-infection (Selin, Nahill et al. 1994; Selin, Vergilis 
et al. 1996).  The efficiency of such assays, however, is relatively poor.  Later 
studies estimated the number of pMHC-specific CD8+ T cells in a naïve mouse 
by CDR3 sequencing. H-2Kd-restricted HLA 170-179 specific T cells were sorted 
by tetramer from human tumor immunized mice, 6 amino acid long CDR3 regions 
of the dominant responding Vβ chain amplified using Vβ specific primers, and 
then sequenced.  After reaching a plateau, suggesting that the majority of the 
TCR’s in the response had been sequenced, the same primers and exhaustive 
sequencing was used to identify the frequency of these sequences in naïve mice.  
These studies found that there were about 600 CD8+ T cells specific for the Kd-
restricted epitope from HLA-A2 in naïve mice (Bousso, Casrouge et al. 1998).  A 
second strategy used an in vivo competition assay with H-2Db-restricted LCMV 
glyocoprotein (GP)33-specific P14 transgenic T cells to estimate the number of 
GP33-specific CD8 T cells in naïve mice and calculated the number to be 
between 100-200 cells per mouse (Blattman, Antia et al. 2002) and this same 
technique was subsequently used to determine the number of IAb-restricted 
GP61 specific CD4 T cells in naïve mice and calculated ~100 cells per mouse 
(Whitmire, Benning et al. 2006). A modification of this technique has recently 
been used to determine the precursor frequency of self antigen-specific CD8 T 
cells.  In these studies, mice that had received a sublethal dose of irradiation 
were adoptively constituted with heterogeneous naïve CD8+ T cells along with 
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varying concentrations of pmel-1 transgenic T cells that are specific for a tumor-
encoded epitope derived from a melanosomal membrane glycoprotein.  In this 
instance, the CD8+ T cell precursor frequency to a self-specific epitope, H-2Db 
mgp100 25-33, was estimated to be about 1 in 1,000,000 (Rizzuto, Merghoub et 
al. 2009).  Others estimated numbers of pMHC specific T cells by sequencing the 
CDR3β regions of antigen-specific T cells that had expanded during an acute 
infection.  By calculating a measure of CDR3 diversity, and then assuming a 
logarithmic distribution of diversity, they extrapolated the number of T cell clones 
that responded to an acute infection.  This technique was used to examine 
responses in the central nervous system after I.N. inoculation of the neurotropic 
JHM strain mouse hepatitis virus (MHV).  Three to five hundred H-2Db-restricted 
MHV encoded S510 clonotypes were calculated to be in the central nervous 
system (CNS) of acutely infected mice, with ~100-900 clonotypes calculated to 
be in chronically infected mice (Pewe, Heard et al. 1999) and later studies by the 
same group used I.P. infection with MHV and an IFNγ capture assay instead of 
tetramer sorting, and estimated 1100-1500 H-2Db-restricted S510-specific 
clonotypes and 600-900 clonotypes of the subdominant H-2Kb-restricted S598 
peptide-specific T cells in the spleens of acutely infected mice (Pewe, Netland et 
al. 2004).  In this later study it was also estimated that there were 1100-1200 
different H-2Db restricted GP33-specific clonotypes that could respond to an 
LCMV infection. 
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More recent assays have taken advantage of magnetic tetramer binding 
enrichment and double tetramer staining of cells from the spleen and lymph 
nodes of naïve mice to determine pMHC precursor frequencies, with the 
assumption that most CD8+ T cells in a naïve mouse reside in lymphoid organs 
and will react with tetramers.  This technique was first described by Moon et al. 
for CD4+ T cells, and it detected ~190 I-Ab 2W1S I-Ab 52-68 specific T cells, ~20 
I-Ab Salmonella typhimurium FLiC 427-441 specific T cells, and ~16 I-Ab chicken 
ovalbumin (OVA) 323-339 specific T cells per mouse (Moon, Chu et al. 2007). 
This same technique was then used to determine numbers of pMHC-specific 
CD8+ T cells to epitopes derived from multiple viruses (LCMV, influenza, and 
VSV) and the model antigen OVA and found ~80-1200 pMHC specific CD8+ T 
cells per mouse, depending on the specificity of the pMHC tetramer used for the 
pull down (Kotturi, Scott et al. 2008; Obar, Khanna et al. 2008).  Further 
experiments using tetramer-based enrichment have recently been used to 
examine the phenotype of pMHC-specific CD8+ T cells in unimmunized mice, 
finding that there are both phenotypically naïve and memory like CD8+ T cells in 
unimmunized mice, suggesting a process whereby some pathogen-specific CD8+ 
T cells in unimmunized mice become memory-like (Haluszczak, Akue et al. 
2009).  In another recent publication, limiting dilutions of T cells were transferred 
into T cell-deficient T cell receptor β/δ-/- mice followed by influenza A virus (IAV) 
infection to look for T cell responses in the lungs of mice of different ages.  The 
results demonstrated a loss of certain pMHC specificities as mice aged (Yager, 
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Ahmed et al. 2008).  Determinations of CD8+ T cell precursor frequencies in 
humans are currently not experimentally attainable, but exhaustive sequencing of 
an HLA-A2.1-restricted IAV M1 58-66 specific T cell response has suggested that 
there are at least 141 different clonotypes that can grow out in response to an in 
vitro stimulation with peptide, providing a possible floor for the number of T cells 
that can respond to a pMHC complex in human beings (Naumov, Naumova et al. 
2003). 
Most of the assays described above estimate the number of T cells 
specific to single peptides in individual mice.  These assays, therefore, do not 
determine the numbers of CD8+ T cells that can proliferate in response to an 
entire virus, especially if the virus is known to have many epitopes, or if epitopes 
for the virus have not been described.  It has been estimated using in vitro LDA 
that a CD8+ T cell can divide up to 15 times after in vivo activation by a foreign 
antigen (Welsh and Selin 2002).  Further, assuming that all pMHC-specific CD8+ 
T cells detected in naïve mice proliferate in response to an infection, and that all 
progeny resulting from each division survive, it can be similarly calculated that 
naïve pMHC-specific CD8+ T cells divide approximately 13-14 times after virus 
infection, this number being calculated by examining the average number of 
pMHC-specific CD8+ T cells in a naïve mouse, and comparing this to the number 
of pMHC- specific CD8+ T cells that are in a mouse at the peak of the T cell 
response (Obar, Khanna et al. 2008).  Considering that the progeny of one 
precursor after only 12 divisions can result in just over 4000 cells, and since 
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recent experiments using H-2Kb-restricted chicken OVA 257-264-specific OT-1 
transgenic T cells have confirmed that the progeny from a single cell can be 
detected in a mouse after infection (Stemberger, Huster et al. 2007), an in vivo 
LDA was set up to take advantage of the extensive division and proliferation of 
virus-specific CD8+ T cells in order to determine virus-specific CD8+ T cell 
precursor frequencies.   
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CHAPTER II:  MATERIALS AND METHODS 
A. Mice and Mouse Procedures 
B6.SJL (Ly5.1+Thy1.2+ host) mice were used between 6-20 weeks of age and 
were either from Taconic Farms (Germantown, NY) or bred in our own mouse-
breeding colony.  B6.Cg-IgHaThy-1aGPi-1a/J (Ly5.2+Thy1.1+ donor) and IFN-αβ 
receptor knockout mice were between 6-32 weeks of age and bred in our own 
mouse-breeding colony.  Transgenic TCR-LCMV-P14 mice were used between 
6-20 weeks of age and bred in our own mouse-breeding colony. B6.MRL-Faslpr/J 
were used between 5 and 7 weeks of age and were bred in our own mouse-
breeding colony. B6Smn.C3-Faslgld/J (B6-gld) mice were between 5 and 7 weeks 
of age and were purchased from The Jackson Laboratory (Bar Harbor, ME). 
IFNαβ R knockout mice (129 strain) were used between 4-12 weeks of age and 
were bred in our own mouse-breeding colony.  SCID (B6 strain) mice were used 
between 7-12 weeks of age and were bred in our own mouse-breeding colony.  
B6-rag1-/- and B6-rag1-/-lpr mice were used between 5-7 weeks of age, were 
kindly provided by Dr. Merav Socolovsky, and were bred in our own mouse-
breeding colony All experiments were done in compliance with the Institutional 
Animal Care and Use Committee of the University of Massachusetts Medical 
School (Worcester, MA). 
B.  Viruses and Viral Infections 
LCMV strain Armstrong was propagated in BHK21 baby hamster kidney cells 
(Welsh, Lampert et al. 1976; Yang, Dundon et al. 1989).  VAC-WR was 
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propagated on L929 cells (Yang, Dundon et al. 1989).  All VAC recombinants 
and VAC-Wy were kindly provided by Pei Wu as part of a collaboration with Elliot 
Kieff (Harvard University).  Mice were inoculated as indicated.  Mice were 
infected I.P. with 5 x 104 PFU’s of LCMV Armstrong or 1 x 106 or 4x106 PFU’s of 
VAC-WR in 0.2ml for acute viral infections, and some of these mice were tested 
for memory T cell responses 2-8 months later.  I.N. delivery of VAC-WR (1x104 or 
2x105 PFU’s) first required anesthetization by methoxyflurane (Anafane) 
purchased from IVESCOTM (Iowa Falls, Iowa).  Mice were anesthetized in a fume 
hood by placement in a covered beaker that contained a small amount of tissue 
paper soaked in a solution of methoxyflurane.  Once mice ceased most 
movement, 50µl of virus diluted in PBS (phosphate buffered saline) was applied 
directly onto the nostril with a 27½ gauge needle on a 1ml syringe.  Skin 
scarification of VAC-Wy or VAC-WR was done by first immobilizing the mouse in 
a mouse holder, and then applying approximately 10µl (one drop) of virus 
properly diluted in PBS on to a mouse’s tail.  Then using, a 27½ gauge needle, 
the region of the tail which contained the drop of virus was lightly scratched 15-
30 times until a small amount of blood appeared.  
C.  Neutralizing Antibody Assay 
1ml of Vero cells were resuspended in complete MEM at 2x105 per ml and plated 
into the individual wells of 12 well plates and placed into a 37°C incubator 
overnight.  On the following day, ½ ml of media was removed from each well and 
discarded and the plates were then placed back into the incubator.  Dilutions of 
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virus in complete MEM (on ice) were prepared so that there were approximately 
100-120 plaques per 100µl complete MEM.  Typically, a large stock of diluted 
virus is prepared and frozen down ahead of time, as this limits assay-to-assay 
variability.  Next, heat inactivated serum (56°C for ½ hour) was diluted in 
complete MEM in a 96 well plate in a cold tray to the appropriate dilutions for the 
assay (done in duplicate).  The sera dilutions were eventually mixed 1:1 with the 
virus, so the sera was at 2x the desired starting dilution.  Next, 100µl of the virus 
dilution was added to each of the diluted serum samples and mixed well (200µl 
total per well, with each well containing 50-60 PFU’s of virus per 100µl).  The 96 
well plates were then incubated at 37°C for one hour.  After 1 hour, 100µl of each 
sera/virus mixture were added to a well of the 12 well plate.  After gently rocking 
the plate to distribute the virus/sera mixtures the, 12 well plate was placed into 
the 37°C incubator.  After 1 ½ hours, 2mls of a 1:1 mixture of 1% Seakem 
agarose (Lonza, 50014, Rockland, ME) and complete 2x EMEM (Lonza 12-668E, 
Walkersville, MD) was gently added to each well of the 12 well plate.  The 
mixture was prepared by first microwaving a 1% Seakem agarose mixture in ultra 
pure dH20 (Invitrogen/Gibco, 10977, Grand Island NY) until it began to bubble, 
and this was then mixed 1:1 with cold complete 2x EMEM.  The mixture was 
allowed to cool, and 2ml was gently added to each well of the 12 well plate. The 
plate was then placed in the 37°C virus incubator for two days.  On day two, 1 ml 
of a neutral red staining solution was added to each well.  A 1:1 mixture of 1% 
Seakem agarose and complete 2x EMEM was made, and to this 16-18ul of 1% 
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neutral red (Sigma-Aldrich, 861251-256, Natick, MA) solution was added per ml 
Seakem Agarose/2xEMEM mixture.  This was then mixed well, and 1ml of this 
was added to each well.  This was placed in the 37°C virus incubator for one day.  
Plaques were counted the next day, if there was neutralizing activity in the 
serum, there will be fewer plaques when compared to the wells containing just 
virus or uninfected sera. 50% endpoints were calculated if neutralizing activity 
diluted out completely, otherwise the serum was re-titered. Serum from an 
uninfected mouse was used as a negative serum control, serum from a VAC-
immune mouse was used as a positive serum control, and a media control 
(straight MEM) was also used in all assays. 
D.  Plaque Assay 
Plaque assay of VAC was done as previously described (Selin, Varga et al. 
1998).  Briefly, organ homogenate was diluted 1:10 in complete MEM, and 100µl 
of this homogenate was plated on 6 well plates containing Vero monolayers.  
This was overlayed 1 ½ hours later with a 1:1 Seakem agarose/complete 
2xEMEM mixture.  Two days later a neutral red stain was added in a 1:1 Seakem 
agarose/complete 2xEMEM mixture, and a day later plaques were counted.  
Values expressed are log10 transformations, and titers are calculated as PFU/ml 
of whole liver, spleens, or both fat pads. 
E.  Antibody Depletion and Antibody Blocking Experiments 
All treatments were given I.P. either one, or two days before, or on the day of the 
virus infection, and the antibody was diluted in PBS (see individual Figures for 
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time of antibody treatment).  Mouse mAb antibodies were purchased from 
BioXCell (10 Technology Dr., Unit 2B, West Lebanon, NH, 03784-1671) and 
were as follows:  Anti-CD4 clone GK1.5 (BE0003-1) made in rat, and the control 
isotype rat IgG2b clone LTF-2 (BE0090), anti-CD8α clone 2.43 (BE00061) made 
in rat, and the control isotype rat IgG2b (as above), anti-γδ clone UC7-13D5 
(BE0070) made in hamster, anti-NK1.1 antibody clone PK136 made in mouse 
(BE0036), and control isotype mouse IgG2a clone CI.18.4 (BE0085), and anti-
IFNγ clone XMG1.2 made in rat, and control isotype rat IgG1 clone HRPN 
(BE0088). 
F.  CFSE and DDAO-SE Label of Mouse Splenocytes 
CFSE (carboxyfluorescein succinimidyl ester) and DDAO-SE (9H-(1,3-dichloro-
9,9-dimethylacridin-2-one-7-yl) phosphate, diammonium salt succinimidyl ester) 
(Molecular Probes, C34553, Carlsbad CA) labeling of splenocytes was 
performed as previously described (Lyons and Parish 1994; Gudmundsdottir, 
Wells et al. 1999).  Briefly, a single cell suspension was prepared from the 
spleen, red blood cells were lysed in an 0.84% NH4Cl solution, and splenocytes 
were washed in cold HBSS (Hank’s balanced salt solution) (Invitrogen, Carlsbad 
CA) and resuspended in HBSS for counting.  Spleen leukocytes were then 
resuspended in HBSS at 2 x 107 per ml and labeled in a solution of 2 µM CFSE 
for 15 minutes in a 37°C water bath, with mixing every 5 minutes.  After CFSE 
labeling, cells were again washed twice with cold HBSS, and counted 
immediately before transfer.  An aliquot of splenocytes was used for a surface 
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stain, and the rest of the splenocytes were diluted in HBSS for adoptive transfer.  
DDAO-SE labeling of splenocytes was the same, except that the DDAO-SE final 
working concentration was 0.5 µM. 
G.  FACS Staining 
Single cell suspensions of the spleen, lymph nodes, bone marrow, blood, PEC’s 
or lung (minced finely with razorblade and filtered) were prepared, red blood cells 
were lysed in an 0.84% NH4Cl solution, and the leukocytes were then washed in 
RPMI 1640 media (Sigma-Aldrich, 11875-093, St. Louis MO).  Cells were then 
counted by hemocytometer and resuspended in FACS buffer for staining.  Fc 
receptors were blocked with antibody to CD16/CD32 (Fcγ III/II Receptor, BD 
Biosciences 553142, San Diego CA), and cells were then stained in 96 well 
plates.  For the in vivo LDA, the single cell suspension from each whole spleen 
was divided into 8-16 wells of a 96 well plate for staining, and later recombined 
for analysis on an LSRII flow cytometer.  After the surface stain with indicated 
antibodies, cells were either fixed using Cytofix (BD, 554655) and resuspended 
in FACS buffer for analysis, or for intracellular assays, permeabilized using 
Cytofix/Cytoperm (BD, 554722), and stained intracellularly with the indicated 
antibodies as per manufacturer’s instructions. 
H.  Antibodies and Peptides 
CD3ε PE-Cy7 (BD  552774), CD8α Pacific Blue (BD 558106), Thy1.1PE (BD 
554898), Ly5.2PerCP-Cy5.5 (BD 552950), and Vα2 APC (eBioscience 17-5812-
80) were used for in vivo LDA’s.  For surface stains and intracellular cytokine 
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assay, mAb to CD3ε FITC (BD 555274), CD3ε PE (BD 555275), CD3ε 
Ly5.2PerCP-Cy5.5 (BD 551163), CD3ε PE-Cy7 (BD 552774), γδ TCR PE (BD 
553178), γδ TCR PE (BD 553177), CD8α PE (BD 55303), CD8α APC (BD 
553035), CD8α V500 (BD 556077), CD8α PE-Cy7 (BD 552877), CD8α Alexa 
Fluor 700 (BD 557959), CD8β (eBioscience 12-0083083), CD44 PE-Cy7 
(eBioscience 25-0441-82), Thy1.1PE (BD 554898), Ly5.2PerCP-Cy5.5 (BD 
552950), CD127 APC  (eBioscience 17-1271-82), CD62L Pacific Blue 
(eBioscience 57-0621-82), CD44 PerCP Cy.5 (eBioscience 45-0441-82), Thy1. 
AF 700 (BioLegend 105319, San Diego CA), Thy1.2 FITC (BD 553004), Thy1.2 
PE (BD 553006), Thy1.2 APC (BD 553007), Ly5.1 PE (BD 553776), Ly5.1 PE-
Cy7 (eBioscience 25-0453-82), Ly5.1 PB (BioLegend 110772), Ly5.1 PerCP-
Cy5.5 (eBioscience 45-0453-82), Thy 1.1 APC (eBioscience 17-0900-82), Thy1.1 
PE-Cy7 (eBioscience 25-0900-82), Thy1.1 PerCP-Cy5.5 (eBioscience 45-0900-
80), Thy1.1 APC (eBioscience 48-0900-80), CD4 FITC (BD 553047), CD4 PE 
(BD 553653), CD4 APC (BD 553051), CD4 AF700 (BD 557956), CD4 PB (BD 
558107), CD44 FITC (BD 553133), CD44 PE (BD 553134), CD44 APC (BD 
559250), CD44 PE-Cy7 (eBioscience 25-0441-82), CD44 AF700 (BioLegend 
103026), CD44 PerCP-Cy5.5 (eBioscience 45-0441-82), NK1.1 PB (BioLegend 
108722), NK1.1 PE (BD 553165), NK1.1 APC (BD 550627), NK1.1 PerCP-Cy5.5 
(BD 551114), NK1.1 APC (BD 550627), DX5 PE-Cy7 (eBioscience 25-5771-82), 
DX5 APC (eBioscience 17-5971-81) and NKp46 PE (12-3351-82) were used for 
surface stain, and mAb to IFNγ APC (BD 554413), IFNγ AF700 (BD 557998), 
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IFNγ eFluor450 (eBioscience 48-7311-80) and IFNγ PerCP-Cy5.5 (eBioscience 
45-7311-80)  was used for the intracellular stain.  Peptides for stimulation were 
purchased from 21st Century Biochemicals (Marlboro, MA).  
I.  Peptide Specific Stimulations 
Peptide stimulations were performed as previously described (Varga and Welsh 
1998). Briefly, single cell suspensions of lymphocytes were cultured for 4.5-5 
(depending on the assay) hours in the presence of 3 µM of the indicated peptides 
(21st Century Biochemicals) or purified mAb to CD3ε (1µg/ml) (BD 553058) for a 
polyclonal stimulation, with human recombinant IL-2 (10 U/ml) and GolgiPlugTM 
(BD 555029). 
J.  In Vivo Limiting Dilution Assay (LDA) 
Splenocytes were labeled with CFSE as described above and diluted in HBSS to 
appropriate concentrations.  To determine the number of surviving CD8+ T cells 
after transfer, the following formula was used:  (number of donor splenocytes 
transferred into host mouse * (1 / %CD8+ T cells in donor population) * donor 
take (in our experiments, and from results from (Cose, Brammer et al. 2006; 
Ganusov and De Boer 2007) calculated to be 0.038).  Pilot experiments gave an 
indication as to the limiting number of T cells that would need to be in host mice 
to respond to each viral infection.  To determine precursor frequencies, 2-fold 
dilutions of splenocytes were made in HBSS.  Each dilution was transferred into 
4-6 (normally 5) host mice.  In each experiment, one mouse at each dilution was 
left uninfected to serve as a negative control.  An infected mouse was scored as 
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a responder if donor Thy1.1+Ly5.2+ CFSElo cells were detected after FACS 
analysis above a determined threshold as described below.  If there were 
Thy1.1+Ly5.2+ CFSElo cells in any dilution of any of the uninfected animals, this 
number of cells was multiplied by three (with a correction for number of cells 
collected), and this would serve as a responder cutoff.  In instances where there 
was no background detected by FACS in the uninfected mice of the individual 
experiment, a cutoff of 10 CFSElo cells was used.  The background value of 10 
CFSElo cells was used because it was three times the average number of 
CFSElo cells detected in all uninfected mice in all experiments, and it was also 
the average number of CFSElo cells in uninfected mice that had detectable 
CFSElo cells plus one standard deviation.  After calculating the number of 
surviving CD8+ T cells after transfer, and determining responders versus non-
responders, probit and Reed and Muench analyses were done to determine 
precursor frequencies for each experiment (Bliss 1934; Reed and Muench 1938).  
These two analyses resulted in comparable, but not identical precursor numbers.  
Almost all individual experiments also included two control host mice that 
received adoptive transfers of a large number of donor splenocytes, with one 
mouse infected and one uninfected, serving as positive and negative controls.   
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CHAPTER III:  VACCINIA VIRUS WYETH IFNγ BINDING PROTEIN 
RECOMBINANTS, PATHOGENICITY AND PROTECTION 
 The role of VAC-Wy encoded IFNγ binding proteins in VAC-Wy 
pathogenesis was examined in the mouse.  The protection afforded to mice by 
immunization with three VAC-Wy recombinants encoding three different IFNγ 
binding proteins, a VAC-Wy recombinant encoding no IFNγ binding protein, or 
the VAC-Wy parental strain to subsequent lethal I.N. infection with VAC-WR was 
also examined. 
Previous experiments have found conflicting roles for the gene encoding 
the B8R protein in the pathogenesis of VAC infections in the mouse.  In two 
studies it was demonstrated with two different strains of VAC (VAC-WR and VAC 
Lister) that B8R knockout viruses were less pathogenic than the revertant or 
parental strain in mice (Verardi, Jones et al. 2001; Denes, Gridley et al. 2006).  In 
a separate study B8R knockout VAC’s had no difference in pathogenicity in mice, 
while a virus where the IFNγR α-chain truncated after Ser-257 so as to be 
secreted as an IFNγ binding protein was found to be more pathogenic in mice 
(Symons, Tscharke et al. 2002). 
 To more closely examine this phenomenon, four VAC-Wy recombinants 
were tested for pathogenicity and virus spread in various mouse models.  The 
recombinants were made in VAC-Wy, as this live virus was the licensed smallpox 
vaccine in the United States.  The four recombinants tested were a B8R 
knockout (B8R-/-) virus, a B8R revertant virus (B8R-R), and two knock-in viruses.  
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One knock-in virus encoded a truncated version of the mouse IFNγR that would 
serve as a decoy receptor (mIFNγR) in place of the B8R gene.  The second 
knock-in virus instead expressed a recombinant B8R/IFNγR fusion protein that 
dimerized the mouse IFNγ receptor (DmIFNγR).  The B8R/IFNγR fusion protein 
was expected to have increased avidity to mouse IFNγ as compared to the 
mouse IFNγR protein as it is known that the IFNγ dimer induces dimerization of 
the IFNγR, but the IFNγR protein itself does not dimerize (Walter, Windsor et al. 
1995). 
  The ability of each of these recombinants to protect mice against a lethal 
I.N. VAC-WR infection was also examined, as testing VAC-Wy variants with 
reduced pathogenicity but a similar immuno-protective phenotype was an 
important goal in examining the VAC-Wy variants.  
A. Virus Pathogenesis of VAC-Wy Parental Strain and VAC-Wy 
Recombinant Strains In Multiple Mouse Backgrounds By Two Different 
Inoculation Routes 
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Table 3.1.  Virus titers and weight loss observed after infection of multiple 
mouse backgrounds with parental VAC-Wy or VAC-Wy B8R recombinants. 
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As seen in Table 3.1, VAC-Wy recombinant infection done in multiple 
backgrounds of mice by many different routes reveals that the VAC-Wy grows 
poorly in the mouse and is only reliably detectable in the lung after high dose I.N. 
infection. 
Table 3.1 led us to the conclusion that the best model to examine virus 
spread and pathogenicity was a high dose (1-2 x 107) I.N. infection, and so the 
rest of our experiments examining VAC-Wy recombinant pathogenicity and virus 
spread were done using this high dose I.N. infection of mice. 
B.  Pathogenicity of VAC-Wy IFNγ  binding protein recombinants in mice 
To more closely examine the virus spread and pathogenicity of the four 
recombinant VAC-Wy viruses in comparison to the parental VAC-Wy, five sets of 
B6 mice were infected with 1x107 PFU’s I.N. 
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Figure 3.1.  At 1x107 PFU’s I.N., VAC-Wy and VAC-Wy B8R variant viruses grow 
to similar titers in the mouse lung, with only the parental VAC-Wy causing weight 
loss. 
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Figure 3.1  At 1x107 PFU’s I.N., VAC-Wy and VAC-Wy B8R variant viruses 
grow to similar titers in the mouse lung, with only the parental VAC-Wy 
causing weight loss.  
B6 mice were infected with 1x107 of each of the indicated viruses I.N. (A) On Day 
4, mice were sacrificed and lung virus titers were determined by plaque assay. 
(B) Mice were weighed each day, and the average and standard deviations of 
each group are plotted as percent of initial weight lost. Wyeth is VAC-Wy, B8R-/- 
is VAC-Wy with the gene encoding the B8R protein knocked out, B8R-R is a 
revertant of the B8R-/- virus, mIFNgR is VAC-Wy with the gene encoding the 
B8R protein replaced with a truncated variant of the gene encoding the mouse 
IFNγR, and DmIFNgR is VAC-Wy with the gene encoding the B8R protein 
replaced with a recombinant B8R/IFNγR dimer that allows dimerization of the 
protein before IFNγ protein binding. 
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No profound differences in viral titer were found after infection with any of 
the recombinants or the parental VAC-Wy strain (Figure 3.1A).  Mice were also 
weighed as a measure of pathogenicity, expecting that mice would lose weight if 
sick.  Only mice that were infected with the VAC-Wy parental strain lost weight, 
with no weight loss differences noted when mice were infected with any of the 
recombinant viruses (Figure 3.1B).  To more closely examine the growth of the 
B8R-/- VAC-Wy recombinant, experiments were repeated with the same virus 
load, but with an increased number of mice.  In this experiment, day five titers 
were examined instead.   
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Figure 3.2.  B8R-/- VAC-Wy grows to similar titers as B8R revertant VAC-Wy and 
VAC-Wy parental strain. 
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Figure 3.2.  B8R-/- VAC-Wy grows to similar titers as B8R revertant VAC-Wy 
and VAC-Wy parental strain.  
B6 mice were infected with 1x107 of each of the indicated viruses I.N.  On Day 5, 
mice were sacrificed and lung virus titers were determined by plaque assay.  P 
values were determined by Student’s t-test. Wye is VAC-Wy, B8R-/- is VAC-Wy 
with the gene encoding the B8R protein knocked out, B8R-R is a revertant of the 
B8R-/- virus. 
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There was no significant difference in day 5 lung virus titers after infection 
with the B8R-/- VAC-Wy, B8R-R VAC-Wy, or the parental VAC-Wy in 
experiments that included a larger number of mice (Figure 3.2).  Combined with 
other results with the other recombinants (described later in the manuscript, and 
in Table 3.1), it was likely that the mouse may not be the best model to measure 
VAC-Wy pathogenicity as VAC-Wy grows poorly in the mouse, but might still be 
a good model to examine protection induced by the recombinants.  This 
conclusion was reached as it was found that even at doses where virus was only 
barely detectable in the lung after recombinant VAC-Wy infection at Day 3, with 
no detectable virus at Day 6 (see Table 3.1, Experiments 7 and 8), there was a 
detectable VAC-specific CD8+ T cell response.   
C.  VAC-specific CD8+ T cell response induced by infection of mice with 
parental VAC-Wy or VAC-Wy IFNγ  binding protein recombinants 
Interestingly, the B8R protein contains the peptide that encodes the 
immunodominant epitope in B6 mice, and so using an intracellular cytokine 
assay after peptide stimulation, confirmation of B8R knockout viruses is 
demonstrated. 
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Figure 3.3.  VAC-specific CD8+ T cell response after I.N. infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87
Figure 3.3.  VAC-specific CD8+ T cell response after I.N. infection.   
B6 mice were infected with 5x105 of each of the indicated viruses I.N.  On Day 6, 
mice were sacrificed and splenocytes were cultured for five hours with the B8R 
peptide or A47L peptide from VAC in the presence of GolgiPlug. This was 
followed by an intracellular IFNγ assay with fluorescent antibodies, and FACS 
analysis.  All plots are gated on CD8+ cells.   
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All viruses were able to induce a detectable VAC-specific CD8+ T cell 
response, as stimulation with A47L resulted in IFNγ+ CD8+ T cells (Figure 3.3).  
When splenocytes were stimulated with the B8R peptide instead, IFNγ+ CD8+ T 
cells were only detected in mice that had been infected with viruses that encode 
the B8R gene.  It was also observed that infection with the parental strain of the 
virus resulted in greater CD8+ T cell responses when compared with all 
recombinant viruses at this dose.  This may be because at this dose, the Wyeth 
parental strain grew to higher titers in vivo, although at higher doses the titers of 
the parental strain and recombinants were the same (see Table 3.1 and Figure 
3.1A and 3.2).  As a mimic of smallpox vaccination, mice were infected with VAC-
Wy parental strain and the revertant B8R recombinant VAC-Wy strain by skin-
scarification. 
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Figure 3.4. VAC-specific CD8+ T cell response after skin-scarification.  
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Figure 3.4. VAC-specific CD8+ T cell response after skin-scarification.  
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification.  On Day 17, mice were sacrificed and splenocytes were cultured for 
five hours with the B8R peptide or A47L peptide from VAC in the presence of 
GolgiPlug. This was followed by an intracellular IFNγ assay with fluorescent 
antibodies, and FACS analysis.  All plots are gated on CD8+ cells.  Stimulations 
were with the B8R peptide and A47L peptide from VAC. 
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Skin-scarification with the parental VAC-Wy or the recombinant VAC-Wy 
revertant was able to induce similar numbers of VAC-specific IFNγ+ CD8+ T cells 
as detected by an intracellular cytokine assay with either the B8R or A47L 
peptide (Figure 3.4). 
D.  VAC-Wy IFNγ  Binding Protein Recombinants Protect Mice as Well as 
VAC-Wy Against A Lethal Dose of VAC-WR, and the VAC-Specific CD8+ T 
Cell Responses After Challenge 
The ability of each of the recombinants and the parental strain of VAC-Wy 
to provide protection against a lethal dose (20 LD50’s, 2x105 PFU’s) VAC-WR 
was next examined, and the VV-specific CD8+ T cell response in the surviving 
mice was next examined. 
 
 
 
 
 
92
 
A. 
B.  
 
Figure 3.5. Weight loss and VV-specific CD8+ T cell response after 20 LD50’s 
VAC-WR challenge of VAC-Wy or B8R recombinant VAC-Wy immune mice.  
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Figure 3.5. Weight loss and VV-specific CD8+ T cell response after 20 
LD50’s VAC-WR challenge of VAC-Wy or B8R recombinant VAC-Wy 
immune mice. 
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification.  On Day 71, mice were infected I.N. with 20 LD50’s of VAC-WR 
(2x105). (A) Mice were weighed each day, and the average of each group is 
plotted as percent of initial weight lost (5-6 mice per group) Immunizing virus 
designations are as described in (B). (B) 6 days later the surviving mice were 
sacrificed and splenocytes were cultured for five hours with the B8R peptide or 
A47L peptide from VAC in the presence of GolgiPlug. This was followed by an 
intracellular IFNγ assay with fluorescent antibodies, and FACS analysis.  All plots 
are gated on CD8+ cells.  Numbers displayed are the average +/- standard 
deviations IFNγ+CD44+. 
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Immunization with any of the recombinants or the parental strain by skin-
scarification was able to provide protection against a lethal I.N. dose of VAC-WR 
given on day 71, as all non-immunized mice died by day 6, while all mice in the 
immunized groups, after an initial drop in weight, began to gain weight by day 3, 
and no immunized mouse died from the high dose infection (Figure 3.5A).  The 
VAC-specific CD8+ T cell response in the remaining mice was also examined. 
Mice immunized with any VAC-Wy recombinant that encoded the B8R protein 
had detectable B8R-specific CD8+ T cells, while mice immunized with VAC-Wy 
recombinants that did not encode the B8R protein had very few B8R-specific 
CD8+ T cells after I.N. infection with 20 LD50’s of VAC-WR (Figure 3.5B).  The 
challenge virus, VAC-WR, normally induced expansion of B8R-specific CD8+ T 
cells, so this result suggests that the CD8+ T cell response in an immunized host 
will largely be of memory origin when the challenge virus is largely homologous.  
All immunized surviving animals had similar levels of A47L-specific CD8+ T cells 
(Figure 3.5B). 
The immunization was then repeated, and VAC-WR challenged mice were 
instead sacrificed on day 5 after lethal viral challenge, to allow measurement of 
virus load after challenge in immunized and un-immunized hosts, and to examine 
day 5 VAC-specific memory CD8+ T cell recall responses. 
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A. B.  
                           C.  
Figure 3.6. Skin-scarification immunization with either VAC-Wy or the B8R VAC-
Wy recombinants resulted in decreased virus loads after VAC-WR challenge. 
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Figure 3.6. Skin-scarification immunization with either VAC-Wy or the B8R 
VAC-Wy recombinants resulted in decreased virus loads after VAC-WR 
challenge.  
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification.  On Day 162, mice were infected I.N. with 20 LD50’s of VAC-WR 
(2x105).  Mice were sacrificed on day 5 after the challenge, and viral titers in the 
(A) livers (B) lungs and (C) spleens were determined by plaque assay (the dotted 
line represents the limit of detection of the assay). Wyeth is VAC-Wy, B8R-/- is 
VAC-Wy with the gene encoding the B8R protein knocked out, B8R-R is a 
revertant of the B8R-/- virus, mIFNgR is VAC-Wy with the gene encoding the 
B8R protein replaced with a truncated variant of the gene encoding the mouse 
IFNγR, and DmIFNgR is VAC-Wy with the gene encoding the B8R protein 
replaced with a recombinant B8R/IFNγR dimer that allows dimerization of the 
protein before IFNγ protein binding. 
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Mice that had been immunized by skin-scarification with any of the 
recombinant VAC-Wy’s or the parental VAC-Wy had approximately 4 logs lower 
virus in the lungs after 20 LD50’s VAC-WR challenge in comparison to 
unimmunized mice (Figure 3.6B).  No virus was found in the livers of immunized 
mice, while unimmunized mice had almost five logs of virus in the livers, and only 
two VAC-Wy-immunized mice had detectable virus in the spleens while the non-
immunized mice had almost five logs of virus in the spleen (Figure 3.6A and 
3.6C).  The VAC-specific CD8+ T cell response in the spleen after 20 LD50’s 
VAC-WR was next examined by intracellular cytokine stain. 
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A. B.  
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Figure 3.7. VAC-specific CD8+ T cell response in skin-scarified mice on day 5 
after VAC-WR challenge.  
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Figure 3.7. VAC-specific CD8+ T cell response in skin-scarified mice on day 
5 after VAC-WR challenge.  
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification.  On Day 162, mice were infected I.N. with 20 LD50’s of VAC-WR 
(2x105), and 5 days later mice were sacrificed and splenocytes were cultured for 
five hours with the (A) B8R peptide, (B) A47L peptide, or (C) K3L peptide from 
VAC in the presence of GolgiPlug. This was followed by an intracellular IFNγ 
assay with fluorescent antibodies, and FACS analysis.  Wyeth is VAC-Wy, B8R-/- 
is VAC-Wy with the gene encoding the B8R protein knocked out, B8R-R is a 
revertant of the B8R-/- virus, mIFNgR is VAC-Wy with the gene encoding the 
B8R protein replaced with a truncated variant of the gene encoding the mouse 
IFNγR, and DmIFNgR is VAC-Wy with the gene encoding the B8R protein 
replaced with a recombinant B8R/IFNγR dimer that allows dimerization of the 
protein before IFNγ protein binding. 
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After I.N. challenge with 20 LD50’s of VAC-WR, only mice immunized with 
a virus that encoded B8R had CD8+ T cells that produced IFNγ upon stimulation 
with the B8R peptide, even though the challenge virus was not a B8R knockout 
virus (Figure 3.7A).  This again suggests that in immunized mice, the CD8+ T cell 
response was entirely of memory origin, as infection of mice that had been 
immunized with a virus that did not contain the B8R gene, had no detectable 
B8R-specific CD8+ T cell response.  This was even in light of the decreased virus 
loads in the mice that had been immunized with the B8R knockout viruses 
(Figure 3.7).  VAC-specific CD8+ T cell responses could be detected when the 
peptide stimulation was with two peptides that are part of subdominant CD8 T 
cell epitopes, A47L (Figure 3.7B) and K3L (Figure 3.7C). 
E.  Chapter Conclusion  
Although no difference in pathogenicity or virus growth was found using 
these IFNγ binding protein VAC-Wy recombinants, all recombinants protected 
mice as well as the Wyeth parental strain.  The apparent lack of pathogenicity 
differences with the different IFNγ binding protein VAC-Wy recombinants may 
have been due to the poor growth of VAC-Wy in mice, and so it might be 
interesting to instead examine these knockout and knock-in variants in a mouse 
adapted strain of VAC such as VAC-WR.  Interestingly, all recombinants 
provided similar protection to a lethal I.N. challenge with VAC-WR, even though 
B8R knockout immunization could not stimulate the normally immunodominant 
CD8+ T cell response. 
101
CHAPTER IV: VACCINIA VIRUS WYETH VACCINE CANDIDATES DELETED 
FROM B8R, C12L, AND C3L(C21L) GENES 
 Recombinant VAC-Wy viruses were tested for differences in virus growth 
in our I.N. mouse model of infection.  These recombinant VAC-Wy were 
knockouts of one, two, or three genes that code for immunomodulatory proteins.  
The protection afforded to mice by immunization with VAC-Wy or a VAC-Wy 
recombinant where all three genes were knocked out (VAC-Wy-/-/-), to a typically 
lethal I.N. infection with VAC-WR was also examined.  
 Both C12L knockout VAC’s (Born, Morrison et al. 2000; Symons, Adams 
et al. 2002) and C21L (C3L) knockouts have been shown to be less pathogenic 
in in vivo animal models (Isaacs, Kotwal et al. 1992).  These knockout viruses as 
well as double and triple knockout viruses were tested for pathogenicity 
differences in our mouse I.N. model.  The immunological memory induced by 
skin-scarification of the VAC-Wy-/-/- in comparison to the VAC-Wy parental 
strain, as well as the ability of VAC-Wy-/-/- inoculation by skin-scarification to 
protect against a lethal VAC-WR challenge, in comparison to immunization with 
the VAC-Wy strain or PBS immunization was also examined.   
 Pathogenicity differences between the single knockout, double knockout, 
or triple knockout VAC-Wy recombinants and the parental VAC-Wy were first 
examined in a high dose I.N. mouse model. 
A. Virus Growth of Multiple VAC-Wy Recombinants After I.N. Infection of 
Mice 
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Figure 4.1. Knockout VAC-Wy variants and revertant VAC-Wy grow to similar 
titers in mouse lung. 
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Figure 4.1. Knockout VAC-Wy variants and revertant VAC-Wy grow to 
similar titers in mouse lung. 
B6 mice were infected with 1x107 of each of the indicated viruses I.N.  On Day 4, 
mice were sacrificed and lung virus titers were determined by plaque assay. C3L-
/- is VAC-Wy with the gene encoding the C3L protein knocked out, C3L-R is a 
revertant of the C3L-/- virus, C3L-/-B8R-/- is a double knockout VAC-Wy with the 
genes encoding the C3L and B8R proteins knocked out, C3L-/-C12L-/- is another 
double knockout VAC-Wy with the genes encoding the C3L and C12L proteins 
knocked out, and C3L-/-C12L-/-B8R-/- is a triple knockout VAC-Wy with the 
genes encoding the C3L, C12L, and B8R proteins knocked out. 
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No significant difference in day 4 lung virus titers was found when 
comparing any of the recombinants, probably owing to the poor growth of Wyeth 
in the mouse (Figure 4.1).   
B.  VAC-specific Immune Response Induced by VAC-Wy-/-/- and VAC-Wy 
Parental Strain Immunization, and the Protection the Immunizations 
Provide Against Lethal VAC-WR Challenge. 
Mice were next inoculated with PBS, the VAC-Wy parental strain, or the 
VAC-Wy-/-/- by skin-scarification, and the VAC-specific immunological memory 
induced by each was examined. 
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                                B.  
 
Figure 4.2. Similar numbers of VAC-specific CD8+ T cells and amount of 
neutralizing antibody in VAC-Wy and  VAC-Wy-/-/- immune mice. 
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Figure 4.2. Similar numbers of VAC-specific CD8+ T cells and amount of 
neutralizing antibody in VAC-Wy and  VAC-Wy-/-/- immune mice.  
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification. (A) On day 207, mice were bled, and blood lymphocytes were 
cultured for five hours with the B8R peptide, A47L peptide, or K3L peptide from 
VAC in the presence of GolgiPlug. This was followed by an intracellular IFNγ 
assay with fluorescent antibodies, and FACS analysis.  All plots are gated on 
CD8+ cells. (B) Heat inactivated sera from the mice were used to measure 
neutralizing antibody activity against VAC-WR. P values were determined by 
Student’s t-test. 
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Only mice immunized with the parental VAC-Wy strain had CD8+ T cells 
that produced IFNγ upon stimulation with the B8R peptide, as was expected as 
the VAC-Wy-/-/- does not express B8R (Figure 4.2A).  Interestingly, there were 
similar numbers of CD8+ T cells that produced IFNγ upon stimulation with the 
A47L stimulation (Figure 4.2A), with similar titers of neutralizing antibody in both 
the VAC-Wy immunized and VAC-Wy-/-/- immunized mice (Figure 4.2B).  These 
mice were next I.N. infected with 20 LD50’s of VAC-WR (2x105 PFU). 
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A. B.  
C.  D  
 
Figure 4.3. Weight loss and virus titers after 20 LD50’s I.N. VAC-WR challenge in 
VAC-Wy, VAC-Wy-/-/-, or PBS skin-scarified mice. 
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Figure 4.3. Weight loss and virus titers after 20 LD50’s I.N. VAC-WR 
challenge in VAC-Wy, VAC-Wy-/-/-, or PBS skin-scarified mice.  
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification.  On Day 210, mice were infected I.N. with 20 LD50’s of VAC-WR 
(2x105).  (A) Mice were weighed each day, and the average and standard 
deviations of each group are plotted as percent of initial weight lost (9-10 mice 
per group).  Mice were sacrificed on day 5 after the challenge, and viral titers in 
the (B) livers, (C) lungs, and (D) spleens were determined by plaque assay (the 
dotted line represents the limit of detection of the assay). P values were 
determined by Student’s t-test.  PBS is phosphate buffered saline, Wyeth is 
parental VAC-Wy, and -/-/- is a VAC-Wy with the genes encoding the C3L, C12L, 
and B8R proteins knocked out. 
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In this case, the immunization with VAC-Wy or the VAC-Wy-/-/- might 
have stopped weight loss by day 5, but this result was not significant (Figure 
4.3A) and was not as striking as had been seen in Figure 3.5A.  This result may 
be because of the increased time between immunization and challenge (71 days 
after immunization in Figure 3.5, 210 days after immunization in Figure 4.3A). 
Next, on day 5 after the 20 LD50’s VAC-WR challenge, as it has been 
previously demonstrated that un-immunized mice succumb to this virus dose at 
day 6 (Figure 3.5A), mice were sacrificed to determine virus titers.  Mice that had 
been immunized with either VAC-Wy-/-/- or the parental VAC-Wy had 
approximately five logs less virus in the lungs (Figure 4.3B), with no virus 
detectable virus in the livers or the spleens in comparison to approximately 2.5 
logs of virus in the spleen and 5 logs of virus in the livers of the PBS-immunized 
group (Figure 4.3C and 4.3D). There was an increased titer on average in the 
mice that had detectable virus in mice immunized with Wy-/-/- (Figure 4.3B).  
This result might be due to the lack of the immunodominant CD8+ T cell epitope 
in the immunization, and although the result did not differ significantly from the 
VAC-Wy immunization, further experiments might reveal a role of memory CD8+ 
T cells in protection against VAC-WR challenge.  The VAC-specific CD8+ T cell 
response after challenge with 20 LD50’s of VAC-WR was next measured by an 
intracellular cytokine stain after peptide stimulation.   
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A. B.  
C. D.  
 
Figure 4.4. VAC-specific CD8+ T cell response after 20 LD50’s VAC-WR 
challenge in PBS, VAC-Wy, or VAC-Wy-/-/- skin-scarified mice. 
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Figure 4.4. VAC-specific CD8+ T cell response after 20 LD50’s VAC-WR 
challenge in PBS, VAC-Wy, or VAC-Wy-/-/- skin-scarified mice.  
B6 mice were infected with 2x105 of each of the indicated viruses by skin-
scarification.  On Day 210, mice were infected I.N. with 20 LD50’s of VAC-WR 
(2x105), and 5 days later mice were sacrificed and splenocytes were cultured for 
five hours with the B8R peptide, A47L peptide, or K3L peptide from VAC, or with 
a mAb against CD3ε in the presence of GolgiPlug. This was followed by an 
intracellular IFNγ assay with fluorescent antibodies, and FACS analysis.  All plots 
are gated on CD8+ cells.(A) Polyclonal CD3ε stimulation (B) B8R peptide 
stimulation (C), A47L peptide stimulation (D), or K3L peptide stimulation. P 
values were determined by Student’s t-test. PBS is phosphate buffered saline, 
Wyeth is parental VAC-Wy, and -/-/- is a VAC-Wy with the genes encoding the 
C3L, C12L, and B8R proteins knocked out. 
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After challenge with 20 LD50’s of VAC-WR, only mice immunized with the 
parental VAC-Wy, had CD8+ T cells that produced IFNγ upon stimulation with the 
B8R peptide, even though the challenge virus was not a B8R knockout virus 
(Figure 4.4B).  This again suggests that in immunized mice at this time point, the 
CD8+ T cell response was entirely of memory origin.  Interestingly, fewer CD8+ T 
cells produced IFNγ after a polyclonal stimulation with an antibody against CD3ε 
in mice that had been immunized with the VAC-Wy-/-/- when compared to mice 
that had been immunized with the parental VAC-Wy (Figure 4.4A).  This 
decrease might be due to the lack of the gene that encodes the B8R protein from 
the VAC-Wy-/-/-, and therefore does not contain the peptide that forms the 
immunodominant epitope in B6 mice.  Furthermore, there were increases in the 
number of CD8+ T cells that produce IFNγ after either K3L (Figure 4.4D) or A47L 
(Figure 4.4C) peptide stimulation, possibly compensating for the lack of B8R-
specific CD8+ T cells.   
C.  CHAPTER CONCLUSION 
Although virus pathogenesis was not affected by the lack of these three 
immunomodulatory proteins, the skin-scarification immunization with the VAC-
Wy-/-/- protected mice as well as the parental VAC-Wy strain to 20 LD50’s I.N. 
challenge with VAC-WR.  The apparent lack of pathogenicity differences could 
be due to the poor growth of VAC-Wy inside of the mouse, as we noted poor 
growth of the B8R recombinants made in VAC-Wy in the mouse in our earlier 
study.  Interestingly, the lack of a B8R-specific CD8+ T cell response from the 
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skin-scarification immunization did not have a significant effect on virus titers, 
although we did find increased numbers of CD8+ T cells that produced IFNγ upon 
stimulation with two subdominant determinants, and this might be a 
compensation mechanism, and is discussed further in the Discussion. 
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CHAPTER V: INCREASED PROTECTION FROM HIGH DOSE VACCINIA 
VIRUS INFECTION IN MICE GENETICALLY PRONE TO 
LYMPHOPROLIFERATIVE DISORDERS 
Individuals that have mutations that code for hypoactive versions of either 
the Fas or Fas ligand protein are more susceptible to many autoimmune 
disorders.  It is also possible that these mutations might lead to increased 
protection from some infections as the immune systems in these individuals 
might be considered to be in a continuously activated state.  To examine this 
possibility, the immune response to high dose VAC-WR infections was examined 
in Fas mutant mice. 
Fas/FasL interactions have been shown to lead to AICD in T cells 
repeatedly stimulated through their TCR’s. Early studies done in our lab had 
demonstrated that lethal I.N. infection of mice with VAC-WR resulted in few VAC-
specific CD8+ T cells detectable in spleens.  As this high dose infection might be 
driving cells into AICD, it was possible that mice that had mutations in Fas or Fas 
ligand that result in decreased Fas/FasL signaling might have increased T cell 
responses as the mechanism of the decreased T cell response might be Fas 
induced AICD.   
Interestingly, concurrent with the time of my graduate studies, 
observations in one animal model suggested that hosts that have mutations in 
this pathway may be better able to fight off certain infections.  Specifically, it had 
been demonstrated that BALB/c-gld mice lose less weight and had better survival 
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when compared to their BALB/c wild type counterparts after high dose influenza 
virus infections, and this had been attributed to the increased CD8+ T cell 
response in the BALB/c-gld mice (Legge and Braciale 2005).  In this model, it 
was described that as the influenza dose was increased to lethal levels, FasL 
would be up-regulated on DC’s, and this FasL up-regulation would then cause 
activated CD8+ T cells to be eliminated through apoptosis, resulting in a 
hampered influenza-virus specific CD8+ T cell response.  It has also been 
demonstrated that HIV-infected individuals with combined hypoactive mutations 
in Fas or FasL performed better after anti-retroviral therapy than those with no 
mutations (Nasi, Pinti et al. 2005).  The observation that hosts that have 
mutations that often lead to autoimmune disorders might be able to fight off or 
survive certain infections more readily may explain why these mutations continue 
to be seen in the population.  To more closely study this phenomenon using 
VAC-WR, the immune response and control of lethal VAC-WR infections was 
examined with Fas or Fas ligand mutant mice.  
A.  B6-lpr Mice Have Reduced Weight Loss, Have Reduced Virus Loads, 
And Have Increased Numbers Of CD8+ T Cells On Day 6 In Response To A 
Normally Lethal I.N. or I.P. VAC-WR Challenge 
 To examine if Fas-induced AICD was leading to decreased T cell 
responses after lethal VAC-WR infection, B6 and B6-lpr mice were infected I.N. 
with 1x104 VAC-WR. 
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A. B.  
                                          C.  
 
Figure 5.1. Decreased weight loss and liver virus titers on day 6 after lethal I.N. 
VAC-WR challenge in B6-lpr mice. 
 
 
 
 
 
     Liver
B6
B6
-lp
r
0
2
4
6
8
0.0141
P
F
U
/m
l (
lo
g
1
0
)
     Lung
B6
B6
-lp
r
0
2
4
6
8 0.4076
P
FU
/m
l (
lo
g1
0)
118
Figure 5.1. Decreased weight loss and liver virus titers on day 6 after lethal 
I.N. VAC-WR challenge in B6-lpr mice.  
B6 or B6-lpr mice were infected with 1x104 PFU’s of VAC-WR by I.N. inoculation. 
Mice were weighed each day, and the average and standard deviations of each 
group are plotted as percent of initial weight lost (5 mice per group, * = p<0.05) 
(A) Mice were sacrificed on day 6 after the challenge, and viral titers in the livers 
(B) and lungs (C) were determined by plaque assay (the dotted line represents 
the limit of detection of the assay) P values were determined by Student’s t-test. 
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B6-lpr mice lost less weight (Figure 5.1A) and had almost 2 logs less virus 
in the livers (Figure 5.1B) when compared to B6 wild type mice after I.N. infection 
with an amount of VAC-WR that typically causes death, with no difference in lung 
virus titers (Figure 5.1C).  Interestingly, B6-lpr mice weighed more throughout the 
time course of the infection when compared to the B6 wild type mice, even 
though both sets of mice weighed the same at the time of infection (data not 
shown).  The lymphocyte subsets and VAC-specific CD8+ T cell responses in the 
mediastinal lymph nodes (MLN) after I.N. infection were next examined. 
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Figure 5.2. Increased percentage and number of T Cells and B8R-specific CD8+ 
T cells in MLN after lethal VAC-WR I.N. infection in B6-lpr mice. 
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Figure 5.2. Increased percentage and number of T Cells and B8R-specific 
CD8+ T cells in MLN after lethal VAC-WR I.N. infection in B6-lpr mice. 
B6 or B6-lpr mice were infected with 1x104 PFU’s of VAC-WR by I.N. inoculation.  
On day 6 after infection, the MLN was prepared and lymphocytes were cultured 
for five hours with the B8R peptide in the presence of GolgiPlug. This was 
followed by an intracellular IFNγ assay with fluorescent antibodies, and FACS 
analysis.  The average and standard errors of the mean are shown. (A) CD4+ 
percentage (B) CD8+ percentage (C) total CD4+ numbers (D) total CD8+ numbers 
(E) and number of IFNγ+ CD8+ T cells after B8R peptide stimulation are shown.  
P values were determined by Student’s t-test. 
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There was an increased percentage and number of CD4+ and CD8+ T 
cells on day 6 in the MLN’s of B6-lpr mice in comparison to B6 wild type mice 
after VAC-WR infection (Figure 5.2A, 5.2B, 5.2C and 5.2D).  There was also an 
increased number of IFNγ+CD8+ T cells after B8R peptide stimulation in the 
MLN’s of B6-lpr mice in comparison to B6 wild type mice (Figure 5.2E).  B6 or 
B6-lpr mice were next infected with a lethal dose of VAC-WR I.P. to determine if 
a separate inoculation route with a lethal dose of virus would also result in an 
increased number of T cells in B6-lpr mice in comparison to B6 mice, and to find 
if B6-lpr mice were better protected from high dose I.P. infections as well. 
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Figure 5.3. Decreased weight loss and virus titers on day 6, and increased 
numbers of T cells in day 6 spleens after lethal I.P. VAC-WR challenge In B6-lpr 
mice. 
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Figure 5.3. Decreased weight loss and virus titers on day 6, and increased 
numbers of T cells in day 6 spleens after lethal I.P. VAC-WR challenge In 
B6-lpr mice.  
B6 or B6-lpr mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation. 
(A) Mice were weighed each day, and the average and standard deviations of 
each group are plotted as percent of initial weight lost.  On day 6 after infection, 
splenocytes were cultured for five hours with the B8R peptide in the presence of 
GolgiPlug. This was followed by an intracellular IFNγ assay with fluorescent 
antibodies, and FACS analysis. (B) CD4+ numbers and (C) CD8+ numbers with 
the average and standard deviation are shown.  Viral titers in the (D) fat pads, 
and (E) livers were determined by plaque assay.  All P values were determined 
by Student’s t-test. (5 mice per group, * = p<0.05).  Unf. are uninfected mice. 
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After 4x106 VAC-WR I.P. infection, B6-lpr mice lost less weight (Figure 
5.3A) when compared to B6 wild type mice, and B6-lpr mice also had almost 2 
logs less virus in the fat pads and livers at day 6 in comparison to the B6 wild 
type mice (Figure 5.3D and 5.3E).  There was an increased number of CD4+ and 
CD8+ T cells in the spleens of B6-lpr mice in comparison to B6 wild type mice 
(Figure 5.3B and Figure 5.3C), although there was not an increase in the number 
of VAC-specific CD8+ T cells as detected by an intracellular IFNγ assay (data not 
shown).  In a lethal influenza model of virus infection, there was an increased 
number of CD8+ T cells responding to an influenza virus infection when 
adoptively transferred into mutant BALBc-gld mice in comparison to wild type 
BALB/C mice, and this was assumed to be because of the decreased apoptosis 
of activated CD8+ T cells (Legge and Braciale 2005).  Adoptive transfer 
experiments were next set up to determine if CD8+ T cells that lack Fas would 
proliferate more extensively in comparison to CD8+ T cells that normally express 
Fas.  Splenocytes from B6-lpr (Ly5.2+Thy1.2+) or IgHa wild type (Ly5.2+Thy1.1+ 
donor) were mixed 1:1 and adoptively transferred into B6.SJL (Ly5.1+Thy1.2+ 
host) mice, and one day later, mice were infected with 4x106 VAC-WR I.P. 
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Figure 5.4. Adoptively transferred B6-lpr CD8+ T cells do not have increased 
proliferation or survival in comparison with wild type CD8+ T cells at day 6 after 
lethal I.P. VAC-WR infection. 
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Figure 5.4. Adoptively transferred B6-lpr CD8+ T cells do not have 
increased proliferation or survival in comparison with wild type CD8+ T 
cells at day 6 after lethal I.P. VAC-WR infection.  
0.75x107 B6-lpr (Ly5.2+Thy1.2+ donor) and 0.75x107 IgHa (Ly5.2+Thy1.1+ donor) 
splenocytes were CFSE labeled mixed 1:1 and adoptively transferred into 
B6.SJL (Ly5.1+Thy1.2+ host) mice, and one day later, some of the mice were 
infected with 4x106 VAC-WR I.P.  On day 6 after infection, splenocytes were 
stained with the appropriate fluorescent antibodies, and FACS analysis was 
performed.  All analyses shown is gated on CD8+ T cells.  (A) Donor subset of 
uninfected mice. (B) CFSE dilution of each donor type after 4x106 VAC-WR I.P. 
(C) % of donor CD8+ T cells after 4x106 VAC-WR I.P. 
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Similar percentages of donor B6-lpr (Ly5.2+Thy1.2+) and IgHa 
(Ly5.2+Thy1.1+ donor) wild type CD8+ T cells were found in uninfected mice, 
confirming the 1:1 mix of donor splenoctyes (Figure 5.4A).  After infection with 
4x106 VAC-WR I.P., similar percentages of CFSElo B6-lpr (Ly5.2+Thy1.2+) and 
CFSElo IgHa (Ly5.2+Thy1.1+ donor) wild type CD8+ T cells were detected in the 
host mice (Figure 5.4B).  There was also a similar percentage of B6-lpr 
(Ly5.2+Thy1.2+) and IgHa (Ly5.2+Thy1.1+ donor) wild type CD8+ T cells in the host 
mice (Figure 5.4C), suggesting that CD8+ T cells that lack Fas do not survive 
high dose VAC-WR I.P. infection better than CD8+ T cells that can normally 
express Fas.  Similar experiments were performed using the high dose VAC-WR 
I.N. infection model, and it was found that CD8+ T cells that lack Fas do not 
survive high dose VAC-WR I.N. infection better than CD8+ T cells that can 
normally express Fas (data not shown).  This suggests that the increased 
protection of B6-lpr from high dose VAC-WR infection did not occur by the same 
mechanism as had been noted after high dose influenza virus infection (Legge 
and Braciale 2005).  It was noted that weight loss induced by normally lethal 
doses of VAC-WR was significantly ameliorated in B6-lpr mice in both the I.N. 
and I.P. infection model in comparison to B6 wild type mice at early time points 
(Figure 5.1A and Figure 5.3A), and there was also an increased NK% (0.84 +/- 
0.48 in B6 vs. 1.63 +/- 0.22 in B6-lpr) and γδ T cell%  (0.21 +/- 0.04 in B6 vs. 0.44 
+/- 0.05) found in day 6 infected B6-lpr mice.  These observations pointed to 
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increased protection of B6-lpr mice at earlier time points, and so virus titers at 
early time points after high dose VAC-WR infection was examined.   
B.  Fas Mutant Mice Have Reduced Virus Loads At Day 2 And Day 3 Time 
Points in Response To A Normally Lethal I.P. VAC-WR Challenge 
B6 or B6-lpr mice were infected with a typically lethal dose of VAC-WR 
I.P., and virus titers were examined at day 2 or day 3. B6 or B6-gld mice were 
also infected with a typically lethal dose of VAC-WR I.P., and virus titers were 
examined on day 2. 
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Figure 5.5. Fas mutant mice have decreased amounts of virus at early time 
points after lethal I.P. VAC-WR infection. 
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Figure 5.5. Fas mutant mice have decreased amounts of virus at early time 
points after lethal I.P. VAC-WR infection.  
B6 or B6-lpr mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
On day 2 (A,B,C) or day 3 (D,E,F) after infection, viral titers in the (A, D) fat pads, 
(B,E) livers, and (C,F) spleens were determined by plaque assay. B6 or B6-gld 
were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  On day 2 viral 
titers in the (G) fat pads, (H) livers, and (I) spleens were determined by plaque 
assay. All P values were determined by Student’s t-test. 
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After 4x106 VAC-WR I.P. infection, B6-lpr mice had slightly less virus in 
the fat pads (Figure 5.5A), approximately one log less virus in livers (Figure 
5.5B), and about ½ a log less virus in spleens (Figure 5.5C) at day 2 in 
comparison to the B6 wild type mice and at day 3, B6-lpr mice had ¾ of a log 
less virus in the livers (Figure 5.5E), and about a log less virus in the spleens 
(Figure 5.5F) than B6 wild type mice. B6-gld mice had ½ a log less virus in the fat 
pad (Figure 5.5G), and about a log less in the livers (Figure 5.5H) and spleens 
(Figure 5.5I) when compared to B6 wild type mice.  In light of these data 
suggesting that B6-lpr mice were better protected than B6 wild type mice as early 
as day 2, and because earlier data suggested that the NK cell % and γδ T cell % 
were increased in B6-lpr mice infected as compared to B6 wild type infected 
mice, uninfected B6-lpr and B6 mice were examined for increases in NK and γδ T 
cell numbers, as these lymphocytes are thought to be able to exert effector 
functions early in virus infections. 
C.  Uninfected B6-lpr Mice Have More Innate Like Leukocytes, and More 
Memory Like T Cells than B6 Mice, But Antibody Depletions of Individual 
Subsets in B6-lpr Mice Does not Increase Virus Titers. 
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Figure 5.6. Increased NK, γδ+ T cells, and memory phenotype T cells, and IFNγ+ 
CD8+ T cells after polyclonal stimulation in B6-lpr mice. 
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Figure 5.6. Increased NK, γδ+ T cells, and memory phenotype T cells, and 
IFNγ+ CD8+ T cells after polyclonal stimulation in B6-lpr mice. 
Six week old uninfected B6 or B6-lpr mice were sacrificed, and splenocytes were 
cultured for five hours with a mAb against CD3ε in the presence of GolgiPlug. 
This was followed by an intracellular IFNγ assay with fluorescent antibodies, and 
FACS analysis. (A) NK1.1+CD3-%, (B) NK1.1+CD3-#’s, (C) γδ+CD3+%, (D) 
γδ+CD3+#’s, (E) CD3+CD4+ CD44+%, (F) CD3+CD8+ CD44+%, and the (G) 
IFNγ+CD8+%, (H) IFNγ+CD8+#’s after CD3ε stimulation.  All P values were 
determined by Student’s t-test. 
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Increases in the NK1.1+CD3-% (Figure 5.6A), NK1.1+CD3-#’s (Figure 
5.6B), γδ+CD3+% (Figure 5.6C), γδ+CD3+#’s (Figure 5.6D), and increases in the 
number of CD44+ CD4+ and CD44+ CD8+ T cells were demonstrated in 6 week 
old uninfected B6-lpr mice as compared to 6 week old uninfected B6 wild type 
mice (Figure 5.6E and 5.6F).  There was also an increased percentage and 
number of CD8+ T cells that were IFNγ+ after a polyclonal CD3ε stimulation 
(Figure 5.6G and 5.6H).  It has been demonstrated that γδ+ T cell knockout mice 
have increased VAC titers when compared to wild type mice, and that treatment 
with an antibody against the γδ+ TCR exacerbates VAC infection (Selin, 
Santolucito et al. 2001).  To examine if the increased γδ+ T cell number resulted 
in increased protection in B6-lpr mice, γδ antibody blocking experiments were 
performed in B6-lpr mice. 
It has also been suggested that NK cells have a role in controlling VAC 
infections, as depletion of NK cells exacerbates VAC infection (Bukowski, Woda 
et al. 1983; Kawakami, Tomimori et al. 2009).  As there were more NK cells in 
uninfected B6-lpr mice as compared to B6 mice, NK depletion experiments were 
also performed in B6-lpr mice. 
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Figure 5.7. γδTCR antibody treatment does not result in increased virus titers in 
B6-lpr mice. 
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Figure 5.7. γδTCR antibody treatment does not result in increased virus 
titers in B6-lpr mice.  
B6-lpr mice were treated with 200µl PBS or 200µl PBS containing 100µg of 
γδTCR-blocking antibody.  One day later both groups of mice were I.P. infected 
with 4x106 PFU’s of VAC-WR.  On day 3 splenocytes were stained with the 
appropriate fluorescent antibodies, and (A) FACS analysis was performed to 
ensure of the antibody blocking effect. Viral titers in the (B) fat pads, (C) livers, 
and (D) spleens were determined by plaque assay.  All P values were 
determined by Student’s t-test.  γδd is γδTCR monoclonal antibody treatment, and 
PBS is phosphate buffer saline treated mice. 
 
 
 
 
 
138
 
Figure 5.8. NK antibody treatment does not result in increased virus titers in B6-
lpr mice. 
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Figure 5.8. NK antibody treatment does not result in increased virus titers 
in B6-lpr mice.  
B6-lpr mice were treated with 200µl PBS or 200µl PBS containing 50µg of NK-
depleting antibody.  One day later both groups of mice were I.P. infected with 
4x106 PFU’s of VAC-WR.  On day 3 splenocytes were stained with the 
appropriate fluorescent antibodies, and (A) FACS analysis was performed to 
ensure of the NK depletion.  Viral titers in the (B) fat pads (C) livers and (D) 
spleens were determined by plaque assay.  All P values were determined by 
Student’s t-test. NKd is NK monoclonal antibody treatment, and PBS is 
phosphate buffer saline treatment. 
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Splenocytes form B6-lpr mice treated with a γδTCR-blocking antibody did 
not stain with an antibody against the γδTCR (Figure 5.7A), confirming the 
blocking effect, but treatment with the γδTCR-blocking antibody had no effect on 
virus titer in the fat pad (Figure 5.7B), liver (Figure 5.7C) or spleen (Figure 5.7D).   
B6-lpr mice treated with an NK depleting antibody did not have any 
detectable NK cells in the spleen (Figure 5.8A), confirming the NK depletion, but 
there were no differences in viral titers in the fat pads (Figure 5.8B), livers (Figure 
5.8C), or spleens (Figure 5.8D) of NK depleted vs. undepleted B6-lpr mice. 
  Increases in the percentage of memory-like CD4+ and CD8+ T cells 
(CD44hi) had also been demonstrated in uninfected B6-lpr mice (Figure 5.6E-H).  
It is possible that the increase in the number of memory phenotype T cells might 
allow T cells to act earlier in B6-lpr mice.  This might then allow T cells to have an 
early immuno-protective role in high dose VAC-WR infections in B6-lpr animals, 
even though the antiviral properties of these populations are thought to occur 
after T cell expansion in B6 mice, so depletions experiments using CD4 and CD8 
antibodies were performed in B6-lpr mice.   
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Figure 5.9. CD4 antibody treatment does not result in increased virus titers in B6-
lpr mice.  
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Figure 5.9. CD4 antibody treatment does not result in increased virus titers 
in B6-lpr mice.  
B6-lpr mice were treated with 200µl PBS containing 25µg of the isotype antibody 
or 200µl PBS containing 25µg of the CD4-depleting antibody.  One day later both 
groups of mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
On day 3 splenocytes were stained with the appropriate fluorescent antibodies, 
and (A) FACS analysis was performed to ensure of the CD4 depletion.  Viral 
titers in the (B) fat pads, (C) livers, and (D) spleens were determined by plaque 
assay.  All P values were determined by Student’s t-test. CD4d is CD4 
monoclonal antibody treatment, and iso is isotype control monoclonal antibody 
treatment. 
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Figure 5.10. CD8 antibody treatment does not result in increased virus titers in 
B6-lpr mice. 
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Figure 5.10. CD8 antibody treatment does not result in increased virus 
titers in B6-lpr mice. 
B6-lpr mice were treated with 200µl PBS containing 25µg of the isotype antibody 
or 200µl PBS containing 25µg of the CD8-depleting antibody.  One day later both 
groups of mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
On day 3 splenocytes were stained with the appropriate fluorescent antibodies, 
and (A) FACS analysis was performed to ensure of the CD8 depletion.  Viral 
titers in the (B) fat pads (C) livers and (D) spleens were determined by plaque 
assay.  All P values were determined by Student’s t-test. CD8d is CD8 
monoclonal antibody treatment, and PBS is phosphate buffer saline treatment. 
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B6-lpr mice treated with a CD4 depleting antibody did not have any 
detectable CD4+ T cells in the spleen (Figure 5.9A), confirming the CD4 
depletion, but no difference in virus titers in the fat pads (Figure 5.9B), livers 
(Figure 5.9C), or spleens (Figure 5.9D) of depleted vs. non-depleted mice were 
noted. 
B6-lpr mice treated with a CD8 depleting antibody did not have any 
detectable CD8+ T cells in the spleen (Figure 5.10A), confirming the CD8 
depletion, but no difference in virus titers in the fat pads (Figure 5.10B), livers 
(Figure 5.10C), or spleens (Figure 5.10D) in CD8 depleted vs. non-depleted B6-
lpr mice were found.   
As none of the individual depletions was able to explain the decreased 
virus titers in B6-lpr mice, the cellular immune response induced at early time 
points after high dose VAC-WR I.P. infection was examined, as this might give 
an indication to effector mechanisms that might be involved in the increased 
protection of B6-lpr from high dose I.P. VAC-WR infections. 
D. Increased Numbers of Splenocytes in B6-lpr Mice After High Dose VAC-
WR Infection, With More IFNγ+ Leukocytes, But Not An Inherent Protection 
of B6-lpr Leukocytes From VAC-WR Induced Depletion 
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Figure 5.11. Increased number of splenocytes, IFNγ producing NK, CD4+, and 
CD8+ T cells in B6-lpr mice after lethal VAC-WR I.P. infection on day 2. 
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Figure 5.11. Increased number of splenocytes, IFNγ  producing NK, CD4+, 
and CD8+ T cells in B6-lpr mice after lethal VAC-WR I.P. infection on day 2. 
B6 or B6-lpr mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
On day 2 after infection, splenocytes were cultured for 4.5H in the presence of 
GolgiPlug. This was followed by an intracellular IFNγ assay with fluorescent 
antibodies, and FACS analysis..  The average and standard errors of the mean 
are shown.  (A) Splenocyte numbers (B) CD3+CD8+ numbers (x107) (C) 
NK1.1+CD3- numbers (x107) (D) CD3+γδ+ numbers (x107) (E) and IFNγ+CD3+γδ+ 
numbers (F) IFNγ+NK1.1+CD3- numbers (G) IFNγ+CD3+CD8-γδ- numbers (G) and 
IFNγ+CD3+CD8+ numbers.  P values were determined by Student’s t-test. 
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After 4x106 VAC-WR I.P. infection, B6-lpr mice had increased numbers of 
splenocytes (Figure 5.11A), increased numbers of CD8+ T cells (Figure 5.11B), 
increased number of NK cells (Figure 5.11C), and increased number of γδ+ T 
cells (Figure 5.11D) when compared to B6 wild type mice.  B6-lpr mice also had 
increased numbers of IFNγ+ NK cells (Figure 5.11F), increased numbers of 
IFNγ+CD3+CD8-γδ- cells (Figure 5.11G), and increased numbers IFNγ+CD8+ T 
cells (Figure 5.11H) when compared to B6 wild type mice.  The increase in CD8+ 
T cells was due to the increase in splenocyte numbers (CD8 % in B6 6.34 +/- 
0.36, in B6-lpr 6.93 +/- 0.46), while increases in NK cells and γδ+ T cells was due 
to the increased splenocyte number and the increased percentage of these 
subsets within the splenocyte population (B6 NK% in B6 1.33 +/- 0.23, in B6-lpr 
2.03 +/- 0.15, γδ+ T % in B6 0.23 +/- 0.01 in B6-lpr 0.35 +/- 0.02).  The increased 
spleen numbers after high dose VAC-WR infection of B6-lpr mice when 
compared to B6 wild type mice suggested that there might be an inherent defect 
in splenocyte death in B6-lpr mice, possibly through a decreased AICD 
dependent mechanism, and this protection from death might allow for increased 
protection from high dose virus infections.  To examine this hypothesis, adoptive 
transfer experiments at day 2 time points were examined. 
 
 
149
 
Figure 5.12. Adoptively transferred B6-lpr CD8+ T cells do not have increased 
proliferation or survival in comparison with wild type CD8+ T cells at day 2 after 
lethal I.P. VAC-WR infection.  
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Figure 5.12. Adoptively transferred B6-lpr CD8+ T cells do not have 
increased proliferation or survival in comparison with wild type CD8+ T 
cells at day 2 after lethal I.P. VAC-WR infection.  
4.5x107 B6-lpr (Ly5.2+Thy1.2+) splenocytes were labeled with DDAO-SE and 
4.5x107 IgHa wild type (Ly5.2+Thy1.1+ donor) splenocytes were CFSE labeled 
and mixed 1:1 and adoptively transferred into B6.SJl (Ly5.1+Thy1.2+) mice, and 
one day later, some mice were infected with 4x106 VAC-WR I.P.  On day 2 after 
infection, splenocytes were stained with the appropriate fluorescent antibodies, 
and FACS analysis was performed. Donor % of two uninfected mice is on the far 
left in all rows, infected with 4x106 VAC-WR I.P. in three mice on the right in all 
rows. (A) Total donor % in splenocytes (B). γδ+CD4-CD8- donor % (C), NK+CD4-
CD8- donor % (D) CD4+ and CD8+ cells in CFSE+ and DDAO+ splenocytes. 
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Similar percentages of donor DDAO+ B6-lpr (Ly5.2+Thy1.2+) and CFSE+ 
IgHa wild type (Ly5.2+Thy1.1+ donor) splenocytes cells were detected in 
uninfected mice, confirming the 1:1 mix of donor splenoctyes (Figure 5.12A).  
After infection with 4x106 VAC-WR I.P., similar percentages of DDAO+ B6-lpr 
(Ly5.2+Thy1.2+) and CFSE+ IgHa wild type (Ly5.2+Thy1.1+ donor) splenocytes 
cells were detected in host mice (Figure 5.12A).  In further analysis γδ+CD4-CD8- 
cells (Figure 5.12B), NK+CD4-CD8- cells (Figure 5.12C), CD4+ cells and CD8+ 
cells (Figure 5.12D) survived 4x106 VAC-WR I.P. infection similarly if adoptively 
transferred from B6 or B6-lpr mice.   This suggests that Fas dependent AICD 
mechanisms are most likely not the reason for increased splenocyte number 
after infection in B6-lpr mice, and that no single lymphocyte subset from the B6-
lpr is protected from high dose I.P. VAC-WR challenge. 
Lymphocyte depletion experiments in multiple combinations were also 
performed on day 2, but it was found that no depletion combination consistently 
resulted in reducing protection of B6-lpr mice in comparison with B6 wild type 
mice (data not shown).  While depletion experiments were not able to identify a 
single lymphocyte subset or combination of subsets that resulted in the increased 
early protection of B6-lpr mice from high dose VAC-WR infection, it did provide 
us with a large number of B6 wild type and B6-lpr mice infected with two stocks 
of VAC-WR that replicated to the same extent in vivo.  This cohort of mice 
allowed for a closer examination of early correlates of protection early in high 
dose VAC-WR I.P. infection.  In all experiments B6 wild type and B6-lpr mice 
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were age and weight matched, but to determine whether a difference in weight 
would make a difference in virus titers, virus loads in the fat pad, livers, and 
spleens were plotted against the initial weights of the mice. 
E.  Correlates of Reduced Virus Load In B6 wild type and B6-lpr mice 
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Figure 5.13. Initial mouse weight negatively correlates with virus titers in B6 and 
B6-lpr mice. 
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Figure 5.13. Initial mouse weight negatively correlates with virus titers in 
B6 and B6-lpr mice.  
B6 or B6-lpr mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
Weights at time of infection are plotted against D2 viral titers in the (A) fat pad, 
(B) liver, and (C) spleen.  
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Figure 5.14. Initial mouse weight negatively correlates with virus titers in B6 or 
B6-lpr mice. 
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Figure 5.14. Initial mouse weight negatively correlates with virus titers in 
B6 or B6-lpr mice.  
B6 or B6-lpr mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
Weights at time of infection are plotted against D2 viral titers in the (A) B6 fat 
pad, (B) B6 liver, (C) B6 spleen, (D) B6-lpr fat pad, (E) B6-lpr liver, or (F) B6-lpr 
spleen. 
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It was found that initial weight negatively correlated with viral titers in B6 
wild type combined with B6-lpr mice (Figure 5.13).  The more the mice weighed 
the lower the amount of virus in all three organs.  The initial weight vs. day 2 
virus titers in the individual sets of B6 wild type or B6-lpr mice was next plotted. 
Initial weight again negatively correlated with viral titers in B6 wild type or 
B6-lpr mice (Figure 5.14).  The more mice weighed the lower the amount of virus 
in all three organs.  It was found that this correlation was typically strongest in the 
liver (Figure 5.13B), in the B6 wild type (Figure 5.13B) or B6-lpr mice (Figure 
5.13D). Each experiment was carefully age and weight matched, and when all 
the initial weights of the B6 or B6-lpr were compared, there was no significant 
difference in the weights of the B6 or B6-lpr groups (P=0.12).  Although, this data 
suggested the B6-lpr mice were not better protected because of increased 
weight, initial weight was divided by virus titers and these results are shown to 
confirm that increased weight was not the reason for decreased titers in B6-lpr 
mice. 
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Figure 5.15. B6-lpr mice have decreased virus loads on day 2, even if initial 
weight is taken into consideration. 
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Figure 5.15. B6-lpr mice have decreased virus loads on day 2, even if initial 
weight is taken into consideration. B6 or B6-lpr mice were infected with 4x106 
PFU’s of VAC-WR by I.P. inoculation.  On day 2 after infection, viral titers in the 
(A) fat pads, (B) livers, and (C) spleens were determined by plaque assay.  In (D) 
(E) and (F), the viral titers are first divided by the initial weights, and the result is 
then plotted.  All P values were determined by Student’s t-test. 13 grouped 
experiments. 
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When including all mice, B6-lpr mice had less virus in the fat pads (Figure 
5.15A), livers (Figure 5.15B), and spleens (Figure 5.15C) after 4x106 PFU’s of 
VAC-WR I.P. when compared to B6 wild type mice.  Even after accounting for 
the discrepancy that initial weight might cause in viral titers by dividing the day 2 
titers by the initial weight, B6-lpr mice still had less virus in the fat pads (Figure 
5.15D), livers (Figure 5.15E), and spleens (Figure 5.15F) per gram of initial 
weight when compared to the B6 wild type mice.   
Although splenocytes from B6-lpr mice were not inherently more resistant 
to lymphocyte depletion by high dose VAC-WR I.P. infection (Figure 5.12) and no 
single cell depletion or combination of depletions consistently resulted in loss of 
protection in B6-lpr mice, it still seemed likely that the increased splenocyte 
number in B6-lpr (Figure 5.11) mice might negatively correlate with virus loads, 
and so this correlation was next examined. 
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Figure 5.16. Day 2 splenocyte number negatively correlates with virus titers in B6 
and/or B6-lpr mice. 
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Figure 5.16. Day 2 splenocyte number negatively correlates with virus titers 
in B6 and/or B6-lpr mice. 
 B6 or B6-lpr mice were infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  
D2 splenocyte counts are plotted against D2 viral titers in the (A) B6 and B6-lpr 
fat pad, (B) B6 and B6-lpr liver, (C) B6 and B6-lpr spleen, (D) B6 fat pad, (E) B6 
liver, (F) B6 spleen, (G) B6-lpr fat pad, (H) B6-lpr liver, and (I) B6-lpr spleen. 
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Day 2 splenocyte number negatively correlated with fat pad (Figure 5.16 
A,D,G), liver (Figure 5.16 B,E,H), and spleen (Figure 5.16 C,F,I) viral titers in B6 
wild type, B6-lpr mice, or the combination of the two groups of mice.  Although 
this negative correlation was expected in the combination group as B6-lpr had 
decreased virus loads and increased splenocyte numbers when compared to B6 
mice, the observation that the negative correlation was apparent in the individual 
groups suggested that the negative correlation was not just due to two individual 
overlapping observations. 
In further correlation analyses such as this, but instead focusing on 
lymphocyte subsets, it was found that γδ+ T cell percentage significantly 
negatively correlated with VAC titers in the fat pad (P=0.0560, R2=0.02913), liver 
(P<0.0001, R2=0.12827) and spleen (P<0.0001, R2=0.20836) in the combination 
of B6 wild type and B6-lpr group, and in the fat pad (P=0.0520, R2=0.0615), 
spleen (P=0.0096, R2=0.10649), but not the liver (P=0.1311, R2=0.03758) of B6 
wild type group, but not in the B6-lpr group.  It was also found that CD8+ T cell 
percentage significantly negatively correlated with VAC titers in the fat pad 
(P<0.0001, R2=0.33935), liver (P<0.0001, R2=0.26592), and spleen (P<0.0001, 
R2=0.26027) in the combination of B6 wild type and B6-lpr group, in the fat pad 
(P<0.0001, R2=0.32216), liver (P<0.0001, R2=0.2768), and spleen (P=0.0006, 
R2=0.17849) B6 wild type group, and in the fat pad (P<0.0001, R2=0.3078) and 
spleen (P=0.00136, R2=0.09419) of B6-lpr mice, and suggestive (P=0.0756, 
R2=0.05003) in the liver.  This might suggest that γδ+ T cells and CD8+ T cells are 
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protective at a day 2 time point in response to high dose I.P. VAC-WR infection, 
but none of the depletion studies gave a clear answer as to lymphocyte subsets 
involved in protection.  Although NK depletion studies in B6-lpr mice did not 
affect virus titers (Figure 5.8), it was possible that NK cells might still play some 
role in VAC-WR virus control as has previously been suggested with poxviruses 
(Bukowski, Woda et al. 1983; Parker, Parker et al. 2007; Martinez, Huang et al. 
2008).  To more closely examine if NK cells played any role in VAC-WR virus 
control in high dose I.P. VAC-WR infection, we next performed experiments in B6 
recombinase activating gene 1 (RAG) knockout (B6-rag1-/-) and B6-lpr 
recombinase-activating gene 1 knockout (B6-rag1-/-lpr) mice. 
F. B6-rag1-/-lpr Uninfected Mice Have More Splenocytes and NK Cells 
When Compared to B6-rag1-/- Mice, and Depletion of NK Cells Increases 
Virus Loads In Both Groups of Mice 
 Experiments in uninfected B6 and B6-lpr mice had already demonstrated 
that B6 mice with the lpr mutation had an altered immune makeup with increased 
NK cell numbers when compared to mice without the mutation (Figure 5.6).  The 
lpr mutation might also result in an altered immune makeup in B6-rag1-/- mice as 
well, and to examine this possibility, splenocyte number and NK cell numbers 
were examined in B6-rag1-/- and B6-rag1-/-lpr mice. 
 
 
 
166
                                              A.  
 
B. C.  
 
Figure 5.17. Increased splenocyte # and NK cell # in uninfected B6-rag1-/-lpr in 
comparison to B6-rag1-/- mice.  
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Figure 5.17. Increased splenocyte # and NK cell # in uninfected B6-rag1-/-
lpr in comparison to B6-rag1-/- mice.  
Six week old uninfected B6-rag1-/- and B6-rag1-/-lpr mice were sacrificed, and 
splenocytes were stained with the appropriate fluorescent antibodies followed by 
FACS analysis. (A) Splenocyte #’s (B) NK1.1+CD3-%, (C) NK1.1+CD3-#’s.   All P 
values were determined by Student’s t-test. 
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Six week old uninfected B6-rag1-/-lpr mice had increased numbers of 
splenocytes (Figure 5.17A) and NK1.1+NKp46+ cells in the spleen (Figure 5.17C) 
in comparison to six week old uninfected B6-rag1-/- mice.  Although there was an 
increase in the number of NK cells in the spleen, the NK1.1+NKp46+ % was the 
same in B6-rag1-/-lpr and B6-rag1-/- mice (Figure 5.17B). 
To examine if the increased NK cell number in B6-rag1-/-lpr in comparison 
to B6-rag1-/- resulted in decreased virus titers after infection, and whether NK 
depletion in B6-rag1-/-lpr and B6-rag1-/- mice results in increased virus loads, 
B6-rag1-/-lpr and B6-rag1-/- were either depleted of NK cells by a mAb against 
NK or left untreated or treated with an isotype control mAb, and then infected 
with 4x106 PFU’s of VAC-WR I.P.  All experiments done had similar trends, so 
the experimental results were next combined and plotted. 
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A.  B.  
C.  D.  
 
Figure 5.18. B6-rag1-/-lpr have decreased amounts of virus in the livers and 
spleens when compared to B6-rag1-/-, and treatment with anti-NK antibody 
results in increased virus titers in B6-rag1-/-lpr spleens and B6-rag1-/- and B6-
rag1-/-lpr livers. 
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Figure 5.18. B6-rag1-/-lpr have decreased amounts of virus in the livers and 
spleens when compared to B6-rag1-/-, and treatment with anti-NK antibody 
results in increased virus titers in B6-rag1-/-lpr spleens and B6-rag1-/- and 
B6-rag1-/-lpr livers. B6-rag1-/- or B6-rag1-/-lpr mice were treated with 200µl 
PBS (or 200µl PBS containing 100µg IgG2A isotype antibody) or 200µl PBS 
containing 100µg of NK-depleting antibody.  One day later the mice were I.P. 
infected with 4x106 PFU’s of VAC-WR.  On day 2 splenocytes were stained with 
the appropriate fluorescent antibodies, and (A) FACS analysis was performed to 
ensure of the NK depletion and viral titers in the (B) fat pads (C) livers and (D) 
spleens were determined by plaque assay.  All P values were determined by 
Student’s t-test. NKd is NK monoclonal antibody treatment, and iso is isotype 
control monoclonal antibody treatment. 
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B6-rag1-/-lpr had about ½ a log less virus in the livers (Figure 5.18C) and 
¼ a log less virus in the spleens (Figure 5.18D) when compared to B6-rag1-/- 
mice, with a comparable amount of virus in the fat pad (Figure 5.18B) after I.P. 
infection with 4x106 VAC-WR. B6-rag1-/- and B6-rag1-/-lpr mice treated with a 
mAb to NK1.1 did not have any detectable NK1.1+ cells in the spleen (B6-rag1-/-
lpr shown in Figure 5.18A), confirming the NK depletion.  Treatment with the NK 
depleting antibody resulted in an approximate 1 log increase in liver virus titers in 
B6-rag1-/- and B6-rag1-/-lpr mice after 4x106 VAC-WR I.P. infection (Figure 
5.18C).  NK depleting antibody also increased spleen virus titers significantly in 
B6-rag1-/- and suggestively in B6-rag1-/-lpr mice by approximately ¼ of a log 
after infection (Figure 5.18D), with small but significant decreases in fat pad virus 
titers in B6-rag1-/-lpr after NK depletion, and no difference in fat pad titers 
noticed in any other comparisons (Figure 5.18B).  These results were obtained 
by the combination of 6 different experiments, so while it seems that NK cells 
play a protective role after this high dose I.P VAC-WR challenge, it seems likely 
that the antiviral role might be limited. 
It has been demonstrated that blocking IFNγ increases VAC titers and 
decreased survival after infection, and that mice that are deficient in either the 
IFNγ gene or IFNγR gene have higher titers of VAC and decreased survival after 
infection in comparison to wild type controls ((Ruby and Ramshaw 1991; Huang, 
Hendriks et al. 1993; Karupiah, Fredrickson et al. 1993; Cantin, Tanamachi et al. 
1999).  In light of these studies demonstrating the importance of IFNγ in control of 
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poxvirus spread and survival of poxvirus infections, and the observation that 
there were increased numbers of IFNγ+ NK cells, IFNγ+ CD8+ T cells, and IFNγ+ 
CD4+ T cells in B6-lpr mice when compared to B6 mice, B6 and B6-lpr mice were 
next treated with a mAb against IFNγ, and infected with high dose VAC-WR I.P.  
In three individual experiments, a trend was demonstrated that antibody against 
IFNγ increased virus titers in B6 mice, and more so in B6-lpr mice.  The 
experimental results were next combined, and plotted. 
G.  B6 or B6-lpr Mice Treated With an Antibody Against IFNγ  Have 
Increased Viral Loads in Livers and Spleens, with Virus Titers no Longer 
Being Decreased In B6-lpr Mice In Comparison To B6 Mice 
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A.  B.  
                               C.   
 
Figure 5.19. IFNγ antibody treatment increases virus titers in livers and spleens 
of B6 and B6-lpr mice, and decreases virus titer in fat pad, with treatment making 
virus titers similar in both groups. 
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Figure 5.19. IFNγ  antibody treatment increases virus titers in livers and 
spleens of B6 and B6-lpr mice, and decreases virus titer in fat pad, with 
treatment making virus titers similar in both groups.  
B6 or B6-lpr mice were treated with 200µl PBS containing 350µg of the isotype 
antibody or 200µl PBS containing 350µg of an IFNγ blocking antibody two days 
before infection, and on the day of infection.  Both groups of mice were then 
infected with 4x106 PFU’s of VAC-WR by I.P. inoculation.  On day 2 viral titers (A) 
in the fat pads (B) livers (C) and spleens were determined by plaque assay.  All P 
values were determined by Student’s t-test.  3 grouped experiments. 
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B6 or B6-lpr mice treated with an IFNγ blocking antibody had significantly 
increased virus in the livers and spleen when compared to their genetic 
counterparts treated with an isotype control antibody (Figure 5.19B and 5.19C).  
Interestingly, in the fat pad, treatment with an IFNγ blocking antibody significantly 
decreased virus titers in the B6 or B6-lpr mice (Figure 5.19A), possibly because 
of decreased infiltration of VAC-infected leukocytes into the fat.  Another 
interesting observation was that B6 mice treated with an antibody against IFNγ 
had similar virus amounts in comparison to B6-lpr mice treated with an antibody 
against IFNγ in the spleen (Figure 5.19C), with lower virus titers in the livers of 
B6-lpr mice treated with an antibody against IFNγ that were close to, but not 
significantly different (Figure 5.19B, P=0.065).  This would suggest that IFNγ 
plays an important role in protection against VAC infection in the spleen and liver, 
as has been previously demonstrated, and may play an increased role in B6-lpr 
mice in comparison to B6 wild type mice. 
H.  Chapter Conclusion 
 These experiments demonstrate an altered immune makeup in B6-lpr 
before the onset of a full lymphoproliferative disorder that might lead to increased 
protection from high dose virus infections.  These results do not suggest that 
decreased AICD during the course of infection of B6-lpr mice leads to increased 
protection, but the increased number of NK and γδ+ T cells, already present and 
perhaps due to reduced apoptosis, and the increased numbers of IFNγ-producing 
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cells of multiple subsets might lead to an immuno-protective phenotype from high 
dose viral infections. 
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CHAPTER VI: HIGH FREQUENCIES OF VIRUS SPECIFIC CD8+ T CELL 
PRECURSORS 
An in vivo LDA was designed to estimate the CD8+ T cell precursor 
frequencies to entire viruses.  This was achieved by adoptive transfer of donor 
splenocytes into host mice that differed by two congenic markers (Ly5, Thy1) to 
decrease the fluorescent background when staining for donor CD8+ T cell 
populations, and by increasing the detection limit of resultant T cell progeny by 
counting only CD8+ events by FACS.  By ignoring non-CD8+ events, we increase 
the total number of CD8+ events we are able to collect, and we are able to collect 
just over 4 x 106 CD8+ events, about 1/5 of the total number of CD8+ T cells from 
an uninfected animal (assuming 2 x 107 CD8 T cells per mouse) (Ganusov and 
De Boer 2007), and because of T cell proliferation, approximately 5% of all 
CD3+CD8+ events in an LCMV or VAC-infected mouse.  This allows reliable 
detection of donor CD8+ T cell progeny at limiting dilutions. 
A.  The Phenotype of Adoptively Transferred Donor CD8+ T Cells Is Naïve 
And Shows Linear “Take” After Transfer 
To set up the in vivo LDA, it was first verified that the adoptive transfer of donor 
cells into host mice did not alter the phenotype of donor cells and that adoptive 
transfer of decreasing numbers of T cells resulted in a linear decrease of donor T 
cells in host mice.  
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               A.  
                        B.  
 
Figure 6.1. Adoptively transferred donor CD8+ T cells dilute linearly in host mice 
and have a phenotype that is similar to host CD8+ T cells. 
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Figure 6.1. Adoptively transferred donor CD8+ T cells dilute linearly in host 
mice and have a phenotype that is similar to host CD8+ T cells.  
IgHa (Ly5.2+Thy1.1+ donor) splenocytes were labeled with CFSE, three two-fold 
dilutions were made (mice at highest dilution received 5 x 107 splenocytes), and 
each dilution was adoptively transferred into four B6.SJL (Ly5.1+Thy1.2+ host) 
mice.  On day 5, the mice were sacrificed and FACS analysis performed on 
splenocytes.  (A) Immuno-phenotyping (CD62L, CD127, and CD44) of donor and 
host CD8+ T cells (B). Graph plots the number of donor CD8+ T cells transferred 
into mice against the number of donor CD8+ T cells detected in the spleens of 
host mice.  Mean +/- standard deviation is shown, 4 mice per dilution.  
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Donor CD8+ T cells had phenotypes that remained largely naïve, CD127hi, 
CD62Lhi, and largely CD44lo, and similar to the phenotype of host CD3+CD8+ T 
cells (Figure 6.1A).  As decreasing numbers of T cells were transferred into host 
mice, the number of donor CD8+ T cells detected in the spleen linearly decreased 
with an R2 value of 0.994 (Fig. 6.1B). 
B.  Adoptively Transferred CD8+ T Cells Traffic To Lymphoid Organs and 
Peripheral Sites at Similar Frequencies 
It was next tested whether adoptively transferred T cells would traffic normally 
throughout the body.   
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                Mouse 1        Mouse 2 
 
A.                                                                                      B. 
 
 
Figure 6.2. Adoptively transferred donor CD8+ T cells traffic to similar frequencies 
to lymph organs and to peripheral sites. 
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Figure 6.2. Adoptively transferred donor CD8+ T cells traffic to similar 
frequencies to lymph organs and to peripheral sites.  
Ly5.2+Thy1.1+ donor splenocytes were labeled with CFSE and 1.35 x 107 
splenocytes were adoptively transferred into Ly5.1+Thy1.2+ host mice.  (A) Five 
days later, FACS analysis was performed on lymphocytes from the bone marrow, 
spleen, peribronchial lymph nodes, axillary lymph nodes, and MLN’s to examine 
donor CD8+ T cell take in lymph nodes of host mice (B).  Ly5.2+Thy1.1+ donor 
splenocytes were labeled with CFSE, adoptively transferred into Ly5.1+Thy1.2+ 
host mice and FACS analysis was performed on lymphocytes isolated from the 
spleen, blood, peritoneal cavity, and lungs to examine donor CD8+ T cell take in 
peripheral sites of host mice. 
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CD8+ T cells trafficked at similar frequencies to the MLN, axillary lymph 
nodes (AXLN), peribronchial lymph nodes (PLN), spleen, and to some extent, the 
bone marrow (Figure 6.2a).  When total numbers of recovered Ly5.2+Thy1.1+ 
donor CD8+ T cells were counted from these tissues, 65% of the recovered donor 
CD8+ T cells were in the spleen.  In a separate similar experiment, peripheral 
sites were examined.  There was a reproducibly detectable number of donor T 
cells in peripheral sites such as the PEC’s and lungs, although the “take” in such 
peripheral sites was lower when compared to lymphoid sites such as the spleen 
or MLN (Figure 6.2B).    
C.  Immunodominance Hierarchies of Host and Donor CD8+ T cells Are 
Similar After LCMV or VAC Infection. 
To ensure that transferred T cells had immunodominance hierarchies 
comparable to the ones observed in normal B6 mice, large numbers (~5 x 107) of 
CFSE-labeled Ly5.2+Thy1.1+ donor splenocytes were transferred into 
Ly5.1+Thy1.2+ host mice, and after three days, the mice were infected with LCMV 
or VAC.   
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A.  
B.  
 
Figure 6.3. Transferred donor and host CD8+ T cells have similar 
immunodominance hierarchies to LCMV and VAC infections. 
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Figure 6.3. Transferred donor and host CD8+ T cells have similar 
immunodominance hierarchies to LCMV and VAC infections.  
5 x 107 Ly5.2+Thy1.1+ donor splenocytes were labeled with CFSE and adoptively 
transferred into Ly5.1+Thy1.2+ host mice, which were subsequently I.P. infected 
with LCMV or VAC.  Six (VAC) or seven (LCMV) days later, mice were sacrificed, 
splenocytes isolated, and peptide and polyclonal stimulations performed, 
followed by an intracellular cytokine stain for IFNγ.  FACS analysis was then 
performed. Results are plotted as the percentage of donor or host CD8+ T cells 
that are IFNγ+. (A) Host and donor IFNγ+ after VAC-WR infection. (B) (A) Host 
and donor IFNγ+ after LCMV infection. 
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On Day 6 of VAC-WR infection, intracellular IFNγ assays were performed 
by stimulating spleen cells with VAC peptides or by polyclonal stimulation with 
mAb to CD3ε. The percentages of host and donor CD8+ T cells that produced 
IFNγ when stimulated with mAb to CD3ε or with VAC-specific peptides B8R or 
A47L was similar (Figure 6.3A).  On Day 7 of LCMV infection, intracellular IFNγ 
assays were performed by stimulating spleen cells with LCMV peptides or by 
polyclonal stimulation with mAb to CD3ε.  The percentages of host and donor 
CD8+ T cells that produced IFNγ when stimulated with mAb to CD3ε or with 
LCMV-specific peptides GP33, NP396, GP276, GP118, and NP205 were the 
same in both donor and host CD8+ T cells (Figure 6.3B). 
D.  In Vivo LDA for Virus-Specific T Cells 
To determine virus specific CD8+ T cell precursor frequencies, graded 
amounts of splenocytes were transferred into host mice at limiting dilution 
numbers that result in proliferated donor CD8+ T cells in ~50% of hosts.  
Ly5.2+Thy1.1+ donor splenocytes from uninfected mice were labeled with CFSE 
and transferred at decreasing numbers (5 x 106, 2.5 x 105, 1.25 x 105, 0.625 x 
105) into Ly5.1+Thy1.2+ hosts.   Pilot experiments had demonstrated that in all 
host mice at the 5 x 106 dose, some donor CD8+ T cells proliferated, as shown by 
a CFSElo peak in response to a VAC infection, so this dilution was used in 
subsequent experiments as a positive control.  The 2.5 x 105, 1.25 x 105, and 
0.625 x 105 splenocyte dilutions resulted in responders and nonresponders, so 
these dilutions were used for in vivo LDA calculations.  Typically, five hosts 
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received each in vivo LDA dilution, with one host from each dilution being left 
uninfected as a negative control for background staining (see Materials and 
Methods).  A small aliquot of the transferred splenocytes was stained, and FACS 
analysis was performed to determine the exact number of CD8+ T cells 
transferred into host mice.  
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A. 
B.  
189
C.  
 
Figure 6.4. In vivo limiting dilution assay. 
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Figure 6.4. In vivo limiting dilution assay.  
1.25 x 105 Ly5.2+Thy1.1+ donor splenocytes were labeled with CFSE and 
adoptively transferred into Ly5.1+Thy1.2+ host mice, which were subsequently 
I.P. infected with VAC.  Six days later, mice were sacrificed, and stained for 
FACS analysis.  (A) Gating scheme is shown for the in vivo LDA.  Analysis was 
done, from left to right, gating on singlets by gating on FSC-A vs. FSC-W, 
lymphocytes by FSC-A vs. SSC-A, CD8+ T cells by gating on CD3+CD8+ cells, 
and donor cells by Thy1.1+ and Ly5.2+ gates.  In Ι is an uninfected mouse at a 
limiting dilution dose (1.25 x 105 splenocytes) of donor CD8+ T cells.  In ΙΙ and ΙΙΙ 
are examples of responders at this same dose and IV and V examples of non-
responders  (B). Ly5.2+Thy1.1+ donor splenocytes were labeled with CFSE, two 
two-fold dilutions made, and each dilution was adoptively transferred into five 
Ly5.1+Thy1.2+ host mice.  At each dilution, one mouse was left uninfected, the 
other mice were infected with VAC-WR I.P., and FACS analysis was performed 
on splenocytes as described as in Figure 6.4A. Responders vs. non-responder 
determinations were as described in Materials and Methods (Cose, Brammer et 
al. 2006; Ganusov and De Boer 2007) (C) Splenocytes from Ly5.1+ H-2Db-
restricted LCMV GP33-specific P14 transgenic animals were labeled with CFSE, 
and two two-fold dilutions were adoptively transferred into five B6 (Ly5.2+Thy1.2+ 
host) mice.  Gating scheme, and responder non-responder determinations as in 
(A). 
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Previous experiments (data not shown) indicated that VAC-specific CD8+ 
T cell responses peaked at day 6, so on day 6 mice were sacrificed and their 
splenocytes analyzed by FACS under two conditions.  For each spleen a small 
aliquot was run, analyzing all events to determine the CD3+CD8+ percentage, 
and then, to allow detection of the small number of donor CD3+CD8+ progeny at 
limiting dilutions, the rest of the spleen was analyzed with the threshold set to 
only collect CD8+ events.  Figure 6.4A is an example of a transfer at limiting 
dilution in VAC-infected or uninfected mice.  Responders vs. non-responders 
were scored as described in Materials and Methods.  Figure 6.4B is an example 
of a full in vivo LDA for VAC-WR, where the number of responders per 
concentration is 3 of 4 at the high concentration, 2 of 4 at the intermediate 
concentration, and 1 of 4 at the low concentration.   
This assay also allowed for a rough estimate of the number of divisions a 
single virus-specific CD8+ T cell by the time of harvest.  These results suggested 
that a CD8+ T cell at limiting dilution underwent an average of 11 divisions by day 
6 of VAC infection, which is in line with what can be calculated from experiments 
performed by others (Obar, Khanna et al. 2008).  This number can be calculated 
from tetramer pull-down assays by calculating the number of divisions it requires 
to get from the naïve precursor number CD8+ T cell number to the peak CD8+ T 
cell number.  For the in vivo LDA this is a rough calculation where the total 
number of donor CFSElo events in a responder is divided by the total number of 
CD8+ events collected to get a CFSElo donor frequency, this is then multiplied by 
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the total number of CD8+ T cells in the spleen, and the dilution that this 
responder occurred at is then multiplied or divided to get the dilution that is 
expected to give a single CD8+ precursor, and this resulting value is then 
multiplied by 1 1/3 with the assumption that approximately 67% of CD8 T cells 
are present in the spleen (Cose, Brammer et al. 2006; Ganusov and De Boer 
2007).  These calculations assume no cell death during division.  So, instead of a 
true calculation for the number of divisions a T cell has undergone, the 
calculations instead estimate the least number of divisions a T cell must have 
undergone to result in the number of progeny detected. 
As a validation for the efficiency of the in vivo LDA, Ly5.1+ H-2Db-restricted 
LCMV GP33-specific P14 transgenic T cells (P14 transgenic T cells) were 
transferred into B6 (Ly5.2+) mice at limiting dilution numbers, and the mice were 
subsequently infected with LCMV  
In this experiment, the number of responders per concentration was 3 of 4 
at the high concentration, 1 of 4 at the intermediate concentration, and 0 of 4 at 
the lowest concentration (Figure 6.4C).  
E.  Determination of Donor “Take” 
One caveat of determination of precursor frequencies using an adoptive 
transfer method is the donor “take”.  It has been known that after adoptive 
transfer, not all donor CD8+ T cells survive in the host, and the percentage that 
do survive in a host mouse has been referred to as donor “take”.  
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Figure 6.5.  Determination of donor take.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
194
Figure 6.5.  Determination of donor take.  
The number of donor CD8+ T cells transferred was plotted against the number of 
donor CD8+ T cells detected in host spleens after transfer.  Graph is from 91 
uninfected mice used in 26 different experiments.  Determination of donor take 
was calculated by using the equation generated, and assuming that splenic CD8+ 
T cells account for 67% of CD8+ T cells. 
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Figure 6.5 is a graph of 91 uninfected mice and plots the number of 
Ly5.2+Thy1.1+ donor CD8+ T cells transferred into Ly5.1+Thy1.2+ hosts against 
the number of Ly5.2+Thy1.1+ donor CD8+ T cells found in the spleen.  The “take” 
of Ly5.2+Thy1.1+ donor CD3+CD8+ cells in Ly5.1+Thy1.2+ host mice was 
determined by plotting the log10 of the number of donor CD3+CD8+ cells 
transferred by the log10 of the number of CD3+CD8+ donor cells recovered in the 
spleens of uninfected host mice.  Mice that received less than 1.25 x 105 
splenocytes were not included in the analysis because at this number 
transferred, donor CD3+CD8+ cells were not reproducibly detectable in uninfected 
hosts.  The resulting formula was then used to calculate a percent take in the 
spleen.  Then using the assumption that 67% of all CD3+CD8+ cells in a naïve 
uninfected mouse reside in the spleen (Cose, Brammer et al. 2006; Ganusov and 
De Boer 2007) (this may be a slight overestimate when compared to the results 
above, that suggest that less than 65% of donor CD3+CD8+ cells reside in the 
spleen (Figure 6.2)), the calculation of a total donor take is possible.  The CD8+ T 
cell “take” was calculated to be 3.8%. 
F.  Precursor Frequency Determination 
Using multiple in vivo LDA’s, the above take value, and probit analysis 
(Bliss 1934) T cell precursor frequencies in naïve and immune mice can be 
calculated as shown in Table 3 and described in Materials and Methods.  There 
were about 1 in 2958 +/- 392 CD8+ T cells in naïve mice that proliferated in 
response to LCMV, while there were almost twice as many, 1 in 1444 +/- 171 
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CD8+ T cells that proliferated in response to VAC (P<0.0001 in comparison to 
LCMV precursors). The number of CD8+ T cells in VAC-immune mice that 
proliferated in response to VAC was, as expected, greatly increased, with 1 in 13 
+/- 2 CD8+ T cells able to proliferate in response to this homologous infection 
(P<0.0001 in comparison to naïve immune state).  As expected, the LCMV-
specific CD8+ T cell precursor frequency was not elevated in VAC-immune mice; 
in fact it was slightly, although significantly, decreased, with about 1 in 4425 +/- 
1705 CD8+ T cells proliferating (P<0.05 in comparison to naïve immune state).   
P14 cells are monoclonal transgenic T cells that recognize the H2Kb 
LCMV GP33 peptide, and this monoclonal T cell population allows us to perform 
an in vivo LDA with T cells of a single specificity.  The number of P14 transgenic 
T cells that responded to an LCMV infection was next calculated by the in vivo 
LDA, and the precursor frequency by probit analysis was calculated to be 1 in 
0.93 +/- .04.  This suggests a virtually 100% efficiency in the outgrowth of the 
transgenic T cells and supports the calculations made concerning T cell “take” 
after transfer.  
The commonly used Reed and Muench 50% endpoint analysis was also 
employed to determine precursor frequencies (Reed and Muench 1938), and 
these calculations result in precursor frequencies comparable but not identical to 
the probit method.  By Reed and Muench analysis, naïve mice had 1 in 3121 +/- 
291 CD8+ T cells specific to LCMV and 1 in 1615 +/- 409 CD8+ T cells specific to 
VAC, while in VAC-immune mice, 1 in 3956 +/- 787 were specific to LCMV, and 1 
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in 13 +/- 1 were specific to VAC in these immune mice.  Using the Reed and 
Muench method it was calculated that 1 in 1.22 +/- 0.11 P14 transgenic T cells 
responded to an LCMV infection, again a figure close to 100%. 
A summary of B6 mouse precursor frequency determinations by different 
methods is given in Table 3, and is discussed further below.   
G.  Chapter Conclusion 
The in vivo LDA now allows for the enumeration of the number of 
pathogen specific CD8+ T cell in naïve mice with no knowledge of the CD8+ T cell 
determinants encoded within the pathogen.  This technique also allows for the 
calculation of the total number of CD8+ T cells within a mouse that will proliferate 
in response to a pathogen. 
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Table 6.1.  Precursor frequency determination of naïve and immune states 
by in vivo LDA. 
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Table 6.2.  Precursor frequency determination in B6 mice by many  
techniques. 
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CHAPTER VII:  DISCUSSION 
 The World Trade Center attacks on September 11, 2001 and the anthrax 
letters sent through the mail soon after revitalized the national will to protect 
against future terrorist attacks, one of these being a biological attack with a 
poxvirus agent.  This renewed interest brought about increased funding of 
program projects whose ultimate goal was to improve smallpox vaccines so that 
the new vaccines would have the same immuno-protective profile but have 
decreased pathogenicity when given to a large population.  This led to a 
collaboration of our group with a consortium at Harvard to first, work on 
generating vaccines with improved prophylactic profiles, to second, understand 
the pathogenesis of high dose poxvirus infections and understand the immune 
mechanisms that can provide protection from these infections, and third, to 
develop a better basic understanding of the immune response against poxvirus 
infections and develop tools that might aid in discovering improved vaccines. 
The recent publications of the long lived nature of smallpox vaccination 
using VAC as the immunization (Crotty, Felgner et al. 2003; Hammarlund, Lewis 
et al. 2003), especially considering the fact that most individuals tested have not 
been re-challenged, provided great incentive to further work on VAC as a vector 
to improve smallpox vaccine efficacy.  This work might also advance the effort to 
establish VAC as a vector for immunization against other pathogens, and this 
approach has already proved effective for rabies (Pastoret and Brochier 1996) 
and for rinderpest using a capripox recombinant (Ngichabe, Wamwayi et al. 
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2002), and it could be imagined this might be extended to human vaccinations.  
This strategy may become even more attractive as the population ages, as the 
percentage of individuals that have been vaccinated against smallpox decreases 
with time as the originally vaccinated population succumbs to old age.  The 
inclusion of proteins that might provide protection against other pathogens might 
actually be seen as doubly beneficial, as it would be expected, as has been 
described (Harrington, Most et al. 2002), that poxvirus specific immunity would 
be retained if genes encoding other proteins are included in the genome. 
 VAC variants used as smallpox vaccines have been characterized as 1st 
generation (original vaccines originally grown in many different ways Ex. 
Dryvax), 2nd generation (the 1st generation vaccines adapted to grow in cell 
culture, ACAM2000), 3rd generation (passaging of virus in cell culture to 
attenuate Ex. MVA) and 4th generation (VAC recombinants with targeted 
mutations to enhance immunity or decrease pathogenicity) (Kennedy, 
Ovsyannikova et al. 2009).  One of the hopes for the fourth generation vaccines 
would be to knock out regions of the VAC genome that have already been shown 
to increase virus spread, thereby possibly accelerating the process of discovery 
of improved variants.  The three proteins targeted were an IFNγBP (B8R), IL-
18BP (C12L), and CBP (C3L, C21L).  Using poxviruses strains that did not 
include VAC-Wy, which is used for smallpox vaccination, infections with all three 
of these gene knockout variants have been demonstrated to have decreased 
pathogenicity (Miller, Shchelkunov et al. 1997; Sroller, Ludvikova et al. 2001; 
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Symons, Adams et al. 2002) with two in various animal models demonstrating 
decreased pathogenicity (Isaacs, Kotwal et al. 1992; Sroller, Ludvikova et al. 
2001), and with the their respective activities being described in various 
poxviruses, suggesting that the proteins they encode would be widely pathogenic 
(Spriggs, Hruby et al. 1992; Alcami and Smith 1995; Miller, Shchelkunov et al. 
1997; Smith, Bryant et al. 2000).  Promisingly, one of the B8R-/- VAC variants 
has been demonstrated to reduce pathogenicity in an attenuated strain of VAC 
(VAC Lister) (Denes, Gridley et al. 2006).   
Single knockout, double knockout, and triple knockout VAC variants along 
with IFNγ binding protein variants were tested for differences in virus spread and 
pathogenicity, with no difference being detected in various knockout mouse 
models, strains, or through the use of different infection routes (Table 3.1, 
Figures 3.1 and 3.2, Figure 4.1).  This may have been due to the attenuated 
character of the VAC-Wy strain inside of mice.  It took 50x the normally lethal I.N. 
dose of VAC-WR to even begin to detect virus in the lungs of infected mice.  It 
was promising to note that all recombinants tested grew at similar rates and to 
similar titers in vitro (communicated by Pei Wu), but this outcome precluded the 
study of the pathogenesis of the different IFNγBP knock-in and knock out viruses.   
The relative poor growth of VAC-Wy in the mouse model had already 
been illustrated (Hayasaka, Ennis et al. 2007), but the generation of these 
knockouts within VAC-Wy was done to allow for quick transition to human 
vaccination.  In light of the fact that the parental virus grows poorly in mice, and 
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that these gene knockout variants have demonstrated reduced pathogenicity in 
other animal models and poxvirus strains, it still seems likely that testing the 
knockout recombinants in an appropriate animal model would demonstrate 
reduced virus spread and pathogenicity. 
However, I.N. infection of the recombinants at doses that just barely 
allowed virus detection by plaque assay (Table 3.1), still induced a VAC-specific 
CD8+ T response (Figure 3.3), and skin-scarification induced similar amounts 
CD8+ T cells by the VAC recombinant infection as the VAC-Wy infection (Figure 
3.4).  The comparable immune responses induced by the skin-scarification route 
was promising as recent studies have demonstrated the increased efficacy of the 
skin-scarification immunization with VAC in comparison with intra-dermal, intra-
muscular, or sub-cutaneous inoculation in providing protection against either 
cutaneous, or lethal I.N. VAC challenge (Liu, Fuhlbrigge et al. 2006; Liu, Zhong 
et al. 2010) 
The identity of the B8R knockout was also confirmed, as the 
immunodominant CD8+ T cell epitope in the B6 mouse is encoded within the B8R 
protein.  Mice infected with viruses that did not contain the B8R gene did not 
have a B8R-specific response, but still had CD8+ T cells that responded to 
peptide stimulation with a peptide from a subdominant epitope in VAC (Figure 
3.3).  
Promisingly, immunization with the Wyeth parental or with the four B8R 
recombinant VAC’s was able to protect mice from death induced by 20 LD50’s of 
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VAC-WR (Figure 3.5A), with all groups of immunized mice gaining weight starting 
at day 3.  Further experiments examining viral loads after 20 LD50’s of VAC-WR, 
demonstrated that immunization with any of the B8R recombinants or the Wyeth 
parental strain resulted in almost no virus being detected in the livers or spleens 
of the immunized mice, as compared to the almost 5 logs of virus being detected 
in the livers and spleens of non-immunized mice, with significant reductions of 
virus also found in the lung in immunized mice (Figure 3.6).  These results 
suggest that the protection provided by the recombinants was similar to the 
protection induced by the parental VAC-Wy strain.  Previous studies have 
examined the pathogenicity (Sroller, Ludvikova et al. 2001; Verardi, Jones et al. 
2001; Symons, Tscharke et al. 2002; Denes, Gridley et al. 2006) and VAC-
specific immune responses (Verardi, Jones et al. 2001; Denes, Gridley et al. 
2006) induced by B8R-/- VAC variants, but none have examined immuno-
protective profiles, and these results establish that skin-scarification with any of 
the IFNγ BP recombinants or the parental strain provide protection against lethal 
VAC-WR challenge.  The similar protection induced by the B8R knockout and the 
dimer mIFNγ knock-in is also important to point out.  These two viruses might be 
thought to encode two opposite ends of a spectrum, one encodes a secreted 
protein with high affinity to IFNγ, and the other no longer encodes a protein that 
binds IFNγ, and the fact that both are able to induce similar amount of protection 
to a VAC-WR challenge was promising. 
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These viruses also allow another unique opportunity, as it is possible to 
immunize with a virus that lacks the protein that encodes the immunodominant 
epitope, and challenge with a strain that encodes this epitope.  Interestingly, lack 
of the B8R epitope from the immunization virus had no effect on protection from 
the 20 LD’50’s of VAC-WR challenge, and in mice immunized with a B8R 
knockout virus 167 day previously, there was almost no detectable B8R-specific 
CD8+ T cell response on day 5 after VAC-WR challenge, even though the 
challenge virus contained the epitope (Figure 3.7B) or on day 6 (Figure 3.5B).  
This suggests that the CD8+ T cell response to a homologous infection is almost 
entirely of memory origin (Figure 3.7 and Figure 3.5B).  This may simply be an 
issue of numbers.  From tetramer-pulldown assays it has been estimated that in 
a naïve mouse, about 1 in 10,000 naïve CD8+ T cells are B8R-specific 
(Haluszczak, Akue et al. 2009), while in an immunized mouse, about 1 in 1,000 
CD8+ T cells were specific to A47L as shown by intracellular cytokine assay 
(Figure 4.2A).  Memory CD8+ T cells are also not suspected to be necessary in 
recall responses against VAC in the mouse, as previous depletion studies have 
described them as dispensable in a VAC-WR challenge model after vaccination 
(Belyakov, Earl et al. 2003).  These results in some ways support this study, as 
the lack of an immunodominant CD8+ T cell epitope from immunization does not 
change the immunoprotective phenotype when examining near homologous virus 
challenge.  
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The VAC-specific memory induced by the VAC-Wy-/-/- (B8R-/-, C3L-/-, 
C12L-/) immunization was also examined, and it was found that the triple VAC-
Wy-/-/- and the VAC-Wy parental strain were able to induce the same level of 
neutralizing antibody and VAC-specific CD8+ T cells to a subdominant epitope 
(Figure 4.2A).  Once again, although no pathogenic difference was demonstrated 
in mice (Figure 4.1), it was of interest to note that the VAC-Wy-/-/- recombinant 
with three genes that encode for immunomodulatory proteins knocked out was 
able to induce the same level of VAC-specific immunological memory as the 
Wyeth parental strain from which it was generated.  Either vaccination with VAC-
Wy or the VAC-Wy-/-/- provided significant protection from I.N. challenge of 20 
LD50’s VAC-WR, as there was no detectable virus in livers or spleens of these 
immunized mice with about 2.5 logs of virus detected in the lungs.  There was an 
increased, but not statistically different amount of virus in the lungs of VAC-Wy-/-
/- -immunized mice in comparison to Wyeth-immunized mice.  In the PBS -
immunized mice on the other hand, 5 logs of virus was detected in the livers, 7 
logs of virus in the lungs, and about 2 1/2 logs of virus in the spleen (Figure 4.3).  
It is known that each of these immunomodulatory proteins contribute to 
pathogenesis in other mouse and rabbit poxvirus infection models (Isaacs, 
Kotwal et al. 1992; Symons, Adams et al. 2002; Denes, Gridley et al. 2006).  
Interestingly, the MVA virus contains a fragmented version of B8R with both C3L 
and C12L being completely deleted (Antoine, Scheiflinger et al. 1998), but a 
recombinant VAC encoding the six major deletions of MVA which include C3L 
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and C12L deletions but not a B8R deletion was not as attenuated as MVA 
(Meisinger-Henschel, Spath et al. 2010).  This result then gives rise to the 
question of, what else is attenuating in MVA, and why does it take increased 
virus to induce responses that are as protective as the usual smallpox 
vaccination.  The observation that the VAC-Wy-/-/- recombinant is able to induce 
similar immune responses as the VAC-Wy parental strain in a skin-scarification 
infection with similar protection as the VAC-Wy parental strain supports the 
continued investigation of targeted gene knockouts of VAC as a method to 
develop improved smallpox vaccines.  
Further evidence of a CD8+ T cell response to a homologous infection 
being almost entirely of memory origin (Figure 3.7) is demonstrated again as 
immunizing mice with a VAC-Wy-/-/-  that lacks the protein B8R, results in a 
CD8+ T cell response to VAC-WR I.N. challenge that includes almost no B8R-
specific CD8+ T cells  (Figure 4.4B).  Further results from these experiments 
demonstrate a decrease in the number of CD8+ T cells that respond to a 
polyclonal stimulation in the VAC-Wy-/-/- -immune mice challenged with 20 
LD50’s VAC-WR as compared to the VAC-Wy immune mice challenged with 20 
LD50’s VAC-WR I.N. (Figure 4.4A).  This decrease is most likely due to the lack 
of the peptide that encodes the immunodominant epitope in the immunization 
virus, but in this experiment that included a larger number of mice, there were 
increases in the number of CD8+ T cells responding to subdominant epitopes in 
the VAC-Wy-/-/- -immune mice as compared to the VAC-Wy vaccination and 
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challenge, and this might represent a compensation mechanism (Figure 4.4C 
and 4.4D).  This compensation mechanism does not look to be complete, 
however, as the response to a polyclonal stimulation was lower.  However, these 
experiments cannot rule out that other non-tested or cryptic epitopes combine to 
make up for the lack of the B8R-specific response, as it has been demonstrated 
in HSV mouse models that deletion of an immunodominant epitope can result in 
detection of other epitopes that normally cannot be detected with a parental virus 
infection (Wallace, Keating et al. 1999). 
These results in total are supportive of further study of these 
recombinants, both as a vaccine against smallpox, and possibly as a vector for 
vaccines to other infections.  Further analysis in other models might yet 
demonstrate that these viruses are less pathogenic than the Wyeth parental 
strain. The MVA virus that is deficient in these three genes, among many others 
requires multiple inoculations to be as protective as Wyeth (Earl, Americo et al. 
2004), while in our hands the VAC-Wy-/-/- recombinant provides similar 
protection as VAC-Wy to a lethal I.N. VAC-WR challenge in the mouse model, 
and this supports the continued investigation of this variant of VAC-Wy as a new 
smallpox vaccine.   
The description of improved vaccines is an important step in the study of 
immunology, but improved understanding of acute infections, and what factors 
are important in resolving them allows for better therapeutic intervention and 
prognostic markers.  It is also important to study acute infection in models that 
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mimic human disease, such as SLE, as these investigations may provide insight 
into the infection, and to the disorder.   
Many cell types have been implicated in resolution of acute poxvirus 
infections, B cells (Morita 1973; Belyakov, Earl et al. 2003; Fang and Sigal 2005), 
CD8+ T cells (Belyakov, Earl et al. 2003; Fang and Sigal 2005), CD4+ T cells (Xu, 
Johnson et al. 2004), γδ+ T cells (Selin, Santolucito et al. 2001), and NK cells 
(Bukowski, Woda et al. 1983; Fang, Lanier et al. 2008; Martinez, Huang et al. 
2008), but how resolution of a typically lethal infection might occur is not as well 
studied. 
Early studies in our lab had demonstrated that lethal I.N. doses of VAC-
WR in mice would result in few VAC-specific CD8+ T cells detectable in the 
mouse spleens.  As this decreased number of VAC-specific CD8+ T cells seemed 
to occur only after high dose lethal I.N. infections, it was thought that VAC-
specific CD8+ T cells might be being eliminated by AICD.  AICD is a 
phenomenon whereby continued stimulation of the TCR’s of T cells results in 
their apoptosis (Takahashi, Maecker et al. 1989; Ucker, Ashwell et al. 1989; 
Russell, White et al. 1991), and it has been demonstrated with acute LCMV 
infection and with LCMV that grow to high titers inside of mice, that continued 
stimulation of CD8+ T cells can result in their apoptosis (Moskophidis, Lechner et 
al. 1993; Razvi and Welsh 1993).  AICD has, in some cases, also been linked to 
Fas expression, as T cells from B6-lpr (Russell, Rush et al. 1993) and B6-gld 
have defects in in vitro induced AICD (Russell and Wang 1993).  This Fas 
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dependent AICD might not be a primary mechanism in vivo though, as apoptosis 
of T cells during the contraction phase of the response after acute LCMV 
infection does not seem to be exclusively dependent on Fas (Razvi, Jiang et al. 
1995) and the T cell apoptosis (exhaustion) induced after infection with an LCMV 
variant that grows to high titers inside of a mouse also seems not to be 
exclusively dependent on Fas (Lohman and Welsh 1998).   
Although this mechanism did not seem to be the primary mechanism of 
AICD in LCMV infections, it was still a possibility that Fas might be contributing to 
an AICD phenomenon after high dose I.N. VAC-WR infection.  B6-lpr were 
indeed found to have increased percentages and numbers of CD4+ and CD8+ T 
cells in the MLN’s with an increased number of B8R-specific CD8 T cells after 
high dose I.N. VAC-WR infection (Figure 5.2).  In fact, even after high dose I.P. 
VAC-WR infection, there was an increased number of CD4+ and CD8+ T cells in 
the B6-lpr spleens (Figure 5.3B and 5.3C). Interestingly, B6-lpr mice infected with 
a high dose of VAC-WR I.N. lost less weight, and had a decrease of almost 2 
logs of virus in the livers  (no difference in lungs) when compared to B6 wild type 
(Figure 5.1).  B6-lpr mice infected with a lethal dose of VAC-WR I.P. also lost 
less weight over the infection period and had almost 2 logs less virus in fat pads 
and spleens (Figure 5.3).  These results seem to be consistent with the idea that 
AICD was leading to increased apoptosis of T cells, and in the B6-lpr mice, the 
decreased Fas-dependent AICD was allowing increased T cell responses 
allowing for decreased virus titers and less weight loss.  
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Intriguingly, work had recently been published that suggested a 
mechanism by which high dose virus infection might be causing CD8+ T cell 
immuno-suppression by Fas/FasL interactions.  In this influenza model of 
infection, lethal doses of influenza virus up-regulated FasL on dendritic cells, 
which would then kill off activated CD8+ T cells, thereby limiting the influenza 
virus specific CD8+ T cell response (Legge and Braciale 2005).  This model could 
explain the observations noted with high dose VAC-WR infections, but further 
experiments would needed to be performed to test the hypothesis that high dose 
infection was up-regulating FasL on cells leading to increased apoptosis of virus 
specific T cells. 
In competitive adoptive transfer experiments, in which CFSE- labeled B6-
lpr and CFSE- labeled wild type IgHa cells were transferred into B6.SJL mice, 
which were then infected with a lethal dose of VAC-WR I.P., CD8+ T cells from 
B6-lpr mice did not survive or proliferate more extensively than CD8+ T cells from 
a B6 wild type mouse (Figure 5.4).  There was no difference in either the 
percentage of CD8+ T cells that were CFSElo when comparing the IgHa and B6-
lpr donor cells (Figure 5.4B), nor was there a difference in total numbers of donor 
cells surviving (Figure 5.4C).  These results were not consistent with the 
hypothesis that increased FasL was killing off activated CD8+ T cells. 
As the protection from weight loss in B6-lpr mice in comparison to B6 mice 
was seen early in both I.N. and I.P. infections (Figure 5.1A and 16A), and FACS 
staining revealed increases in NK and γδ+ T cell percentage in B6-lpr infected 
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mice it was possible that there was an early mechanism of protection occurring in 
B6-lpr mice.  Both cell types have been demonstrated to provide protection from 
poxvirus infections (Bukowski, Woda et al. 1983; Selin, Santolucito et al. 2001; 
Fang and Sigal 2005; Martinez, Huang et al. 2008), and both NK cells and γδ+ T 
cell might work early in the infection to provide B6-lpr mice protection against hi-
dose VAC-WR infection. 
To further examine the protection in B6-lpr mice, virus titers after lethal 
VAC-WR I.P. infection at days 2 and 3 in B6-lpr mice in comparison to B6 wild 
type mice were examined, and day 2 titers of B6-gld mice and B6 wild type mice 
were compared. These experiments demonstrated that Fas mutant mice had 
decreased virus titers in the livers and spleens in comparison to B6 wild type 
mice (Figure 5.7), with decreases in fat pad titer only noted at day 2 in the Fas 
mutant mice.  This result suggested there was some early mechanism at work 
that either decreased virus loads, or did not allow the virus to grow in Fas mutant 
mice.  Interestingly, although Fas/FasL interactions are typically described as 
important mechanisms by which T cells can eliminate infected cells (Price, 
Huang et al. 2005; Chen, Hsu et al. 2006), it has been shown that B6-lpr mice 
and mice receiving an antibody that blocks FasL (DcR3) subcutaneuosly 
throughout an experiment in comparison to untreated B6 mice have decreased 
amounts of bacteria in the lung at day 2 after an I.N. Streptococcus pneumoniae 
infection (Matute-Bello, Liles et al. 2005), although the mechanisms of protection 
in these experiments were not detailed.  
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As the mechanism of protection seemed to act very early, uninfected B6-
lpr mice were examined.  There were about 1.5-2x as many NK cells and γδ+ T 
cells, with increases in the number of memory like (CD44+) CD4+ and CD8+ T 
cells in B6-lpr mice as compared to B6 wild type mice (Figure 5.6 A,B,C,D).  
There was also an increased percentage and number of CD8+ T cells that were 
IFNγ+ (Figure 5.6E and 5.6F) after a polyclonal stimulation.  All subsets 
mentioned had been described to provide protection against acute poxvirus 
infections (Selin, Santolucito et al. 2001; Belyakov, Earl et al. 2003; Xu, Johnson 
et al. 2004; Martinez, Huang et al. 2008), so these subsets were depleted or 
blocked individually in B6-lpr mice through use of mAb. None of the single 
depletion treatments significantly changed virus titers at day 3 in the fat pads, 
livers, or spleens (γδ block Figure 5.7, NK depletion Figure 5.8, CD4 depletion 
Figure 5.9, CD8 depletion Figure 5.10).  While no one subset was demonstrated 
to be the subset providing protection against VAC-WR in B6-lpr mice, it was still 
a possibility that multiple subsets were acting together or redundantly to provide 
protection. 
Indeed, when examining splenocytes in day 2 infected mice, it was found 
that B6-lpr mice had increased numbers of splenocytes, and increased number 
of NK, CD4+, and CD8+ T cells that spontaneously produced IFNγ after a five 
hour culture when compared with B6 mice (Figure 5.11).  As it had been 
demonstrated that IFNγ can play a significant role in resolving VAC infections, 
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this result was intriguing and merited further follow-up (Huang, Hendriks et al. 
1993; Karupiah, Fredrickson et al. 1993). 
Another interesting observation noted in Figure 5.11A was the protection 
of B6-lpr mice from the VAC-WR induced lymphocyte deficiency in the spleen, 
and one explanation for this result would be the lack of an early Fas dependent 
AICD mechanism.  This hypothesis was tested by high dose (4x106 PFU I.P.) 
VAC-WR infection of B6.SJL mice that had received a 1:1 mix of DDAO labeled 
B6-lpr splenocytes and CFSE labeled IgHa splenocytes.  The adoptive transfer 
results did not support this conclusion, as both splenocytes populations survived 
equally well (Figure 5.12A), with no increased survival in γδ+ T cells (Figure 
5.12B), NK cells (Figure 5.12C), or CD4+ or CD8+ T cells (Figure 5.12D) in B6-lpr 
donor cells versus IgHa wild type donor cells.    
At this point there had been no specific subset that could be depleted that 
removed the increased protection in B6-lpr, and adoptive transfer experiments 
had suggested that both B6-lpr splenocytes and IgHa wild type splenocytes were 
as susceptible to VAC-WR induced lymphocyte depletion.   
In examining all day 2 mice, it was confirmed that B6-lpr mice had 
decreased virus loads when compared to B6 wild type mice (Figure 5.15A, 
5.15B, and 5.15C), and if viral titers were divided by initial weight, B6-lpr still had 
decreased titers when compared to B6 mice, thus suggesting that weight was not 
the reason behind the increased protection in B6-lpr mice (Figure 5.15D, 5.15E, 
and 5.15F).   
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In the correlation studies, CD8+ T cells and γδ+ T cells were found to 
negatively correlate with virus titers and in B6-rag1-/- and B6-rag1-/-lpr, depletion 
of NK cells was found to increase virus titers in most organs (Figure 5.18).  
These results, in combination with the observation that no single depletion 
decreased virus titers in B6-lpr mice makes it seem likely that multiple leukocyte 
types were working together or redundantly to provide the increased protection 
from high dose VAC-WR infection in B6-lpr mice. 
The observation in Figure 5.11 of increased numbers of IFNγ+ NK, IFNγ+ 
CD4+, and IFNγ+ CD8+ T cells in B6-lpr mice compared to B6 wild type mice, and 
the knowledge that IFNγ was important in resolving poxvirus infections (Ruby and 
Ramshaw 1991; Huang, Hendriks et al. 1993; Karupiah, Fredrickson et al. 1993; 
Cantin, Tanamachi et al. 1999), left open the possibility that several different 
types of leukocytes could be cooperatively or redundantly producing IFNγ in 
response to this high dose infection in B6-lpr mice and thereby provide increased 
protection.  This possibility was studied by using treatment with an anti-IFNγ 
antibody, and it was found that after combining three studies, as each study 
demonstrated similar trends, anti-IFNγ antibody increased VAC titers in B6-lpr 
and B6 mice in the livers and spleens, with a decrease in virus titers in fat pads 
(Figure 5.19).  The increased titer in fat pad was unexpected, but the block of 
IFNγ in the fat pad may instead work to impede infected leukocyte cell migration 
into the fat.  It may also be possible that different mechanisms are required for 
virus clearance in the fat pad versus the liver or spleen as has been 
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demonstrated with MCMV, where production of IFNγ by NK cells, is more 
important in clearance of MCMV in the livers of mice, while perforin seems more 
important in virus clearance in the spleen (Tay and Welsh 1997; Selin, Varga et 
al. 1998).  Interestingly, anti- IFNγ treatment of B6-lpr and B6 mice resulted in 
spleen and liver virus titers that were not significantly different between the 
groups,.  This seems to suggest that IFNγ may play a heightened role in the 
increased early protection of B6-lpr mice when compared to B6 mice. 
These results suggest a paradox, where mice that are prone to develop an 
autoimmune disorder are better protected against high dose virus infections.  A 
similar phenomenon has been described in HIV-infected patients, in that patients 
with two hypoactive mutations in Fas or FasL recovered their CD4+ T cell counts 
more quickly after anti-retroviral treatment (Nasi, Pinti et al. 2005).  Thus, the 
altered immune system in mice, months before they develop pathogenic signs of 
an auto-lymphoproliferative disorder, suggests that mutations in the Fas pathway 
may significantly alter the way in which they respond to high dose infections, and 
further suggests that there might be a more vigorous early immune response to 
high dose virus infections in those with Fas hypoactive mutations. 
The generation of protective, non-pathogenic vaccines, and the 
identification of correlates of protection after acute infection or re-challenge 
provide a lot of information about how the different components of the immune 
system are acting together to fight off a pathogen.  One of the most fascinating 
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things about the immune system as a whole, however, is the complexity of 
pathogens to which it can respond and eliminate.  
The broad possible pMHC reactivity generated by random gene 
rearrangements of α and β TCR chains on T cells would seem to ensure 
reactivity against a diverse array of pathogens, but this broad diversity then begs 
the question of how many T cells in a host would respond to a specific pMHC 
complex or against an entire pathogen.  Many determinations of CD8+ T cell 
precursor frequencies have now been used to calculate the number of pMHC-
specific CD8+ T cells within a mouse (Table 3), but the determination of the total 
number of CD8+ T cells that could respond to a viral infection would be possible 
with these methods only if all of the epitopes of the virus were known.  These 
assays are useful for viruses that have a strongly immunodominant epitope or a 
very limited number of epitopes, but the numbers of epitopes found to stimulate T 
cell responses are now becoming quite large, as means for detecting them have 
become more sensitive.  A virus like VAC is now reported to encode close to 50 
H-2Kb and H-2Db-restricted epitopes (Moutaftsi, Peters et al. 2006), a number 
that would make it very difficult, if not prohibitive, if the precursor frequency to the 
entire virus was to be determined with the usual methods.  The in vivo LDA 
allows for the determination of the number of virus-specific CD8+ T cells within a 
mouse, and so we next compare our results with other methods of precursor 
frequency determination.   
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It is interesting to note the differences calculated for T cell precursor 
frequencies depending on the method used (Table 3).  Extrapolation of clonotype 
number per spleen by calculation of a measure of diversity by examining the 
CDR3 sequences of pMHC-specific populations as done in (Pewe, Heard et al. 
1999; Pewe, Netland et al. 2004) and (Kedzierska, Day et al. 2006) gives 
precursor frequencies on the high end of most estimates, with the highest 
number of H-2Db LCMV GP33-specific CD8+ T cells calculated among all 
methods.  This is interesting in that this method is assumed to be an 
underestimate, because it does not include TCRα diversity, and it also does not 
account well for redundancy in T cell populations, i.e. there may be more than 
one cell of a single clone in a naïve mouse.  However, there is some uncertainty 
in these numbers because they rely on extrapolations of the numbers and 
diversities of sequenced molecular clones to estimate T cell precursor 
frequencies.  When compared to the above results, this extrapolation method 
would probably assume the above results to be underestimates.  If there are 
1100-1200 GP33-specific CD8+ T cells per naïve mouse spleen, and the GP33-
specific CD8+ T cell response is approximately 10% of the total LCMV-specific 
response, it might be expected that there would be about twice as many LCMV-
specific precursors.  Instead of the 6760 per mouse as calculated, 11,000-12,000 
LCMV-specific CD8+ T cells would be expected.  If precursor frequencies are 
instead calculated by transgenic T cell competition, where transferred 
monoclonal transgenic T cells compete against heterogeneous endogenous T 
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cell populations to determine precursor frequencies, these results look to be an 
overestimate.  Assuming a 10% take and 2 x 107 CD8+ T cells per mouse, this 
method estimates ~100 H-2Db LCMV GP33-specific CD8+ T cells (Blattman, 
Antia et al. 2002).  This take is much higher than we have calculated, although 
we remain confident in our value as the P14 transgenic T cell transfer seems to 
confirm the 3.8% figure in our hands.  This result, however, would put the above 
LCMV-specific CD8+ T cell precursor determination on the high end.  The 
tetramer-based enrichment assay, which makes use of pMHC tetramers, 
magnetic bead enrichment and double tetramer FACS staining of spleens and 
lymph nodes to identify pMHC-specific CD8+ T cells (assuming that most naïve T 
cells reside in lymph organs) seems to yield numbers that are in line with results 
determined by the in vivo LDA.  Depending on the individual determination, there 
are ~287 (Obar, Khanna et al. 2008) or ~449 (Kotturi, Scott et al. 2008) H-2Db 
LCMV GP33-specific CD8+ T cells in all lymph organs of a naïve mouse, and this 
result would be on the low end, yet still compatible with what the above results 
might predict for a GP33-specific CD8+ T cell naïve precursor frequency.  For 
VAC-WR, the in vivo LDA calculates about 13,850 responsive CD8+ T cells per 
B6 mouse.  The tetramer-based enrichment assay estimated 1200 CD8+ T cells 
specific for the H-2Kb VAC B8R epitope in the spleen, lymph nodes, and ovaries 
(Haluszczak, Akue et al. 2009), and those results would  seem consistent with 
the results described, considering that the B8R peptide response may represent 
about 10% of the VAC-specific response.  
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About twice as many T cells were responsive to VAC-WR than to LCMV 
(P<0.0001).  This might in part reflect the observations that the T cell response to 
VAC-WR peaks earlier than that of LCMV.  Having more CD8+ T cells that are 
specific to VAC-WR may increase the likelihood that VAC specific CD8+ T cells 
interact with stimulating antigen-presenting cells earlier, allowing peak T cell 
proliferation to occur earlier.  VAC also encodes more proteins than LCMV, with 
almost twice as many VAC epitopes described in the B6 mouse, and consistent 
with almost twice as many VAC-specific precursor T cells than LCMV-specific 
CD8+ T cells (Moutaftsi, Peters et al. 2006; Kotturi, Peters et al. 2007). 
The in vivo LDA results also estimate that 8% of CD8+ T cells in VAC-
immune mice are VAC-responsive, and these data are supported by results from 
VAC-immune mice using peptide stimulations and intracellular cytokine stains 
that estimate that anywhere from 2-11% of CD8+ T cells are specific to the VAC-
encoded immunodominant B8R epitope in D21 or D40 VAC-immune mice 
(Tscharke, Karupiah et al. 2005; Salek-Ardakani, Moutaftsi et al. 2008), and my 
results from intracellular cytokine assays estimate that 0.5-2% of CD8+ T cells in 
VAC-immune mice are specific to the VAC B8R epitope at 3-8 months post-
infection.  This increase in CD8+ T cell precursor frequency to VAC in VAC-
immune animals by greater than two orders of magnitude (P<0.0001) 
demonstrates the expected considerable increase of VAC-specific CD8+ T cell 
precursor frequency after VAC infection.  As expected, there was no increase in 
the number of CD8+ T cells that respond to LCMV in VAC-immune mice, and this 
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helps to validate the specificity of the in vivo LDA assay.  The small, but 
significant decrease in LCMV CD8+ T cell precursor frequency in VAC-immune 
mice is interesting and may suggest that memory cells may displace some naïve 
cells in the immune response.  This has been not systematically addressed as 
there is a high degree of heterologous immunity in this virus sequence, and the 
immunity, due to private specificities in the immune repertoire, has such high 
variability that the in vivo LDA would likely suffer from reproducibility issues (Kim, 
Cornberg et al. 2005). 
It is possible to make an approximation of the number of divisions a CD8+ 
T cell undergoes after stimulation by examining the burst size, or recovered cell 
number at limiting dilution.  By determining the frequency of CFSElo donor cells 
among all CD8+ events collected, multiplying that frequency by the total number 
of CD8+ T cells found in the spleen, and then multiplying that number using the 
assumption that 67% of all CD8+ T cells are present in the spleen during 
infection, a calculation of the approximate number of divisions a CD8+ T cell 
undergoes after virus infection can be made.  The number of divisions a VAC-
specific precursor undergoes by day 6 (~11 divisions) or an LCMV-specific 
precursor undergoes by day 7 (~12-13 divisions) (P=0.07) fall within predicted 
ranges.  However, it can be calculated that a P14 transgenic T cell undergoes 
~14 divisions by day 7 of an LCMV infection, and this is significantly different 
(P=0.023) when compared to the ~12-13 divisions that a naïve CD8+ T cell from 
a heterogeneous population of T cells undergoes.  This may reflect differences in 
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avidity between the transgenic T cells and the heterogeneous populations as a 
whole, or may instead be related to the examination of a monoclonal T cell 
population that responds to a highly expressed immunodominant epitope versus 
a heterogeneous population of CD8+ T cells that contains T cells responding to 
immunodominant and subdominant epitopes. 
My calculated “take” of CD8+ T cells is not the normally quoted 10% figure. 
If a 10% value is instead used for take, my calculated precursor frequencies 
would be decreased, with a naïve mouse having about 1 in 7,805 +/- 1,034 CD8+ 
T cells specific for LCMV, 1 in 3,809 +/- 452 CD8+ T cells specific for VAC, and a 
VAC–immune mouse would have about 1 in 34 +/- 6 and 1 in 12,036 +/- 4812 
CD8 T+ cells specific for VAC or LCMV respectively.  The rough estimates from 
results above (Figure 6.2), would suggest that less than 67% of CD8+ T cells 
reside in the spleen, in contrast to what has been suggested (Ganusov and De 
Boer 2007).  This would lower the take value, but given that my analysis of cell 
recovery in different tissues was not exhaustive, and that the take would probably 
only change by at most a 20-30% value, it is probable that the calculations are 
within a reasonable range of total virus specific CD8+ T cell precursor 
frequencies.  Further, experiments using P14 transgenic T cells also strongly 
support the estimation of take, because the calculations of numbers of 
precursors equals the number of transgenic T cells using my 3.8% take value.  
Further, this in vivo LDA calculated at a 3.8% take gives frequencies with high 
concordance with the anticipated number of VAC-specific memory cells, which 
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can be measured directly by intracellular cytokine assays.  Considering the large 
amount of data in generating the 3.8% figure (Figure 6.5), this estimate of take is 
reasonably accurate in these experiments.  
Whereas tetramer-based enrichment assays measure the number of cells 
that are reactive to a particular pMHC complex, the in vivo LDA requires CD8+ T 
cell division and proliferation, measuring instead the number of CD8+ T cells that 
do proliferate in response to a viral infection.  It might seem likely that not all 
virus-specific T cells would react with tetramer, and not all tetramer-specific T 
cells would be capable of proliferating in response to their cognate antigen.  
Remarkably though, while the in vivo LDA described here tells us something 
different than the tetramer-based enrichment assays described recently, it gives 
reasonable concordance with those techniques. 
 In closing, this thesis describes VAC-Wy recombinants engineered to be 
less pathogenic in vivo that have the same immuno-protective profile as the 
VAC-Wy parental strain from which they were generated to a lethal poxvirus 
challenge in a mouse model.  One of these recombinants lacks three genes that 
code for immuno-modulatory proteins that have previously been shown to 
increase pathogenesis in other models, but still induces similar amounts of 
immunological memory when given at equal doses as the parental strain, and 
protects mice as well as the parental VAC-Wy to a lethal poxvirus infection.  This 
supports the further analysis of this recombinant as a potential smallpox vaccine 
and vector for other immunizations.  This work also describes a paradox, where 
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mice that have mutations in the Fas/FasL system that predispose them to 
lymphoproliferative disorders, are better protected at early time points to high 
dose VAC-WR infections.  These mutant mice were found to have increases in 
multiple leukocyte types before infection, and it seems the protection from high 
dose VAC-WR infection was largely due to the co-operative or redundant 
production of IFNγ by multiple leukocyte populations.  This might suggest that 
hypoactive Fas mutations might provide protection against high dose virus 
infections.  Finally, we describe a technique, the in vivo LDA, that allows for 
enumeration of the total number of virus-specific CD8+ T cells within a mouse.  
We also describe results of experiments with the in vivo LDA, and find large 
numbers of LCMV and VAC-specific CD8+ T cell in naïve mice, with 100x 
increases being noted in VAC-immune mice when measuring the number of 
VAC-specific precursors. This technique can now be used to determine CD8 T 
cell precursor frequencies to entire pathogens, and may also be useful in testing 
immunization protocols. 
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